[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 295297
1. Ketter R, Rahnenführer J, Henn W, Kim YJ, Feiden W, Steudel WI, Zang KD, Urbschat S: Correspondence of tumor localization with tumor recurrence and cytogenetic progression in meningiomas. Neurosurgery; 2008 Jan;62(1):61-9; discussion 69-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correspondence of tumor localization with tumor recurrence and cytogenetic progression in meningiomas.
  • OBJECTIVE: Meningiomas are mostly benign tumors that originate from the coverings of the brain and spinal cord.
  • Progression of meningiomas is associated with a non-random pattern of secondary losses of other autosomes.
  • Deletion of the short arm of one chromosome 1 is a decisive step to anaplastic growth in meningiomas.
  • METHODS: Statistical analyses were performed for the karyotypes of 661 meningiomas with respect to localization, progression, and recurrence of the tumor.
  • A mathematical mixture model estimates typical pathogenetic routes in terms of the accumulation of somatic chromosome changes in tumor cells.
  • The model generates a genetic progression score (GPS) that estimates the prognosis as related to the cytogenetic properties of a given tumor.
  • This corresponds to a total rate of recurrence of 8.0% after macroscopically complete tumor extirpation.
  • Higher GPS values were shown to be strongly correlated with tumor recurrence (P = 2.9 x 10(-7)).
  • High-risk tumors, both in terms of histology and cytogenetics, are localized much more frequently at the brain surface than at the cranial base (P = 1.2 x 10(-5) for World Health Organization grade and P = 3.3 x 10(-12) for GPS categorization).
  • [MeSH-major] Chromosome Aberrations. Meningeal Neoplasms / genetics. Meningeal Neoplasms / pathology. Meningioma / genetics. Meningioma / pathology
  • [MeSH-minor] Adult. Aged. Cytogenetics. Disease Progression. Female. Follow-Up Studies. Humans. Karyotyping. Male. Middle Aged. Models, Theoretical. Neoplasm Recurrence, Local. Proportional Hazards Models. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Neurosurgery. 2009 Jun;64(6):E1206; author reply E1206 [19487876.001]
  • (PMID = 18300892.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Plaza JA, Wakely PE Jr, Moran C, Fletcher CD, Suster S: Sclerosing paraganglioma: report of 19 cases of an unusual variant of neuroendocrine tumor that may be mistaken for an aggressive malignant neoplasm. Am J Surg Pathol; 2006 Jan;30(1):7-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sclerosing paraganglioma: report of 19 cases of an unusual variant of neuroendocrine tumor that may be mistaken for an aggressive malignant neoplasm.
  • Nineteen cases of a distinctive variant of paraganglioma characterized by extensive collagen deposition resulting in a pattern of growth that resembled an invasive malignant neoplasm are described.
  • The tumors were located in the carotid body region, parapharyngeal region, and mediastinum.
  • Tumor size ranged from 2 to 6 cm in greatest diameter.
  • Grossly, the tumors were described as rubbery to firm, tan-red, and with extensive areas of sclerosis.
  • Histologic examination showed nests and cords of tumor cells separated by broad bands of fibrous tissue.
  • The tumor cells ranged from round to polygonal with abundant cytoplasm to elongated spindle cells with scant cytoplasm.
  • Nuclear cytomegaly was present focally enhancing the atypical appearance of the tumor cell population in 17 cases.
  • The most striking morphologic feature was the presence of irregular cords and bands of hyalinized fibrous tissue that compartmentalized the lesion into irregular nests, islands, or cords of tumor cells, imparting them with an infiltrative appearance.
  • All the tumors showed positive immunostaining for chromogranin, synaptophysin, and monoclonal neuron specific enolase.
  • Clinical follow-up in 14 cases, ranging from 2 months to 20 years (mean follow-up, 6.6 years) showed evidence of local recurrence in 2 cases and the development of a separate tumor in the contralateral neck in 1 case.
  • Because of the prominent sclerosis, a diagnosis of an invasive malignant neoplasm was initially considered in the majority of cases.
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Carotid Body Tumor / metabolism. Carotid Body Tumor / pathology. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Mediastinal Neoplasms / metabolism. Mediastinal Neoplasms / pathology. Middle Aged. Neoplasm Metastasis / pathology. Pharyngeal Neoplasms / metabolism. Pharyngeal Neoplasms / pathology. Sclerosis

  • Genetic Alliance. consumer health - Pancreatic islet cell tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Surg Pathol. 2006 Sep;30(9):1206-7 [16931970.001]
  • (PMID = 16330936.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


3. Yoo H, Nam BH, Yang HS, Shin SH, Lee JS, Lee SH: Growth rates of metastatic brain tumors in nonsmall cell lung cancer. Cancer; 2008 Sep 1;113(5):1043-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Growth rates of metastatic brain tumors in nonsmall cell lung cancer.
  • BACKGROUND: The purpose of the study was to evaluate the growth kinetics of metastatic brain tumors during chemotherapy and to analyze growth rates and volumetric doubling time of metastatic brain tumors in patients with nonsmall cell lung cancer (NSCLC) with tumor regrowth.
  • Serial magnetic resonance images (MRI) of 30 metastatic brain tumors in 19 patients were reviewed.
  • Tumor growth rates and volumetric tumor doubling time of tumor regrowth were estimated.
  • All patients were treated with front-line chemotherapy until disease progression.
  • RESULTS: The median tumor growth rate was 12.10 mm(3)/day (interquartile range [IQR], 3.09-36.75).
  • The median volumetric tumor doubling time was 58.48 days (IQR, 32.33-98.48).
  • Study results indicated that brain MRI should be obtained at a minimum of 2-month intervals to screen for metastatic brain tumors.
  • [MeSH-major] Brain Neoplasms / pathology. Brain Neoplasms / secondary. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Disease Progression. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged


Advertisement
4. Puff C, Krudewig C, Imbschweiler I, Baumgärtner W, Alldinger S: Influence of persistent canine distemper virus infection on expression of RECK, matrix-metalloproteinases and their inhibitors in a canine macrophage/monocytic tumour cell line (DH82). Vet J; 2009 Oct;182(1):100-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of persistent canine distemper virus infection on expression of RECK, matrix-metalloproteinases and their inhibitors in a canine macrophage/monocytic tumour cell line (DH82).
  • A morbillivirus infection of tumour cells is known to exert oncolytic activity, but the mechanism of this inhibitory action has not been well defined.
  • Matrix metalloproteinases (MMPs) are important enzymes degrading the extracellular matrix and are often upregulated in malignant neoplasms.
  • In this study, real time quantitative polymerase chain reaction (RT-qPCR) was used to determine the effect of persistent infection with canine distemper virus (CDV) infection on the expression of MMPs and their inhibitors (TIMPS) in a canine macrophage/monocytic tumour cell line (DH82).
  • These findings suggest that CDV infection restores RECK expression in tumour cells and may interfere with the intracellular processing of MMPs and TIMPs, thus possibly influencing tumour cell behaviour beneficially for the host.
  • [MeSH-minor] Animals. Cell Line, Tumor. Dogs. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Gene Expression Regulation, Viral. Matrix Metalloproteinase 2 / genetics. Matrix Metalloproteinase 2 / metabolism. Matrix Metalloproteinase 9 / genetics. Matrix Metalloproteinase 9 / metabolism. Matrix Metalloproteinase Inhibitors. Neoplasm Invasiveness. Neoplasm Metastasis. Polymerase Chain Reaction

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18684651.001).
  • [ISSN] 1532-2971
  • [Journal-full-title] Veterinary journal (London, England : 1997)
  • [ISO-abbreviation] Vet. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Matrix Metalloproteinase Inhibitors; 0 / Tissue Inhibitor of Metalloproteinases; EC 3.4.24.- / Matrix Metalloproteinases; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


5. Leroux S, Comperat E, Bitker MO, Lefebvre G, Delcourt A, Richard F: [Left paravesical cystic urothelial tumour: an exceptional case?]. Prog Urol; 2006 Apr;16(2):208-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Left paravesical cystic urothelial tumour: an exceptional case?].
  • [Transliterated title] Tumeur urothéliale kystique para-vésicale gauche: une observation exceptionnelle?
  • The authors report a rare case of paravesical malformative cyst (Gartner cyst) with left silent kidney.
  • In view of the unusual histology, comprising carcinoma in situ and a transitional cell papillary tumour with metastatic lymph node extension, the authors reviewed the literature on this subject and identified only one similar case (5).
  • [MeSH-major] Cysts / diagnosis. Urinary Bladder Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16734248.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 8
  •  go-up   go-down


6. Kim DJ, Lee MH, Park TI, Bae HI: Expression and mutational analysis of c-kit in ovarian surface epithelial tumors. J Korean Med Sci; 2006 Feb;21(1):81-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and mutational analysis of c-kit in ovarian surface epithelial tumors.
  • Coexpression of Kit ligand and c-kit has been reported in some gynecologic tumors.
  • To determine whether imatinib mesylate is useful in ovarian epithelial tumors, we performed immunohistochemical and mutational analysis.
  • The cases consisted of 33 cases, which included 13 serous cystadenocarcinomas, 1 borderline serous tumor, 8 mucinous cystadenocarcinomas, 6 borderline mucinous tumors and 5 clear cell carcinomas.
  • In the immunohistochemical study, 3 cases (3/6, 50%) of borderline mucinous cystic tumor and two cases (2/8, 25%) of mucinous cystadenocarcinoma show positive staining for KIT protein.
  • However, two cases of borderline mucinous tumors and one case of mucinous cystadenocarcinoma had mutations at exon 17.
  • Although, KIT protein expression showed higher incidence in mucinous tumors than serous tumors, they lack KIT-activating mutations in exon 11.
  • Thus, ovarian surface epithelial tumors are unlikely to respond to imatinib mesylate.
  • [MeSH-major] Ovarian Neoplasms / pathology. Proto-Oncogene Proteins c-kit / genetics
  • [MeSH-minor] Adult. Aged. Cystadenocarcinoma, Mucinous / genetics. Cystadenocarcinoma, Mucinous / metabolism. Cystadenocarcinoma, Mucinous / pathology. Cystadenoma, Mucinous / genetics. Cystadenoma, Mucinous / metabolism. Cystadenoma, Mucinous / pathology. Cystadenoma, Serous / genetics. Cystadenoma, Serous / metabolism. Cystadenoma, Serous / pathology. DNA Mutational Analysis. DNA, Neoplasm / chemistry. DNA, Neoplasm / genetics. Epithelial Cells / chemistry. Epithelial Cells / metabolism. Epithelial Cells / pathology. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Middle Aged. Mutation. Polymerase Chain Reaction. Polymorphism, Single-Stranded Conformational

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Urol. 1996;14(5):347-52 [8912475.001]
  • [Cites] Semin Oncol. 1998 Jun;25(3):281-304 [9633841.001]
  • [Cites] Am J Pathol. 1999 Jun;154(6):1643-7 [10362788.001]
  • [Cites] Br J Cancer. 2004 Dec 13;91(12):2048-55 [15583695.001]
  • [Cites] Hum Pathol. 1999 Oct;30(10):1213-20 [10534170.001]
  • [Cites] Biol Reprod. 2000 Jun;62(6):1600-9 [10819761.001]
  • [Cites] Int J Cancer. 2000 May 20;89(3):242-50 [10861500.001]
  • [Cites] Leuk Res. 2001 Jul;25(7):571-6 [11377682.001]
  • [Cites] J Clin Oncol. 2002 Mar 15;20(6):1692-703 [11896121.001]
  • [Cites] Hum Pathol. 2002 May;33(5):484-95 [12094373.001]
  • [Cites] Cancer. 2003 Aug 15;98(4):758-64 [12910520.001]
  • [Cites] Oncologist. 2003;8(6):531-8 [14657531.001]
  • [Cites] Ann Oncol. 2004 Apr;15(4):594-7 [15033665.001]
  • [Cites] EMBO J. 1987 Nov;6(11):3341-51 [2448137.001]
  • [Cites] Cancer Res. 1991 May 1;51(9):2416-9 [1707753.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):3049-53 [7514496.001]
  • [Cites] Br J Cancer. 1996 May;73(10):1233-6 [8630284.001]
  • [Cites] Hum Pathol. 2005 Mar;36(3):242-9 [15791568.001]
  • (PMID = 16479070.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  • [Other-IDs] NLM/ PMC2733984
  •  go-up   go-down


7. Samelis GF, Ekmektzoglou KA, Zografos GC: Gastrointestinal stromal tumours: clinical overview, surgery and recent advances in imatinib mesylate therapy. Eur J Surg Oncol; 2007 Oct;33(8):942-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastrointestinal stromal tumours: clinical overview, surgery and recent advances in imatinib mesylate therapy.
  • AIMS: To review the clinical features of gastrointestinal stromal tumours (GISTs), the role of surgery and its principles and molecular targeted therapies.
  • METHODS: A Medline-based literature search on relevant topics was performed in PubMed for key articles concerning the clinical features, biology and the novel strategies in the management, whether surgical and/or pharmaceutical, of gastrointestinal stromal tumours.
  • Some information was obtained from Proceedings of the American Society for Clinical Oncology published recently.
  • For residual, metastatic and/or inoperable disease, treatment options remain under intense and continuous scrutiny.
  • However, their molecular genetics, i.e. the mutations of the genes coding for KIT or platelet-derived growth factor receptor alpha, two receptor tyrosine kinases, have been targeted for therapeutic intervention by imatinib mesylate -- a tyrosine kinase inhibitor.
  • New investigational agents are being developed and participation in promising clinical trials remains a standard of care.
  • [MeSH-major] Gastrointestinal Stromal Tumors / drug therapy. Gastrointestinal Stromal Tumors / surgery. Piperazines / therapeutic use. Protein Kinase Inhibitors / therapeutic use. Pyrimidines / therapeutic use
  • [MeSH-minor] Benzamides. Clinical Trials as Topic. Combined Modality Therapy. Drug Resistance, Neoplasm. Humans. Imatinib Mesylate. Treatment Outcome

  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17196360.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  • [Number-of-references] 78
  •  go-up   go-down


8. Sidoroff A: [Epidemiology of cutaneous vascular neoplasms and malformations in childhood]. Handchir Mikrochir Plast Chir; 2009 Apr;41(2):65-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epidemiology of cutaneous vascular neoplasms and malformations in childhood].
  • [Transliterated title] Epidemiologie kutaner vaskulärer Neu- und Fehlbildungen im Kindesalter.
  • PURPOSE: A representative compilation of data on the incidence and prevalence of benign cutaneous vascular neoplasms and malformations in childhood has been made.
  • Complex vascular malformations or severe cases of vascular tumours are very rare.
  • Complex and/or life-threatening severe vascular tumours and malformations that represent a considerable therapeutic challenge are extremely rare events.
  • [MeSH-major] Arteriovenous Malformations / epidemiology. Hemangioma / epidemiology. Skin / blood supply. Skin Neoplasms / epidemiology. Soft Tissue Neoplasms / epidemiology
  • [MeSH-minor] Age Factors. Austria. Child. Child, Preschool. Cohort Studies. Cross-Sectional Studies. Health Surveys. Hemangioma, Capillary / epidemiology. Hemangioma, Cavernous / epidemiology. Humans. Incidence. Infant. Infant, Newborn. Infant, Premature, Diseases / epidemiology. Neoplasm Regression, Spontaneous. Port-Wine Stain / epidemiology

  • Genetic Alliance. consumer health - Vascular Malformations.
  • MedlinePlus Health Information. consumer health - Arteriovenous Malformations.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19180424.001).
  • [ISSN] 1439-3980
  • [Journal-full-title] Handchirurgie, Mikrochirurgie, plastische Chirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft für Handchirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft für Mikrochirurgie der Peripheren Nerven und Gefässe : Organ der Vereinigung der Deutschen Plastischen Chirurgen
  • [ISO-abbreviation] Handchir Mikrochir Plast Chir
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 39
  •  go-up   go-down


9. Hicks J, Muthuswamy L, Krasnitz A, Navin N, Riggs M, Grubor V, Esposito D, Alexander J, Troge J, Wigler M, Maner S, Lundin P, Zetterberg A: High-resolution ROMA CGH and FISH analysis of aneuploid and diploid breast tumors. Cold Spring Harb Symp Quant Biol; 2005;70:51-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-resolution ROMA CGH and FISH analysis of aneuploid and diploid breast tumors.
  • Combining representational oligonucleotide microarray analysis (ROMA) of tumor DNA with fluorescence in situ hybridization (FISH) of individual tumor cells provides the opportunity to detect and validate a wide range of amplifications, deletions, and rearrangements directly in frozen tumor samples.
  • We have used these combined techniques to examine 101 aneuploid and diploid breast tumors for which long-term follow-up and detailed clinical information were available.
  • We find that diploid tumors exhibit fewer rearrangements on average than aneuploids, but rearrangements occur at the same locations in both types.
  • Diploid tumors reflect at least three consistent patterns of rearrangement.
  • The reproducibility and frequency of these events, especially in very early stage tumors, provide insight into the earliest chromosomal events in breast cancer.
  • [MeSH-major] Breast Neoplasms / genetics
  • [MeSH-minor] Aneuploidy. DNA, Neoplasm / genetics. Diploidy. Female. Gene Expression Profiling. Gene Rearrangement. Genomics. Humans. In Situ Hybridization, Fluorescence. Oligonucleotide Array Sequence Analysis. Prognosis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16869738.001).
  • [ISSN] 0091-7451
  • [Journal-full-title] Cold Spring Harbor symposia on quantitative biology
  • [ISO-abbreviation] Cold Spring Harb. Symp. Quant. Biol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5R01-CA78544-07
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


10. de Las Mulas JM, Millán Y, Dios R: A prospective analysis of immunohistochemically determined estrogen receptor alpha and progesterone receptor expression and host and tumor factors as predictors of disease-free period in mammary tumors of the dog. Vet Pathol; 2005 Mar;42(2):200-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective analysis of immunohistochemically determined estrogen receptor alpha and progesterone receptor expression and host and tumor factors as predictors of disease-free period in mammary tumors of the dog.
  • The immunohistochemically determined estrogen receptor (ER) alpha (ERalpha) and progesterone receptor (PR) status, as well as recognized, well-accepted prognostic indicators and host factors were prospectively analyzed in 84 cases of primary canine mammary carcinoma for their effect on disease-free period (recurrence free, metastasis free, or combined) (DFP) after an observation period of 18 months.
  • The presence of one or both receptors, as well as tumor size, lymph node status, histologic grading, intravascular growth, and necrosis, were of prognostic value for DFP.
  • In multivariate analysis, only tumor size and histologic grading proved to be independent prognosticators.
  • ERalpha, PR, or both were detected in 173 out of 228 tumors: 70 ERalpha and PR; 5 ERalpha only; 98 PR only.
  • Statistically significant differences regarding the presence of one or both receptors were observed between benign and malignant tumors and between complex, mixed, and simple histologic subtypes of benign and malignant tumors.
  • In the group of malignant tumors (n=155), the presence of one or both receptors was more frequent in tumors smaller than 3 cm, without lymph node metastasis, with tubulopapillary rather than solid patterns of growth among simple carcinomas, of histologic grades I and II, without both intravascular growth and necrosis, and with lymphocyte cell infiltrates.
  • The most frequent groups of hormone receptors-positive tumors were the ERalpha-positive and PR-positive group among benign and the ERalpha-negative and PR-positive group among malignant tumors.
  • [MeSH-major] Dog Diseases / pathology. Estrogen Receptor alpha / physiology. Gene Expression / physiology. Mammary Neoplasms, Animal / pathology. Receptors, Progesterone / physiology
  • [MeSH-minor] Animals. Dogs. Female. Immunohistochemistry / veterinary. Neoplasm Metastasis / physiopathology. Neoplasm Recurrence, Local / physiopathology. Predictive Value of Tests. Prospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15753474.001).
  • [ISSN] 0300-9858
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / Receptors, Progesterone
  •  go-up   go-down


11. Russo P, Huang W: The medical and oncological rationale for partial nephrectomy for the treatment of T1 renal cortical tumors. Urol Clin North Am; 2008 Nov;35(4):635-43; vii
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The medical and oncological rationale for partial nephrectomy for the treatment of T1 renal cortical tumors.
  • This article presents the oncological and medical rationale for partial nephrectomy as the treatment of choice whenever possible for T1 renal tumors.
  • The value of partial nephrectomy in the management of small renal cortical tumors is gaining wider recognition thanks to (1) enhanced understanding of the biology of renal cortical tumors;.
  • (2) better knowledge about tumor size and stage migration to small tumors at the time of presentation;.
  • (3) studies indicating the oncologic efficacy of kidney-sparing surgery, and (4) increasing awareness of the wide prevalence of chronic kidney disease.
  • The overzealous use of radical nephrectomy for small renal tumors must now be considered detrimental to the long-term health and safety of the patient with a small renal cortical tumor.
  • [MeSH-major] Carcinoma, Renal Cell / surgery. Kidney Cortex / pathology. Kidney Cortex / surgery. Kidney Neoplasms / surgery. Nephrectomy / methods
  • [MeSH-minor] Disease-Free Survival. Evidence-Based Medicine. Humans. Kidney Function Tests. Renal Insufficiency, Chronic / diagnosis. Renal Insufficiency, Chronic / etiology. Risk Assessment. Risk Factors

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18992617.001).
  • [ISSN] 0094-0143
  • [Journal-full-title] The Urologic clinics of North America
  • [ISO-abbreviation] Urol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 56
  •  go-up   go-down


12. Büyükpamukçu M, Varan A, Yazici N, Akalan N, Söylemezoğlu F, Zorlu F, Akyüz C, Kutluk MT: Second malignant neoplasms following the treatment of brain tumors in children. J Child Neurol; 2006 May;21(5):433-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second malignant neoplasms following the treatment of brain tumors in children.
  • We investigated retrospectively 992 children with central nervous system tumors who were treated at our center between 1970 and 2004.
  • Six patients developed second malignant neoplasms, and their clinical and histopathologic characteristics are reviewed in this article.
  • The second malignant neoplasms were diagnosed as non-Hodgkin lymphoma, myelodysplastic syndrome, basal cell carcinoma, malignant melanoma, Kaposi sarcoma, and high-grade neuroectodermal tumor.
  • The outcome varied according to the histopathologic type of the second tumor.
  • The patients who developed non-Hodgkin lymphoma and myelodysplastic syndrome died of progressive disease.
  • The patients with second skin neoplasms are alive as of the time of this writing.
  • The patient with Kaposi sarcoma developed one of the rare reported second malignant neoplasms following a primary brain tumor in childhood.
  • A wide spectrum of second malignant neoplasms was detected after treatment of primary brain tumors with surgery, radiotherapy, and chemotherapy.
  • Long-term follow-up is therefore necessary for the child who has survived a primary central nervous system tumor.
  • [MeSH-major] Brain Neoplasms / pathology. Brain Neoplasms / therapy. Glioma / pathology. Glioma / therapy. Neoplasms, Second Primary / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16901454.001).
  • [ISSN] 0883-0738
  • [Journal-full-title] Journal of child neurology
  • [ISO-abbreviation] J. Child Neurol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Shen CF, Yuan XR, Qin ZQ: [Clinical significance of the expression of the RCAS1 mRNA and protein in astrocytic tumors]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2007 Oct;32(5):836-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical significance of the expression of the RCAS1 mRNA and protein in astrocytic tumors].
  • OBJECTIVE: To determine the mRNA and protein expressions of RCAS1 in human astrocytic tumors, and to explore the relation between their expression and the genesis and development of tumor.
  • METHODS: The RCAS1 mRNA expression in human astrocytic tumors was evaluated by RT-PCR, and the RCAS1 protein expression was studied by immunohistochemical staining.
  • RCAS1 protein expression was positively correlated with the tumor grade (r=0.573,P<0.001).
  • CONCLUSION: The RCAS1 expression is related to the histological grade of astrocytic tumor.
  • In astrocytic tumors, the RCAS1 expression is regulated transcriptionally and posttranscriptionally.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Astrocytoma / metabolism. Brain Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18007080.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] Controlled Clinical Trial; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / EBAG9 protein, human; 0 / RNA, Messenger
  •  go-up   go-down


14. Chowdhury MM, Khan ZR, Hossain MS: Diagnosis and management of solid pseudopapillary tumours of the pancreas. Mymensingh Med J; 2010 Oct;19(4):640-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and management of solid pseudopapillary tumours of the pancreas.
  • The finding of a solid or cystic mass in the pancreas is becoming more common secondary to the increasing use of cross-sectional imaging and the improved sensitivity of such studies for the detection of pancreatic abnormalities.
  • This review provides an overview of the natural history, diagnostic considerations, and treatment recommendations for the less common tumor of the pancreas which can be misinterpreted as pancreatic cancer: solid pseudopapillary tumors (SPT).
  • It is often possible to obtain an accurate pretreatment diagnosis for this unusual pancreatic tumor and to successfully differentiate them from the more common pancreatic malignancies.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20956914.001).
  • [ISSN] 1022-4742
  • [Journal-full-title] Mymensingh medical journal : MMJ
  • [ISO-abbreviation] Mymensingh Med J
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] Bangladesh
  •  go-up   go-down


15. Khalid A, Funch-Jensen P, Bendix J, Dutoit Hamilton S, Kruse A, Viborg Mortensen F: Intraductal papillary mucinous tumor of the pancreas (IPMT): follow-up of twelve cases. Scand J Surg; 2009;98(1):25-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal papillary mucinous tumor of the pancreas (IPMT): follow-up of twelve cases.
  • INTRODUCTION: Intraductal papillary mucinous tumours (IPMT) were described as a distinct entity in I982.
  • The extent of surgical resection for this disease remains controversial.
  • In the ten patients operated on for IPMT, histological examination showed eight non-invasive- and two invasive carcinomas.
  • CONCLUSION: IPMTs represent a subgroup of pancreatic neoplasms with a favourable prognosis, and the resection should aim at removing all dysplastic foci.
  • In cases with diffuse dilatation of the main pancreatic duct, widespread tumour involvement of the duct system can be expected and total pancreatectomy should be the operation of choice.
  • [MeSH-major] Adenocarcinoma, Mucinous / surgery. Carcinoma, Pancreatic Ductal / surgery. Pancreatectomy. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19447738.001).
  • [ISSN] 1457-4969
  • [Journal-full-title] Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society
  • [ISO-abbreviation] Scand J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


16. Mueller J, Gaertner FC, Blechert B, Janssen KP, Essler M: Targeting of tumor blood vessels: a phage-displayed tumor-homing peptide specifically binds to matrix metalloproteinase-2-processed collagen IV and blocks angiogenesis in vivo. Mol Cancer Res; 2009 Jul;7(7):1078-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeting of tumor blood vessels: a phage-displayed tumor-homing peptide specifically binds to matrix metalloproteinase-2-processed collagen IV and blocks angiogenesis in vivo.
  • Proteolytic degradation of the basement membrane by the matrix metalloproteinase-2 and -9 is an essential step in tumor angiogenesis.
  • The aim of this study was to generate peptides that bind specifically to proteolytically processed collagen IV and to test whether these peptides accumulate in tumor vasculature and are able to block angiogenesis.
  • We then tested the ability of the phage to bind to the vasculature in xenograft tumors and found indeed a significant accumulation of the phage in tumors but not in control organs.
  • The tumor homing of the TLTYTWS phage is specific, as it can be blocked by coinjection chemically synthesized cognate peptide.
  • In conclusion, we report about a novel tumor-homing peptide that specifically binds to proteolytically processed collagen IV, accumulates in tumors, and blocks angiogenesis.
  • This peptide may be a new useful tool for diagnostic and therapeutic procedures in oncology.
  • [MeSH-major] Collagen Type IV / metabolism. Matrix Metalloproteinase 2 / metabolism. Neoplasms / blood supply. Peptide Library. Peptides / pharmacology
  • [MeSH-minor] Animals. Bacteriophages / genetics. Binding Sites. Cell Differentiation / drug effects. Drug Delivery Systems. Female. Humans. Mice. Neoplasm Transplantation. Neovascularization, Pathologic / drug therapy. Neovascularization, Pathologic / metabolism. Neovascularization, Pathologic / pathology. Protein Binding. Tissue Distribution

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19584266.001).
  • [ISSN] 1557-3125
  • [Journal-full-title] Molecular cancer research : MCR
  • [ISO-abbreviation] Mol. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Collagen Type IV; 0 / Peptide Library; 0 / Peptides; EC 3.4.24.24 / Matrix Metalloproteinase 2
  •  go-up   go-down


17. Wowra B, Zausinger S, Drexler C, Kufeld M, Muacevic A, Staehler M, Tonn JC: CyberKnife radiosurgery for malignant spinal tumors: characterization of well-suited patients. Spine (Phila Pa 1976); 2008 Dec 15;33(26):2929-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CyberKnife radiosurgery for malignant spinal tumors: characterization of well-suited patients.
  • The study focused on patients with no more than 2 malignant spinal tumors.
  • METHODS: From August 2005 until October 2007, a consecutive series of 102 patients with a total of 134 malignant spinal tumors were selected for single-fraction, fiducial-free CyberKnife radiosurgery (CKRS).
  • The study was limited to patients with a maximum of 2 tumors.
  • Malignant primaries included breast cancer in 23 (22.6%) patients, renal cancer in 20 (19.6%) patients, gastro-intestinal cancers in 12 (11.8%) patients, prostate cancer each in 12 (11.8%) patients, lung cancer in 9 (8.9%) patients, sarcomas in 7 (6.9%) patients.
  • A variety of other malignant tumors were found in 19 (18.6%) patients.
  • Tumor-associated spinal pain was prospectively scored according to the visual analogue scale (VAS).
  • RESULTS: Of 102 individuals, 22 (21.6%) died due to progression of their systemic disease.
  • Median survival after initial tumor diagnosis was 18.4 years (CI: 15.1-23.4).
  • Two (2%) patients suffered complications after radiosurgery; a tumor hemorrhage occurred in one, and another developed spinal instability.
  • Local tumor control 15 months after CKRS was 98% (95% CI: 89-99%).
  • Tumor-associated pain was observed in 52 (51%) patients.
  • Pain recurrence in correlation with tumor recurrence was observed for 3 (6%) patients.
  • CONCLUSION: Spinal radiosurgery with the CyberKnife technology is a nonivasive, safe, and effective treatment method for patients with 1 or 2 small spinal malignant tumors.
  • The best benefit of the treatment can be expected in patients with good to excellent clinical condition and patients with severe tumor associated pain.
  • [MeSH-major] Patient Selection. Radiosurgery / instrumentation. Spinal Cord Neoplasms / pathology. Spinal Cord Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19092627.001).
  • [ISSN] 1528-1159
  • [Journal-full-title] Spine
  • [ISO-abbreviation] Spine
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Tuluc M, Horn A, Inniss S, Thomas R, Zhang PJ, Khurana JS: Case report: glomus tumor of the colon. Ann Clin Lab Sci; 2005;35(1):97-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case report: glomus tumor of the colon.
  • Glomus tumors are tumors of pericytic origin and are usually found in the distal extremities.
  • Glomus tumors have rarely been reported in viscera.
  • The authors report a glomus tumor of the colon that caused rectal bleeding in a 40-yr-old man and was biopsied and excised endoscopically.
  • The histology and immunohistochemical profile of the tumor are described and the literature on visceral glomus tumors is reviewed.
  • [MeSH-major] Colonic Neoplasms / pathology. Glomus Tumor / pathology
  • [MeSH-minor] Adult. Biopsy. Colonic Polyps / pathology. Colonic Polyps / surgery. Humans. Male. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15830716.001).
  • [ISSN] 0091-7370
  • [Journal-full-title] Annals of clinical and laboratory science
  • [ISO-abbreviation] Ann. Clin. Lab. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Deen S, Duncan TJ, Hammond RH: Malignant female adnexal tumors of probable Wolffian origin. Int J Gynecol Pathol; 2007 Oct;26(4):383-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant female adnexal tumors of probable Wolffian origin.
  • Female adnexal tumors of probable Wolffian origin are rare.
  • Although the histological features of the benign tumors are recognized, features of malignancy are not well defined in published work because these tumors are particularly rare.
  • Immunohistochemical staining and electron microscopy supported the diagnosis of female adnexal tumor of probable Wolffian origin.
  • There was significant and widespread nuclear pleomorphism with increased mitotic activity endorsing the diagnosis of a malignant tumor.
  • [MeSH-minor] Aged, 80 and over. Female. Humans. Hysterectomy. Neoplasm Recurrence, Local / pathology. Uterine Hemorrhage / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17885487.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Cueva del Castillo JF, Francisco Osuna J, Elizondo F, Pérez O, Pérez A, Hernández S, Mejía C: [Use of a xenoimplant for the treatment of bone defects, benign tumors, pseudoarthrosis and arthrodesis. Preliminary report]. Acta Ortop Mex; 2007 Jan-Feb;21(1):31-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Use of a xenoimplant for the treatment of bone defects, benign tumors, pseudoarthrosis and arthrodesis. Preliminary report].
  • [Transliterated title] Aplicación de xenoimplante para el tratamiento de defectos oseos, tumores benignos, seudoartrosis y artrodesis. (Reporte preliminar).
  • OBJECTIVE: To show that the ceramic produced at the Institute for Materials Research, National Autonomous University of Mexico, is an appropriate replacement of bone graft in patients with bone tumors, benign tumors, pseudoarthrosis and arthrodesis treated at "General Ignacio Zaragoza" Regional Hospital.
  • RESULTS: The sample is composed of 14 male and 8 female patients, with a mean age of 46.6 years, and a standard deviation (s=) of 13.8.
  • The most frequent indication was arthrodesis in 10 patients (45.45%), pseudoarthrosis in 6 (27.27%), benign tumors in 3 (13.63%), and bone defects in 3 (13.63%).
  • [MeSH-major] Arthrodesis. Bone Neoplasms / surgery. Bone Transplantation. Pseudarthrosis / surgery. Transplantation, Heterologous

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Bone Grafts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17695206.001).
  • [ISSN] 2306-4102
  • [Journal-full-title] Acta ortopédica mexicana
  • [ISO-abbreviation] Acta Ortop Mex
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


21. Laakkonen P, Zhang L, Ruoslahti E: Peptide targeting of tumor lymph vessels. Ann N Y Acad Sci; 2008;1131:37-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peptide targeting of tumor lymph vessels.
  • In addition to having a blood vasculature, most normal organs and pathologic conditions involve a second vascular system, the lymphatic vasculature, and many tumors induce the growth of new lymphatic vessels.
  • However, compared to the blood vasculature, very little is known about the lymphatic vessels in tumors.
  • We have used the in vivo phage display technology to map tumor-specific differences in the lymphatic vasculature, and identified peptides that specifically home to tumor lymphatics.
  • Each of these peptides recognizes lymphatic vessels in a different set of tumors, and some of them also recognize tumor cells.
  • Furthermore, these peptides can differentiate lymphatic vasculature of a premalignant lesion from that of a full-blown tumor, indicating tumor stage-specific differences in the lymphatic vessels.
  • Conjugation of the lymphatic homing peptides to drugs provides an opportunity to specifically deliver therapeutic agents into tumors using a route not previously exploited.
  • The surprising degree of selectivity of these lymphatic homing peptides suggests extensive molecular specialization of tumor lymphatic vessels, positing the existence of a molecular lymphatic "zip code" system, as has been previously demonstrated for the tumor blood vasculature.
  • [MeSH-major] Lymphatic Vessels / pathology. Neoplasms / pathology. Peptides / metabolism. Peptides / therapeutic use

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18519957.001).
  • [ISSN] 0077-8923
  • [Journal-full-title] Annals of the New York Academy of Sciences
  • [ISO-abbreviation] Ann. N. Y. Acad. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Peptide Library; 0 / Peptides
  • [Number-of-references] 48
  •  go-up   go-down


22. Ferrís I Tortajada J, Berbel Tornero O, Ortega García JA, Claudio-Morales L, García I Castell J, Martí Perales V, Miranda Casas L: [Risk factors for pediatric malignant bone tumors]. An Pediatr (Barc); 2005 Dec;63(6):537-47
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Risk factors for pediatric malignant bone tumors].
  • [Transliterated title] Factores de riesgo para los tumores óseos malignos pediátricos.
  • In the last few decades, pediatric oncology as a whole has progressed, including knowledge of malignant osseous tumors (MOT).
  • b) to disseminate knowledge of the main MOT-related risk factors among our colleagues in order to promote research into these factors, diagnosis and future prevention, and c) to request help from our colleagues in the Environment and Pediatric Cancer research project.
  • The search profiles used were: pediatric/childhood malignant bone tumors, pediatric/ childhood bone cancer/neoplasm, osteosarcoma/bone sarcoma/Ewing's sarcoma and risk factors/etiology/epidemiology.
  • RESULTS: MOT represent 6-7 % of all pediatric neoplasms.
  • The most frequent types are osteosarcoma (OS) and Ewing's sarcoma (ES), representing 56 % and 34 % respectively.
  • OS-related risk factors are the following: a) previous osseous disease (Paget's disease);.
  • b) familial-genetic factors (hereditary retinoblastoma, Li-Fraumeni syndrome, Rothmund-Thompson syndrome, Bloom syndrome, familial OS, Diamond-Blackfan anemia);.
  • ES-related risk factors are the following: a) ethnic-cultural (Caucasian race);.
  • d) maternal obstetric history, and e) other factors (parental smoking and inguinal hernia).
  • Based on different levels of scientific evidence, the main factors implicated in the etiopathogenesis of OS are: Paget's disease, hereditary retinoblastoma, Li-Fraumeni syndrome, antineoplastic drugs, and ionizing radiation.
  • The main factors related to ES are: Caucasian race, parental occupation, parental smoking, and surgery for inguinal hernia.
  • [MeSH-major] Bone Neoplasms / etiology. Osteosarcoma / etiology. Sarcoma, Ewing / etiology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16324620.001).
  • [ISSN] 1695-4033
  • [Journal-full-title] Anales de pediatría (Barcelona, Spain : 2003)
  • [ISO-abbreviation] An Pediatr (Barc)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 59
  •  go-up   go-down


23. Kalyanasundaram K, Parameswaran A, Mani R: Perivascular epithelioid tumor of urinary bladder and vagina. Ann Diagn Pathol; 2005 Oct;9(5):275-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perivascular epithelioid tumor of urinary bladder and vagina.
  • Perivascular epithelioid cell tumors are recently characterized neoplasms composed of large clear HMB-45-positive epithelioid cells arranged in an organoid pattern.
  • The histogenesis of these neoplasms remain obscure.
  • We report here 2 such tumors in young female patients aged 19 and 16 years involving the urinary bladder and vagina, respectively (in the absence of the tuberous sclerosis complex) .
  • Microscopically, both tumors were composed of perivascularly arranged cells with granular eosinophilic fluffy cytoplasm, round-to-oval nuclei, and prominent nucleoli.
  • Melanin pigmentation was present in the vaginal tumor.
  • Immunohistochemically, both tumors strongly expressed HMB-45.
  • They were negative for cytokeratin, vimentin, and S-100.
  • The vaginal tumor recurred 10 months after resection and chemotherapy.
  • The patient with the bladder tumor was lost to follow-up.
  • [MeSH-major] Epithelioid Cells / pathology. Urinary Bladder Neoplasms / pathology. Vaginal Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16198955.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


24. Aisner SC, Dahlberg S, Hameed MR, Ettinger DS, Schiller JH, Johnson DH, Aisner J, Loehrer PJ: Epidermal growth factor receptor, C-kit, and Her2/neu immunostaining in advanced or recurrent thymic epithelial neoplasms staged according to the 2004 World Health Organization in patients treated with octreotide and prednisone: an Eastern Cooperative Oncology Group study. J Thorac Oncol; 2010 Jun;5(6):885-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermal growth factor receptor, C-kit, and Her2/neu immunostaining in advanced or recurrent thymic epithelial neoplasms staged according to the 2004 World Health Organization in patients treated with octreotide and prednisone: an Eastern Cooperative Oncology Group study.
  • BACKGROUND: Advanced or recurrent nonresectable thymic epithelial tumors show only a modest response to standard chemotherapy.
  • A recent study using octreotide and prednisone in thymic tumors, Eastern Cooperative Oncology Group study E1C97, was conducted to verify the activity of octreotide for thymic tumors.
  • The aim of this study was to determine whether epidermal growth factor receptor (EGFR) immunoreactivity correlated with outcomes and to identify new biologic markers for potential targeted therapy.
  • Three markers, EGFR, C-kit, and Her2/neu, were selected for evaluation in patients with advanced thymic epithelial tumors treated on E1C97.
  • Each tumor was assessed to have 0, 1+, 2+, or 3+ immunoreactivity in the cytoplasm or membranes of the neoplastic cells for Her2/neu and EGFR and for the presence or absence of C-kit immunoreactivity.
  • RESULTS: EGFR immunoreactivity of 2+ or 3+ was associated with more aggressive thymic tumors (WHO types B2 and B3).
  • The presence of EGFR within cells was associated with a significantly improved progression-free survival (PFS) and a trend for overall survival (OS).
  • Her2/neu immunoreactivity was uniformly negative for all tumors evaluated.
  • CONCLUSIONS: High EGFR immunoreactivity is seen in more aggressive thymic neoplasms as classified according to the 2004 WHO, but regardless of classification, the presence of EGFR in tumor cells (1+, 2+, and 3+) is associated with improved performance free survival (PFS) and a trend for better OS.
  • These data suggest that EGFR and C-kit may be prognostic, and further studies of these markers in subcategories of thymic malignancies is warranted.

  • MedlinePlus Health Information. consumer health - Steroids.
  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PREDNISONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1981 Dec 1;48(11):2485-92 [7296496.001]
  • [Cites] N Engl J Med. 2004 Jun 17;350(25):2625-6 [15201427.001]
  • [Cites] Annu Rev Biochem. 1987;56:881-914 [3039909.001]
  • [Cites] N Engl J Med. 1997 Jan 23;336(4):263-5 [8995089.001]
  • [Cites] Am J Clin Pathol. 1999 Jun;111(6):826-33 [10361520.001]
  • [Cites] Cancer. 2005 Feb 1;103(3):630-6 [15630697.001]
  • [Cites] Lung Cancer. 2005 Oct;50(1):59-66 [16009453.001]
  • [Cites] Surg Today. 2005;35(10):805-11 [16175459.001]
  • [Cites] Ann Thorac Surg. 2006 Jun;81(6):2328-34 [16731193.001]
  • [Cites] Jpn J Clin Oncol. 2006 Jun;36(6):351-6 [16762968.001]
  • [Cites] Am J Clin Oncol. 2006 Aug;29(4):336-44 [16891859.001]
  • [Cites] Front Biosci. 2007;12:757-61 [17127335.001]
  • [Cites] Cancer Lett. 2007 Apr 18;248(2):186-91 [16919868.001]
  • [Cites] Lung Cancer. 2008 Dec;62(3):316-20 [18448188.001]
  • [Cites] J Cancer Res Clin Oncol. 2002 Mar;128(3):167-70 [11935304.001]
  • [Cites] Cancer Treat Rev. 2004 Feb;30(1):1-17 [14766123.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Apr;130(4):222-4 [14762710.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1985;407(2):119-49 [3927579.001]
  • (PMID = 20421818.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA021115-37; United States / NCI NIH HHS / CA / CA021115-37; United States / NCI NIH HHS / CA / CA66636; United States / NCI NIH HHS / CA / U10 CA021115; United States / NCI NIH HHS / CA / CA107868; United States / NCI NIH HHS / CA / U10 CA049883; United States / NCI NIH HHS / CA / U10 CA107868; United States / NCI NIH HHS / CA / P30 CA082709; United States / NCI NIH HHS / CA / U10 CA066636; United States / NCI NIH HHS / CA / CA49957; United States / NCI NIH HHS / CA / U10 CA016116; United States / NCI NIH HHS / CA / U10 CA023318; United States / NCI NIH HHS / CA / U10 CA049957; United States / NCI NIH HHS / CA / CA49883; United States / NCI NIH HHS / CA / CA21115; United States / NCI NIH HHS / CA / U24 CA114737; United States / NCI NIH HHS / CA / CA23318; United States / NCI NIH HHS / CA / CA16116
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2; RWM8CCW8GP / Octreotide; VB0R961HZT / Prednisone
  • [Other-IDs] NLM/ NIHMS269686; NLM/ PMC3061392
  •  go-up   go-down


25. Kelly PJ, Archbold P, Price JH, Cardwell C, McCluggage WG: Serum CA19.9 levels are commonly elevated in primary ovarian mucinous tumours but cannot be used to predict the histological subtype. J Clin Pathol; 2010 Feb;63(2):169-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum CA19.9 levels are commonly elevated in primary ovarian mucinous tumours but cannot be used to predict the histological subtype.
  • AIMS: CA19.9 is a monosialoganglioside secreted by mucinous tumours of the gastrointestinal tract, including the pancreas and biliary tree.
  • Limited studies have shown that this tumour marker may also be elevated in primary ovarian mucinous neoplasms, but no study has assessed whether serum CA19.9 levels can be used to predict if a primary ovarian mucinous tumour is benign, borderline or malignant.
  • The aim of this study was to correlate the serum CA19.9 level with the histological features in a large series of primary ovarian mucinous neoplasms.
  • METHODS: 144 cases of primary ovarian mucinous neoplasm (79 benign, 45 borderline and 20 malignant) were identified in which a preoperative serum CA19.9 level had been performed.
  • The association between the serum levels and the histological subtype and a variety of other parameters was investigated.
  • In a subset of cases, immunohistochemical staining for CA19.9 was performed on tumour blocks.
  • RESULTS: Serum CA19.9 levels were elevated in 27%, 38% and 40% of mucinous cystadenomas, borderline mucinous tumours and mucinous carcinomas, respectively.
  • Markedly elevated levels of serum CA19.9 were observed in each group, with the highest serum CA19.9 measurements being noted in borderline mucinous tumours.
  • There was no relationship between the serum CA19.9 level and whether the tumours were benign, borderline or malignant (Kruskal-Wallis test p value=0.32).
  • A weak but statistically significant correlation was found between tumour maximum dimension and CA19.9 level (Spearman's rank correlation coefficient=0.17, p=0.04).
  • In those cases in which CA19.9 immunohistochemistry was performed, all tumours showed positive staining for CA19.9, with 60% of these cases being associated with an elevated serum CA19.9 level.
  • CONCLUSION: Preoperative CA19.9 levels cannot be used to predict whether a suspected ovarian mucinous tumour is benign, borderline or malignant.
  • Markedly elevated serum levels (>1000 U/ml) may be found in benign mucinous neoplasms as well as in borderline and malignant tumours.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. CA-19-9 Antigen / blood. Cystadenoma, Mucinous / diagnosis. Ovarian Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20154039.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CA-19-9 Antigen
  •  go-up   go-down


26. Wei G, Xiaodong T, Yi Y, Ji T: Strategy of surgical treatment of sacral neurogenic tumors. Spine (Phila Pa 1976); 2009 Nov 1;34(23):2587-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Strategy of surgical treatment of sacral neurogenic tumors.
  • STUDY DESIGN: Assessment of different surgical approaches and procedures to remove different types of neurogenic tumors (Types I-IV).
  • OBJECTIVE: To aid surgeons faced with operating on a sacral neurogenic tumor by providing guidelines for determining the best surgical approach to use based on the way a neurogenic tumor presents.
  • SUMMARY OF BACKGROUND DATA: It is often difficult to determine the best surgical approach to use when operating on sacral neurogenic tumors.
  • This retrospective study reports on the outcomes of patients with sacral neurogenic tumors and the surgical approach used in each case in order to better assess the most appropriate surgical approach and procedure to use with each tumor type.
  • METHODS: Between July 1998 and July 2006, 48 cases (18 males) with sacral neurogenic tumors were admitted and treated.
  • There were 41 cases with benign tumors and 7 cases of malignant tumors.
  • Depending on how the tumor presented, 1 of 3 surgical approaches was used, an anterior approach (7 patients), a posterior approach (22 patients), or a combined anterior-posterior approach (19 patients).
  • RESULTS: For the cases of Type I and the cases of Type II and III in which tumors grew forward but were lower than S1 level, surgical resection of tumors required a simple posterior approach.
  • The cases of Type II and III in which tumors grew forward and expanded higher than S1 level required a combined anterior-posterior approach.
  • For cases of Type IV, a simple anterior approach for resection of tumors was used.
  • CONCLUSION: In surgical resection of sacral neurogenic tumors, surgical approach depends on the location and size of the tumors.
  • Intraspinal tumors should be excised from a posterior approach.
  • For giant neurogenic tumors that arise from the sacrum and involve the spinal canal, surgical resection should be done by a combined anterior-posterior approach.
  • Giant presacral neurogenic tumors located below the S1 level can be removed by a posterior approach.
  • The anterior surgical approach should be used for giant presacral neurogenic tumors that are located above S1 and do not involve the spinal canal.
  • [MeSH-major] Neurofibroma / surgery. Neurosurgical Procedures / methods. Sacrum / surgery. Spinal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19927109.001).
  • [ISSN] 1528-1159
  • [Journal-full-title] Spine
  • [ISO-abbreviation] Spine
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. King I, Itterson M, Bermudes D: Tumor-targeted Salmonella typhimurium overexpressing cytosine deaminase: a novel, tumor-selective therapy. Methods Mol Biol; 2009;542:649-59
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-targeted Salmonella typhimurium overexpressing cytosine deaminase: a novel, tumor-selective therapy.
  • Genetically modified, nonpathogenic Salmonella offer a potential way to induce direct tumoricidal activity or to deliver tumoricidal agents to tumors.
  • An attenuated strain of Salmonella typhimurium, called VNP20009, and its derivative TAPET-CD (which expresses Escherichia coli cytosine deaminase) are highly selective for tumor tissue and can deliver therapeutic proteins preferentially to tumors in preclinical models.
  • [MeSH-major] Cytosine Deaminase / metabolism. Genetic Therapy / methods. Neoplasms / therapy. Salmonella typhimurium / genetics

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19565926.001).
  • [ISSN] 1064-3745
  • [Journal-full-title] Methods in molecular biology (Clifton, N.J.)
  • [ISO-abbreviation] Methods Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.5.4.1 / Cytosine Deaminase; U3P01618RT / Fluorouracil
  •  go-up   go-down


28. Pinchot SN, Holen K, Sippel RS, Chen H: Carcinoid tumors. Oncologist; 2008 Dec;13(12):1255-69
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoid tumors.
  • Carcinoid tumors are rare, slow-growing neuroendocrine tumors arising from the enterochromaffin cells disseminated throughout the gastrointestinal and bronchopulmonary systems.
  • Though they have been traditionally classified based on embryologic site of origin, morphologic pattern, and silver affinity, newer classification systems have been developed to emphasize the considerable clinical and histopathologic variability of carcinoid tumors found within each embryologic site of origin.
  • These neoplasms pose a diagnostic challenge because they are often innocuous at the time of presentation, emphasizing the need for a multidisciplinary diagnostic approach using biochemical analysis, standard cross-sectional imaging, and newer advances in nuclear medicine.
  • Similarly, treatment of both primary and disseminated carcinoid disease reflects the need for a multidisciplinary approach, with surgery remaining the only curative modality.
  • The prognosis for patients with these tumors is generally favorable; however, it can be quite variable and is related to the location of the primary tumor, extent of metastatic disease at initial presentation, and time of diagnosis.

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 2001 Jun;88(6):865-72 [11412260.001]
  • [Cites] Hepatogastroenterology. 2001 May-Jun;48(39):720-3 [11462912.001]
  • [Cites] Surg Oncol. 2000 Dec;9(4):173-9 [11476988.001]
  • [Cites] Cancer. 2001 Oct 15;92(8):2204-10 [11596039.001]
  • [Cites] Surgery. 2001 Oct;130(4):677-82; discussion 682-5 [11602899.001]
  • [Cites] Hum Pathol. 2001 Oct;32(10):1094-101 [11679944.001]
  • [Cites] Ann Oncol. 2001 Sep;12(9):1295-300 [11697843.001]
  • [Cites] Am J Surg. 2001 Dec;182(6):552-7 [11839316.001]
  • [Cites] Eur J Surg Oncol. 2002 Mar;28(2):140-6 [11884049.001]
  • [Cites] Cancer Control. 2002 Jan-Feb;9(1):67-79 [11907468.001]
  • [Cites] Arch Surg. 2002 Apr;137(4):422-6; discussion 427 [11926946.001]
  • [Cites] Semin Nucl Med. 2002 Apr;32(2):84-91 [11965603.001]
  • [Cites] J Nucl Med. 2002 May;43(5):610-6 [11994522.001]
  • [Cites] World J Surg. 2002 Aug;26(8):991-7 [12016480.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):934-59 [12569593.001]
  • [Cites] N Engl J Med. 2003 Mar 13;348(11):1005-15 [12637610.001]
  • [Cites] Am J Surg Pathol. 2003 Jun;27(6):811-7 [12766586.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2003 Aug;285(2):G245-54 [12851216.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2689-96 [12860945.001]
  • [Cites] Endocr Relat Cancer. 2003 Dec;10(4):451-8 [14713257.001]
  • [Cites] Ann Surg. 2004 Jul;240(1):117-22 [15213627.001]
  • [Cites] J Gastrointest Surg. 2004 Sep-Oct;8(6):742-56 [15358337.001]
  • [Cites] Cancer. 1967 Sep;20(9):1515-9 [6038395.001]
  • [Cites] Cancer. 1971 Oct;28(4):990-8 [4106849.001]
  • [Cites] Hum Pathol. 1976 Jul;7(4):461-9 [939542.001]
  • [Cites] Ann Thorac Surg. 1976 Sep;22(3):270-7 [962413.001]
  • [Cites] Cancer. 1983 Mar 1;51(5):878-81 [6821853.001]
  • [Cites] Lab Invest. 1983 Nov;49(5):519-37 [6138458.001]
  • [Cites] Cancer. 1985 May 15;55(10):2472-6 [3986742.001]
  • [Cites] Am J Surg. 1985 Jun;149(6):775-9 [2409828.001]
  • [Cites] J Pathol. 1986 Feb;148(2):141-7 [3512805.001]
  • [Cites] N Engl J Med. 1986 Sep 11;315(11):663-6 [2427948.001]
  • [Cites] Digestion. 1986;35 Suppl 1:42-55 [3792671.001]
  • [Cites] Am J Med. 1986 Dec 22;81(6B):41-8 [2432780.001]
  • [Cites] Semin Oncol. 1987 Sep;14(3):237-46 [2442815.001]
  • [Cites] N Engl J Med. 1987 Dec 31;317(27):1699-701 [3696178.001]
  • [Cites] Endocrinol Metab Clin North Am. 1989 Jun;18(2):557-68 [2663485.001]
  • [Cites] Respir Med. 1989 Jul;83(4):305-8 [2608951.001]
  • [Cites] Cancer. 1968 Feb;21(2):270-8 [4952505.001]
  • [Cites] J Clin Gastroenterol. 1990;12 Suppl 2:S7-12 [2246496.001]
  • [Cites] Clin Chem. 1992 Apr;38(4):534-40 [1373675.001]
  • [Cites] Eur J Cardiothorac Surg. 1993;7(3):121-4; discussion 125 [8384862.001]
  • [Cites] Ann Surg. 1993 Apr;217(4):385-90 [8466309.001]
  • [Cites] J Clin Invest. 1994 Mar;93(3):1321-5 [8132773.001]
  • [Cites] Dis Colon Rectum. 1994 May;37(5):482-91 [8181412.001]
  • [Cites] Br J Surg. 1994 Jul;81(7):1007-9 [7922047.001]
  • [Cites] Endocrinology. 1994 Dec;135(6):2814-7 [7988476.001]
  • [Cites] Am J Surg. 1995 Jan;169(1):36-42; discussion 42-3 [7817996.001]
  • [Cites] Ann Thorac Surg. 1995 Jan;59(1):78-83 [7818364.001]
  • [Cites] Circulation. 1995 Aug 15;92(4):790-5 [7641358.001]
  • [Cites] World J Surg. 1996 Feb;20(2):168-72 [8661813.001]
  • [Cites] World J Surg. 1996 Feb;20(2):183-8 [8661815.001]
  • [Cites] Eur J Cancer. 1996 Oct;32A(11):1924-32 [8943676.001]
  • [Cites] Cancer. 1997 Feb 15;79(4):813-29 [9024720.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Aug;82(8):2622-8 [9253344.001]
  • [Cites] Gastroenterology. 1997 Sep;113(3):773-81 [9287968.001]
  • [Cites] Surgery. 1997 Oct;122(4):801-8 [9347859.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):858-68 [10080850.001]
  • [Cites] Ann Surg. 1999 Jun;229(6):815-21; discussion 822-3 [10363895.001]
  • [Cites] Ann Oncol. 1999;10 Suppl 2:S3-8 [10399026.001]
  • [Cites] Nature. 1952 May 10;169(4306):800-1 [14941051.001]
  • [Cites] Cancer. 1953 May;6(3):555-67 [13042778.001]
  • [Cites] Lancet. 1963 Feb 2;1(7275):238-9 [14000847.001]
  • [Cites] Acta Oncol. 2004;43(7):617-25 [15545182.001]
  • [Cites] J Surg Oncol. 2005 Mar 1;89(3):151-60 [15719376.001]
  • [Cites] Gut. 2005 Jun;54 Suppl 4:iv1-16 [15888809.001]
  • [Cites] Ann Surg. 2005 Jun;241(6):839-45; discussion 845-6 [15912033.001]
  • [Cites] J Surg Res. 2005 Jun 1;126(1):102-5 [15916982.001]
  • [Cites] Mol Cancer Ther. 2005 Jun;4(6):910-7 [15956248.001]
  • [Cites] Ann Surg. 2005 Jul;242(1):64-73 [15973103.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2005 Oct;289(4):G636-42 [16160079.001]
  • [Cites] Endocr Relat Cancer. 2005 Dec;12(4):683-99 [16322317.001]
  • [Cites] Curr Opin Oncol. 2006 Jan;18(1):9-15 [16357558.001]
  • [Cites] Dis Colon Rectum. 2005 Dec;48(12):2264-71 [16258711.001]
  • [Cites] Anticancer Drugs. 2006 Feb;17(2):139-42 [16428931.001]
  • [Cites] Surg Oncol Clin N Am. 2006 Jul;15(3):463-78 [16882492.001]
  • [Cites] Am Fam Physician. 2006 Aug 1;74(3):429-34 [16913162.001]
  • [Cites] Eur J Cardiothorac Surg. 2007 Feb;31(2):192-7 [17196822.001]
  • [Cites] Ann Diagn Pathol. 2007 Apr;11(2):113-6 [17349570.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1967-73 [17513802.001]
  • [Cites] Hematol Oncol Clin North Am. 2007 Jun;21(3):409-32; vii [17548032.001]
  • [Cites] Chest. 2007 Jun;131(6):1635-43 [17400673.001]
  • [Cites] Endocr Relat Cancer. 2007 Jun;14(2):221-32 [17639039.001]
  • [Cites] J Endocrinol Invest. 2007 Jul-Aug;30(7):601-2 [17848844.001]
  • [Cites] J Gastrointest Surg. 2007 Nov;11(11):1515-20; discussion 1520 [17874277.001]
  • [Cites] Curr Opin Oncol. 2008 Jan;20(1):1-12 [18043250.001]
  • [Cites] Surgery. 2007 Dec;142(6):959-64; discussion 959-64 [18063082.001]
  • [Cites] Radiat Med. 2008 Jan;26(1):28-32 [18236131.001]
  • [Cites] J Surg Oncol. 2008 Mar 1;97(3):253-8 [18264984.001]
  • [Cites] Eur J Surg Oncol. 2008 Mar;34(3):289-96 [18068329.001]
  • [Cites] Tumori. 2007 Nov-Dec;93(6):587-90 [18338494.001]
  • [Cites] J Clin Oncol. 2008 Mar 20;26(9):1489-95 [18349401.001]
  • [Cites] World J Surg. 2008 May;32(5):930-8 [18324347.001]
  • [Cites] J Clin Oncol. 2008 Jun 20;26(18):3063-72 [18565894.001]
  • [Cites] Cancer. 2008 Jul 1;113(1):5-21 [18473355.001]
  • [Cites] Auris Nasus Larynx. 2009 Apr;36(2):228-31 [18617341.001]
  • [Cites] Int J Cardiol. 2008 Oct 13;129(3):318-24 [18571250.001]
  • [Cites] Ital J Gastroenterol Hepatol. 1999 Oct;31 Suppl 2:S198-201 [10604130.001]
  • [Cites] Ann Oncol. 2000 Apr;11(4):491-3 [10847473.001]
  • [Cites] Eur J Cardiothorac Surg. 2000 Aug;18(2):156-61 [10925223.001]
  • [Cites] Digestion. 2000;62 Suppl 1:33-8 [10940685.001]
  • (PMID = 19091780.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA090217-08; United States / NCI NIH HHS / CA / T32 CA090217-09; United States / NCI NIH HHS / CA / T32 CA090217-10; United States / NCI NIH HHS / CA / T32 CA090217; United States / NCI NIH HHS / CA / CA090217-10; United States / NCI NIH HHS / CA / T32 CA090217-08; United States / NCI NIH HHS / CA / CA090217-09
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 114
  • [Other-IDs] NLM/ NIHMS216000; NLM/ PMC2901509
  •  go-up   go-down


29. Ponce Díaz-Reixa JL, Martínez Breijo S, Gómez Veiga F, López García D, Alvarez Castelo L, Chantada Abal V, González Martín M: [Neprhon sparing surgery for renal tumours on kidney transplantation]. Actas Urol Esp; 2010 Oct;34(9):811-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neprhon sparing surgery for renal tumours on kidney transplantation].
  • [Transliterated title] Cirugía conservadora en el tratamiento de los tumores renales de novo en injertos de trasplante renal.
  • INTRODUCTION: Nowadays, nephron sparing surgery for renal carcinoma achieves good oncological results, similar to radical surgery, with the advantage of preserving renal function.
  • Renal cell carcinomas appear de novo in 4.6% of post-transplant patients compared with 3% of tumors in the general population, affecting less than 10% to renal allograft.
  • OBJECTIVE: The purpose is to analyze our experience and make a literature review about the role of nephron sparing surgery to treat de novo renal tumours in renal grafts.
  • MATERIAL AND METHODS: A retrospective and descriptive analysis has been realized, finding four patients who presented with de novo renal tumours over renal graft after kidney transplantation and treated by nephron sparing surgery.
  • Oncological and functional results were reviewed and analyzed.
  • Medium size was 2.4cm. (1.5-3.5) and final histology showed medium tumours size of 3.0cm. (1.7-3.5).
  • CONCLUSIONS: NSS could be an option to treat graft tumours in selected cases, preserving renal function.
  • In our experience, is a safe and efficient treatment in patients with small de novo renal tumours over renal graft.
  • [MeSH-major] Kidney Neoplasms / surgery. Kidney Transplantation. Nephrectomy / methods. Postoperative Complications / surgery


30. Sitic S, Korac P, Peharec P, Zovko G, Perisa MM, Gasparov S: Bcl-2 and MALT1 Genes are not involved in the oncogenesis of uterine tumors resembling ovarian sex cord tumors. Pathol Oncol Res; 2007;13(2):153-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bcl-2 and MALT1 Genes are not involved in the oncogenesis of uterine tumors resembling ovarian sex cord tumors.
  • Uterine tumors resembling ovarian sex cord tumors (UTROSCT) are rare entities.
  • Group I comprises typical endometrial stromal neoplasms with focal areas resembling ovarian sex cord elements and group II are predominantly or completely composed of ovarian sex cord-like elements.
  • The tumor occurred in a 76-year-old woman who presented with vaginal bleeding.
  • The tumor was lobulated, firm, yellow and histologically composed of sex cord-like elements.
  • Tumor cells expressed vimentin, CD10, CD99 and alpha-actin.
  • [MeSH-major] Caspases / physiology. Neoplasm Proteins / physiology. Proto-Oncogene Proteins c-bcl-2 / physiology. Sex Cord-Gonadal Stromal Tumors / physiopathology. Uterine Neoplasms / physiopathology
  • [MeSH-minor] Actins / genetics. Actins / metabolism. Aged. Antigens, CD / genetics. Antigens, CD / metabolism. Antigens, CD99. Cell Adhesion Molecules / genetics. Cell Adhesion Molecules / metabolism. Cell Differentiation / physiology. Female. Gene Expression Regulation, Neoplastic. Humans. Neprilysin / genetics. Neprilysin / metabolism. Translocation, Genetic / genetics. Uterus / pathology. Uterus / physiopathology. Vimentin / genetics. Vimentin / metabolism

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 1999 Jun;30(6):671-9 [10374776.001]
  • [Cites] Am J Clin Pathol. 1976 Sep;66(3):512-25 [961630.001]
  • [Cites] Histopathology. 2000 Jan;36(1):69-86 [10632755.001]
  • [Cites] Am J Surg Pathol. 1998 Jan;22(1):57-63 [9422316.001]
  • [Cites] Virchows Arch. 2001 Jul;439(1):97-101 [11499847.001]
  • [Cites] Gynecol Oncol. 2004 Jan;92(1):347-52 [14751183.001]
  • [Cites] Pathol Int. 1997 Jun;47(6):412-5 [9211530.001]
  • [Cites] J Histochem Cytochem. 1983 Nov;31(11):1333-5 [6619538.001]
  • [Cites] Hum Pathol. 1986 Jan;17(1):91-4 [3943854.001]
  • [Cites] Diagn Mol Pathol. 2003 Sep;12(3):174-80 [12960700.001]
  • [Cites] Am J Surg Pathol. 1998 Sep;22(9):1078-82 [9737240.001]
  • [Cites] Am J Surg Pathol. 1980 Feb;4(1):59-74 [7361995.001]
  • [Cites] Pathol Int. 2002 Feb;52(2):164-8 [11940223.001]
  • [Cites] Cancer Genet Cytogenet. 1984 Oct;13(2):181-3 [6478442.001]
  • [Cites] Int J Gynecol Pathol. 2003 Jul;22(3):297-302 [12819400.001]
  • [Cites] Best Pract Res Clin Haematol. 2005 Mar;18(1):57-68 [15694184.001]
  • [Cites] Pathologe. 1995 Nov;16(6):421-5 [8570562.001]
  • (PMID = 17607378.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Actins; 0 / Antigens, CD; 0 / Antigens, CD99; 0 / CD99 protein, human; 0 / Cell Adhesion Molecules; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Vimentin; EC 3.4.22.- / Caspases; EC 3.4.22.- / MALT1 protein, human; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


31. Kelley SP, Ashford RU, Rao AS, Dickson RA: Primary bone tumours of the spine: a 42-year survey from the Leeds Regional Bone Tumour Registry. Eur Spine J; 2007 Mar;16(3):405-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary bone tumours of the spine: a 42-year survey from the Leeds Regional Bone Tumour Registry.
  • We conducted a review of the Leeds Regional Bone Tumour Registry for primary bone tumours of the spine since establishment in 1958 until year 2000.
  • To analyse the incidence of primary tumours of the spine and to record the site of occurrence, sex distribution, survival and pathology of these tumours.
  • Primary tumours of the spine are particularly rare, accounting for between 4 and 13% of published series of primary bone tumours.
  • The Leeds Bone Tumour Registry was reviewed and a total of 2,750 cases of bone tumours and tumour-like cases were analysed.
  • Consultants in orthopaedic surgery, neurosurgery, oncology and pathology in North and West Yorkshire and Humberside contribute to the Registry.
  • Primary bone tumours of the osseous spine constitute only 126 of the 2,750 cases (4.6%).
  • Chordoma was the most frequent tumour in the cervical and sacral regions, while the most common diagnosis overall was multiple myeloma and plasmacytoma.
  • The mean age of presentation was 42 years and pain was the most common presenting symptom, occurring in 95% of malignant and 76% of benign tumours.
  • Neurological involvement occurred in 52% of malignant tumours and usually meant a poor prognosis.
  • The establishment of Bone Tumour Registries is the only way that sufficient data on large numbers of these rare tumours can be accumulated to provide a valuable and otherwise unavailable source of information for research, education and clinical follow-up.
  • [MeSH-major] Chordoma / pathology. Multiple Myeloma / pathology. Osteosarcoma / pathology. Plasmacytoma / pathology. Registries / statistics & numerical data. Spinal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Bone Joint Surg Am. 1986 Apr;68(4):483-94 [3957973.001]
  • [Cites] Spine (Phila Pa 1976). 1987 Nov;12(9):843-51 [3441830.001]
  • [Cites] Spine (Phila Pa 1976). 1990 Feb;15(2):137-40 [2326708.001]
  • [Cites] Int Orthop. 1994 Jun;18(3):180-3 [7927969.001]
  • [Cites] J Bone Joint Surg Am. 1996 May;78(5):656-63 [8642021.001]
  • [Cites] Pathology. 2005 Aug;37(4):278-83 [16194825.001]
  • [Cites] Neurochirurgia (Stuttg). 1982 Sep;25(5):153-64 [7155253.001]
  • [Cites] J Bone Joint Surg Am. 1967 Jan;49(1):111-21 [6015754.001]
  • [Cites] J Bone Joint Surg Br. 1974 Aug;56B(3):534-40 [4529234.001]
  • [Cites] J Bone Joint Surg Br. 1976 May;58(2):202-11 [932083.001]
  • [Cites] Br J Cancer. 1977 Oct;36(4):511-22 [271010.001]
  • [Cites] J Bone Joint Surg Br. 1978 Aug;60-B(3):406-11 [681419.001]
  • [Cites] Cancer. 1980 Aug 1;46(3):595-604 [6930985.001]
  • [Cites] Cancer Causes Control. 2001 Jan;12(1):1-11 [11227920.001]
  • (PMID = 16865376.001).
  • [ISSN] 0940-6719
  • [Journal-full-title] European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
  • [ISO-abbreviation] Eur Spine J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2200710
  •  go-up   go-down


32. Carl-McGrath S, Lendeckel U, Ebert M, Röcken C: Ectopeptidases in tumour biology: a review. Histol Histopathol; 2006 12;21(12):1339-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ectopeptidases in tumour biology: a review.
  • Ectopeptidases may regulate the release of many growth factors and their receptors into the circulation, as well as activating or inactivating circulating signalling molecules, thereby regulating the availability of ligands for the corresponding receptors.
  • A versatile range of functions, such as the modulation of cell-signalling, matrix degradation, cell adhesion and migration, which are particularly important for tumour cell growth and dissemination, are attributed largely to the ectopeptidases.
  • Even a minor disruption in the normal proteolytic equilibrium can influence tumor progression, and a range of ectopeptidases, including neutral endopeptidase 24.11, aminopeptidase N, dipeptidyl peptidase IV, angiotensin-converting enzyme, and the disintegrin-metalloproteinases, have been shown to be involved in tumour development and metastasis.
  • The ability to degrade and inactivate peptide hormones and growth factors, with the resultant modulation of the tumour-host interface, may play an important role in the pathogenesis, development or progression of a range of cancers, and the extracellular orientation of the ectopeptidases makes them particularly accessible, and therefore interesting, with regard to therapeutical applications.
  • [MeSH-major] Neoplasms / enzymology. Peptide Hydrolases / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16977585.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Membrane Proteins; EC 3.4.- / Peptide Hydrolases
  • [Number-of-references] 211
  •  go-up   go-down


33. Palmer RD, Foster NA, Vowler SL, Roberts I, Thornton CM, Hale JP, Schneider DT, Nicholson JC, Coleman N: Malignant germ cell tumours of childhood: new associations of genomic imbalance. Br J Cancer; 2007 Feb 26;96(4):667-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant germ cell tumours of childhood: new associations of genomic imbalance.
  • Malignant germ cell tumours (MGCTs) of childhood are a rare group of neoplasms that comprise many histological subtypes and arise at numerous different sites.
  • Genomic imbalances have been described in these tumours but, largely because of the paucity of cases reported in the literature, it is unclear how they relate to abnormalities in adult MGCTs and impact on potential systems for classifying GCTs.
  • We have used metaphase-based comparative genomic hybridisation to analyse the largest series of paediatric MGCTs reported to date, representing 34 primary tumours (22 yolk sac tumours (YSTs), 11 germinomatous tumours and one metastatic embryonal carcinoma) occurring in children from birth to age 16, including 17 ovarian MGCTs.
  • The YSTs showed an increased frequency of 1p- (P=0.003), 3p+ (P=0.02), 4q- (P=0.07) and 6q- (P=0.004) compared to germinomatous tumours.
  • Conversely, MGCTs without 12p gain displayed a significantly increased frequency of loss on 16p (P=0.04), suggesting that this imbalance may contribute to tumour development in such cases.
  • This data provides new insight into the biology of this under-investigated tumour group and will direct future studies on the significance of specific genetic abnormalities.
  • [MeSH-major] Chromosome Aberrations. Chromosomes, Human, Pair 12 / genetics. Neoplasms, Germ Cell and Embryonal / genetics
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Follow-Up Studies. Humans. Infant. Infant, Newborn. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Genet Cytogenet. 1990 Mar;45(1):49-53 [2302685.001]
  • [Cites] Cancer Genet Cytogenet. 1988 Nov;36(1):7-11 [2849502.001]
  • [Cites] Genes Chromosomes Cancer. 1993 Jan;6(1):61-3 [7680224.001]
  • [Cites] Cancer Res. 1994 Mar 15;54(6):1542-4 [8137260.001]
  • [Cites] Pediatr Pathol. 1994 Jul-Aug;14(4):695-708 [7971587.001]
  • [Cites] Genes Chromosomes Cancer. 1994 Sep;11(1):40-50 [7529045.001]
  • [Cites] Klin Padiatr. 1995 Jul-Aug;207(4):235-41 [7564160.001]
  • [Cites] Hum Genet. 1995 Dec;96(6):644-50 [8522320.001]
  • [Cites] Genes Chromosomes Cancer. 1995 Oct;14(2):133-44 [8527395.001]
  • [Cites] Cancer Genet Cytogenet. 1996 Jul 15;89(2):146-52 [8697422.001]
  • [Cites] Cancer Genet Cytogenet. 1996 Oct 1;91(1):13-27 [8908162.001]
  • [Cites] Genes Chromosomes Cancer. 1996 Oct;17(2):78-87 [8913724.001]
  • [Cites] Cancer Genet Cytogenet. 1998 Jan 15;100(2):124-8 [9428355.001]
  • [Cites] Cancer Res. 1998 Jul 15;58(14):3105-10 [9679978.001]
  • [Cites] Virchows Arch. 1998 Dec;433(6):571-4 [9870692.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Jun;25(2):134-46 [10337997.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Nov;155(1):25-32 [15527899.001]
  • [Cites] Br J Cancer. 2004 Dec 13;91(12):2063-70 [15545968.001]
  • [Cites] Nat Rev Cancer. 2005 Mar;5(3):210-22 [15738984.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Aug;43(4):367-76 [15880464.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Sep;44(1):65-75 [15937994.001]
  • [Cites] Mod Pathol. 2006 Jun;19(6):766-71 [16547466.001]
  • [Cites] Mod Pathol. 2006 Jun;19(6):864-73 [16607373.001]
  • [Cites] Br J Cancer. 1998;77(2):305-13 [9461002.001]
  • [Cites] Int J Cancer. 1999 Dec 10;83(6):809-14 [10597200.001]
  • [Cites] J Pediatr Hematol Oncol. 2000 Mar-Apr;22(2):100-5 [10779021.001]
  • [Cites] Cancer Res. 2000 Jun 1;60(11):3025-30 [10850452.001]
  • [Cites] J Pathol. 2000 Jun;191(2):187-92 [10861580.001]
  • [Cites] Lab Invest. 2000 Jul;80(7):1055-64 [10908150.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Sep;59(9):815-21 [11005262.001]
  • [Cites] J Clin Oncol. 2000 Nov 15;18(22):3809-18 [11078494.001]
  • [Cites] Oncogene. 2001 Nov 29;20(55):8042-4 [11753688.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1822-31 [11912161.001]
  • [Cites] Genes Chromosomes Cancer. 2002 May;34(1):115-25 [11921289.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Jun;61(6):531-8 [12071636.001]
  • [Cites] Cancer Genet Cytogenet. 2002 May;135(1):57-62 [12072204.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Oct;38(2):117-25 [12939739.001]
  • [Cites] Pediatr Blood Cancer. 2004 Feb;42(2):169-75 [14752882.001]
  • [Cites] Cancer Genet Cytogenet. 1990 Nov 1;50(1):153-60 [2253184.001]
  • (PMID = 17285132.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2360055
  •  go-up   go-down


34. Jaoude WA, Lau C, Sugiyama G, Duncan A: Management of ampullary carcinoid tumors with pancreaticoduodenectomy. J Surg Case Rep; 2010;2010(8):4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of ampullary carcinoid tumors with pancreaticoduodenectomy.
  • A pancreaticoduodenectomy was performed and the pathology was consistent with carcinoid tumor.
  • Carcinoid tumors of the ampulla of Vater are rare tumors of the gastrointestinal tract, accounting for 0.3-1% of gastrointestinal carcinoids.
  • Management of ampullary carcinoid tumor with pancreaticoduodenectomy is in accordance with current recommendations.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © JSCR.
  • (PMID = 24946347.001).
  • [ISSN] 2042-8812
  • [Journal-full-title] Journal of surgical case reports
  • [ISO-abbreviation] J Surg Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3649155
  •  go-up   go-down


35. Haag P, Frauscher F, Gradl J, Seitz A, Schäfer G, Lindner JR, Klibanov AL, Bartsch G, Klocker H, Eder IE: Microbubble-enhanced ultrasound to deliver an antisense oligodeoxynucleotide targeting the human androgen receptor into prostate tumours. J Steroid Biochem Mol Biol; 2006 Dec;102(1-5):103-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microbubble-enhanced ultrasound to deliver an antisense oligodeoxynucleotide targeting the human androgen receptor into prostate tumours.
  • We have shown recently that downregulation of the androgen receptor (AR), one of the key players in prostate tumor cells, with short antisense oligodeoxynucleotides (ODNs) results in inhibition of prostate tumor growth.
  • In fact, transfection of prostate tumor cells with antisense AR ODNs using microbubble-enhanced ultrasound resulted in 49% transfected cells, associated with a decrease in AR expression compared to untreated controls.
  • In vivo, uptake of a digoxigenin-labelled ODN was found in prostate tumour xenografts in nude mice following intratumoral or intravenous injection of loaded microbubbles and subsequent exposure of the tumour to ultrasound, respectively.
  • Uptake of the ODN was also observed in tumors after treatment with ultrasound alone, with only minor differences compared to the combined use of microbubbles and ultrasound.
  • [MeSH-major] Drug Delivery Systems. Oligodeoxyribonucleotides, Antisense / pharmacology. Prostatic Neoplasms / therapy. Receptors, Androgen / metabolism
  • [MeSH-minor] Androgen Receptor Antagonists. Animals. Blotting, Western. Down-Regulation. Gene Expression Regulation, Neoplastic. Genetic Therapy. Humans. Male. Mice. Mice, Inbred BALB C. Mice, Nude. Microbubbles. RNA, Messenger / antagonists & inhibitors. RNA, Messenger / genetics. RNA, Messenger / metabolism. Tumor Cells, Cultured. Ultrasonics. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17055720.001).
  • [ISSN] 0960-0760
  • [Journal-full-title] The Journal of steroid biochemistry and molecular biology
  • [ISO-abbreviation] J. Steroid Biochem. Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / AR protein, human; 0 / Androgen Receptor Antagonists; 0 / Oligodeoxyribonucleotides, Antisense; 0 / RNA, Messenger; 0 / Receptors, Androgen
  •  go-up   go-down


36. Kodama S, Hirano T, Suzuki M: [Endoscopic medial maxillectomy for maxillary sinus tumors: indications and clinical outcome]. Nihon Jibiinkoka Gakkai Kaiho; 2010 Feb;113(2):53-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Endoscopic medial maxillectomy for maxillary sinus tumors: indications and clinical outcome].
  • Endoscopic sinus surgery (ESS) widely conducted in nasal and paranasal sinus surgery provides superior magnification, illumination, and angled visualization, enabling the surgeon to isolate the tumor base and accurately define disease extent.
  • Endoscopic medial maxillectomy (EMM), an advanced ESS procedure, effectively treats benign sinonasal neoplasms such as inverted papilloma.
  • We analyzed a series of EMM cases and their clinical outcomes, including 9 inverted papillomas, 1 solitary fibrous tumor, 1 hemangioma, 1 blood boil and 1 esthesioneuroblastoma.
  • All tumors were treated endoscopically and the postoperative course was uneventful.
  • We found EMM to be safe and efficacious in resecting maxillary sinus tumors thanks to its improved accessibility and visualization.
  • In conclusion, EMM enables complete removal of benign tumors from the maxillary sinus, having the advantages of no external incision, decreased blood loss, low morbidity, shorter hospital stay, and the possibility of repetition in recurrence, compared to conventional approaches.
  • EMM may thus become the treatment of choice for maxillary sinus tumors.
  • [MeSH-major] Endoscopy. Maxillary Sinus / surgery. Maxillary Sinus Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Hemangioma / surgery. Humans. Male. Middle Aged. Papilloma, Inverted / surgery. Solitary Fibrous Tumors / surgery. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20225704.001).
  • [ISSN] 0030-6622
  • [Journal-full-title] Nihon Jibiinkoka Gakkai kaiho
  • [ISO-abbreviation] Nippon Jibiinkoka Gakkai Kaiho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


37. Botteri E, Iodice S, Maisonneuve P, Alfieri M, Burzoni N, Manghi L, Martinetti M, Montanari B, Albertazzi E, Bazolli B, Rotmensz N: Case mix at the European Institute of Oncology: first report of the Tumour Registry, 2000-2002. Ecancermedicalscience; 2009;3:149
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case mix at the European Institute of Oncology: first report of the Tumour Registry, 2000-2002.
  • INTRODUCTION: An institutional and centralized hospital-based tumour registry (TR) is the ideal supporting tool for the organization and management of clinical data in a comprehensive cancer centre.
  • The purpose of this paper is to describe the development of the TR at the European Institute of Oncology (IEO), Milan, Italy, from its origin to its current applications.
  • MATERIAL AND METHODS: After a series of meetings with members of administrative, clinical, research and informatics departments, the TR was activated in March 2006 with the aim of collecting data on all the individuals referred to the institute, with or at risk of developing a tumour.
  • A minimum dataset of variables was defined and data collection was divided into four forms, which together gather all the relevant data on patients, tumours, treatments and subsequent events.
  • RESULTS: After a six-month pilot period, which involved the training of the tumour registrars, adjustments to the structure of the registry, development of a data quality control procedure and finalization of the operative protocol, since September 2006 the data collection has been fully operative.
  • As of March 2009, data on 69,637 individuals and 43,567 tumours has been reviewed, recoded and registered in the TR.
  • Twenty-two per cent of the tumours (n=9578) were first invasive primaries, diagnosed and treated in the IEO; the most common sites were breast (n=4972), lung (n=627), intestines (n=479) and prostate (n=376).

  • Archivio Istituzionale della Ricerca Unimi. Full text from AIR - Univ. Milan .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22276014.001).
  • [ISSN] 1754-6605
  • [Journal-full-title] Ecancermedicalscience
  • [ISO-abbreviation] Ecancermedicalscience
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3223986
  •  go-up   go-down


38. Rohini K, Mathivanan J, Prabhu PD, Subbakrishna DK, Gope ML, Chandramouli BA, Sampath S, Anandh B, Gope R: Loss of heterozygosity of the p53 gene and deregulated expression of its mRNA and protein in human brain tumors. Mol Cell Biochem; 2007 Jun;300(1-2):101-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of heterozygosity of the p53 gene and deregulated expression of its mRNA and protein in human brain tumors.
  • Tumor-specific alterations at the p53 gene locus were analyzed in 40 human brain tumor samples.
  • Structural changes at the intron 1 region of the p53 gene were analyzed in these tumors by Southern blotting.
  • Among the 40 tumors, 33 were informative and 21 of these (63.6%) informative cases showed loss of heterozygosity (LOH).
  • This is the first report showing LOH at the intron 1 region of p53 gene in human brain tumors.
  • The level of p53 mRNA, p53 protein and Ser 392 phosphorylated p53 protein were also analyzed in all tumor samples.
  • Normal sized p53 mRNA and protein were present in all the tumor samples; however, their levels were 1.5- to 4-fold higher compared to the control suggesting deregulated p53 pathway in these tumors.
  • In addition, the percentage of Ser 392 phosphorylated form of p53 protein was lower in meningiomas and other brain tumor types irrespective of tumor grade.
  • These results also indicate that deregulation of p53 gene could occur at various steps in p53 pathway and suggest an overall deregulation of p53 gene in most brain tumor types.
  • [MeSH-major] Brain Neoplasms / genetics. Gene Expression Regulation, Neoplastic. Loss of Heterozygosity. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Adult. Aged. Cell Line, Tumor. Child. Child, Preschool. Female. Humans. Male. Middle Aged. Phosphoserine / metabolism. RNA, Messenger / genetics. RNA, Messenger / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Oncogene. 2005 May 26;24(23 ):3836-41 [15782125.001]
  • [Cites] Science. 1994 Nov 4;266(5186):807-10 [7973635.001]
  • [Cites] Neurosurg Focus. 2005 Nov 15;19(5):E9 [16398473.001]
  • [Cites] Trends Pharmacol Sci. 2004 Apr;25(4):177-81 [15116721.001]
  • [Cites] Chin Med J (Engl). 2000 Jul;113(7):662-6 [11776043.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 3;101(31):11428-31 [15280533.001]
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4749-54 [15256442.001]
  • [Cites] Cancer. 1991 Sep 15;68(6):1394-400 [1873791.001]
  • [Cites] Pathologica. 2002 Feb;94(1):10-5 [11912872.001]
  • [Cites] J Pediatr Endocrinol Metab. 2002 May;15 Suppl 2:669-73 [12092679.001]
  • [Cites] Yonsei Med J. 1995 Dec;36(6):521-6 [8599254.001]
  • [Cites] Genes Dev. 2005 Sep 15;19(18):2122-37 [16131611.001]
  • [Cites] Cell. 1997 Feb 7;88(3):323-31 [9039259.001]
  • [Cites] Genes Dev. 2001 Jun 1;15(11):1311-33 [11390353.001]
  • [Cites] Cell. 1995 Oct 20;83(2):237-45 [7585941.001]
  • [Cites] Mol Cell Biol. 1999 Mar;19(3):1751-8 [10022862.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Jun;64(6):479-89 [15977639.001]
  • [Cites] Cancer. 2004 Nov 15;101(10):2293-9 [15476282.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18556-61 [16339305.001]
  • [Cites] Mol Cell Biochem. 1991 Sep 18;107(1):55-63 [1784274.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):713-8 [15642949.001]
  • [Cites] Cancer Biol Ther. 2004 Dec;3(12 ):1313-21 [15662135.001]
  • [Cites] J Neurooncol. 1996 Sep;29(3):197-205 [8858525.001]
  • [Cites] Int J Biol Markers. 2002 Jan-Mar;17(1):42-8 [11936585.001]
  • [Cites] Mol Carcinog. 2006 Jan;45(1):38-46 [16299809.001]
  • [Cites] DNA Repair (Amst). 2003 Jul 16;2(7):819-26 [12826282.001]
  • [Cites] Cancer Res. 2003 Jan 1;63(1):179-85 [12517796.001]
  • [Cites] EMBO J. 1993 Mar;12(3):1021-8 [8458320.001]
  • [Cites] Int J Cancer. 2006 Mar 1;118(5):1321-4 [16152609.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 May 26;95(11):6399-402 [9600977.001]
  • [Cites] FEBS Lett. 2005 Dec 19;579(30):6705-15 [16313905.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 7;103(6):1888-93 [16443686.001]
  • [Cites] JAMA. 2005 Feb 2;293(5):615-7 [15687318.001]
  • [Cites] Arch Neurol. 1999 Apr;56(4):439-41 [10199332.001]
  • [Cites] Cancer Res. 2004 Nov 15;64(22):8199-207 [15548685.001]
  • [Cites] J Clin Oncol. 2005 Jan 1;23 (1):154-64 [15625370.001]
  • [Cites] J Med Genet. 2006 Mar;43(3):285-7 [15980114.001]
  • [Cites] Cancer Res. 1997 Jan 15;57(2):304-9 [9000573.001]
  • (PMID = 17180249.001).
  • [ISSN] 0300-8177
  • [Journal-full-title] Molecular and cellular biochemistry
  • [ISO-abbreviation] Mol. Cell. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Tumor Suppressor Protein p53; 17885-08-4 / Phosphoserine
  •  go-up   go-down


39. Cho NH, Lee HW, Lim SY, Kang S, Jung WY, Park CS: Genetic aberrance of sporadic MEN 2A component tumours: analysis of RET. Pathology; 2005 Feb;37(1):10-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic aberrance of sporadic MEN 2A component tumours: analysis of RET.
  • AIM: The molecular pathogenesis of familial multiple endocrine neoplasia (MEN) type 2 (parathyroid adenoma with medullary thyroid carcinoma and adrenal pheochromocytoma) is associated with a germ-line mutation in the RET proto-oncogene.
  • We undertook this study to clarify the relationship between the tumorigenesis of apparently sporadic MEN type 2 component endocrine tumours and RET mutations.
  • METHODS: Direct sequencing for RET exon 10, 11, 12, 13, 14, 15 and 16 and immunohistochemistry for RET monoclonal antibody were performed on the archival tissues of 84 cases of sporadic endocrine tumours, including 22 medullary thyroid carcinomas (MTCs), 35 adrenal pheochromocytomas (APCs), 18 paragangliomas (PGs), and nine parathyroid adenomas (PTAs).
  • [MeSH-major] Multiple Endocrine Neoplasia / genetics. Oncogene Proteins / genetics. Receptor Protein-Tyrosine Kinases / genetics
  • [MeSH-minor] Adrenal Gland Neoplasms / genetics. Adrenal Gland Neoplasms / metabolism. Adult. Base Sequence. Female. Humans. Immunohistochemistry. Male. Middle Aged. Molecular Sequence Data. Paraganglioma / genetics. Paraganglioma / metabolism. Parathyroid Neoplasms / genetics. Parathyroid Neoplasms / metabolism. Pheochromocytoma / genetics. Pheochromocytoma / metabolism. Point Mutation. Polymerase Chain Reaction. Proto-Oncogene Proteins c-ret. Thyroid Neoplasms / genetics. Thyroid Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15875728.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Oncogene Proteins; EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.10.1 / RET protein, human; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases
  •  go-up   go-down


41. Loh AH, Ha C, Chua JH, Seow WT, Chan MY, Tan AM, Chui CH: Delays in diagnosis of pediatric solid tumors in Singapore. J Pediatr Hematol Oncol; 2009 Oct;31(10):734-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Delays in diagnosis of pediatric solid tumors in Singapore.
  • OBJECTIVE: To investigate social, clinical, and disease-related factors associated with diagnostic delay.
  • MATERIALS AND METHODS: Two-hundred and 9 solid tumor cases reported to the Singapore Childhood Cancer Registry at KK Hospital between 1997 and 2007 were reviewed retrospectively.
  • The natural logarithms of total delay times were correlated with social, clinical, and disease factors using univariate and multivariate analysis.
  • Tumor type (P<0.01) and site (P=0.001) were also significantly related.
  • After adjustment for other factors, extracranial germ cell tumors, abdominal tumors and first presentation to nonpediatric emergency departments were significantly associated with shorter total delay.
  • Disease stage remained constant over time, with 30% presenting in stage 4.
  • CONCLUSIONS: Patient age, first healthcare contact, tumor type, and site were significantly related to diagnostic delay in pediatric solid tumors.
  • [MeSH-major] Delivery of Health Care / standards. Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Choosing a Doctor or Health Care Service.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19734807.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


42. Solomayer EF, Becker S, Pergola-Becker G, Bachmann R, Krämer B, Vogel U, Neubauer H, Wallwiener D, Huober J, Fehm TN: Comparison of HER2 status between primary tumor and disseminated tumor cells in primary breast cancer patients. Breast Cancer Res Treat; 2006 Jul;98(2):179-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of HER2 status between primary tumor and disseminated tumor cells in primary breast cancer patients.
  • BACKGROUND: The persistence of disseminated tumor cells (DTC) in bone marrow (BM) of breast cancer patients is associated with poor prognosis.
  • The aims of this study were (1) to determine the HER2 status of DTC in BM of breast cancer patients and (2) to compare the HER2 status of DTC and corresponding primary tumors.
  • HER2 status of the primary tumor was immunohistochemically assessed by the HERCEP-test.
  • Concordance rate of HER2 status between primary tumor and DTC was 62%.
  • In 12 of 20 patients with HER2 negative tumors HER2 positive DTC were detected.
  • CONCLUSIONS: HER2 positive DTC can be detected in patients with HER2 negative primary tumors.
  • [MeSH-major] Breast Neoplasms / chemistry. Receptor, ErbB-2 / analysis


43. Bomgaars LR, Bernstein M, Krailo M, Kadota R, Das S, Chen Z, Adamson PC, Blaney SM: Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol; 2007 Oct 10;25(29):4622-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group Study.
  • PURPOSE: A phase II study was performed to determine the efficacy of irinotecan (IRN) in children with refractory solid tumors.
  • CONCLUSION: IRN 50 mg/m2/d for 5 days every 21 days is well tolerated, but was not effective as a single agent in a spectrum of solid tumors, with the possible exception of patients with medulloblastoma (16% response rate).
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / genetics. Camptothecin / analogs & derivatives. Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17925558.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 98543
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 7673326042 / irinotecan; EC 2.4.1.- / UGT1A1 enzyme; EC 2.4.1.17 / Glucuronosyltransferase; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


44. Vaish M, Mandhani A, Mittal RD, Mittal B: Microsatellite instability as prognostic marker in bladder tumors: a clinical significance. BMC Urol; 2005;5:2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microsatellite instability as prognostic marker in bladder tumors: a clinical significance.
  • METHODS: A total of 44 patients with bladder tumors diagnosed with Transitional Cell Carcinomas [TCC] from lower urinary tract were selected for the study.
  • Tumors were staged and graded according to AJCC-UICC (1997) classification and patients were followed with cystoscopy as per the protocol.
  • Polymerase chain reaction (PCR) was done to amplify microsatellite sequences at mononucleotide BAT - 26, BAT - 40, TGFbeta RII, IGFIIR, hMSH3, BAX and dinucleotide D2S123, D9S283, D9S1851 and D18S58 loci in blood (control) and tumor DNA.
  • RESULTS: MSI was observed in 72.7% of tumors at BAT - 26, BAT - 40, D2S123, D9S283, D9S1851 and D18S58 loci.
  • Good association of MSI was seen with tumor stage and grade.
  • MSI - High (instability at > 30% of loci) was frequently observed in high stage (40.6%) and high grade (59.4%) tumors.
  • Of 24 tumors of Ta-T1 stage with different grades, 11 (9/18 high grade and 2/6 low grade tumors) recurred in the mean duration of 36 months.
  • MSI positivity was significantly high in patients who had one or more recurrences (p = 0.02 for high grade and 0.04 for low grade tumors).
  • CONCLUSIONS: MSI may be an independent prognostic marker for assessing risk of recurrence in superficial tumors irrespective of the grade.
  • [MeSH-major] Carcinoma, Transitional Cell / genetics. Microsatellite Repeats. Urinary Bladder Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chromosomal Instability. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Prognosis

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 1998 Aug 21;79(4):396-401 [9699533.001]
  • [Cites] Oncogene. 1997 Oct 2;15(14):1713-8 [9349505.001]
  • [Cites] Urology. 2000 Feb;55(2):287-91 [10688097.001]
  • [Cites] Int J Mol Med. 2002 Jan;9(1):91-4 [11745004.001]
  • [Cites] Oncogene. 2002 Jul 25;21(32):4894-9 [12118368.001]
  • [Cites] Arch Pathol Lab Med. 2003 Feb;127(2):E60-3 [12562253.001]
  • [Cites] Teratog Carcinog Mutagen. 2003;Suppl 1:255-65 [12616616.001]
  • [Cites] Cancer. 2003 Apr 15;97(8 Suppl):2064-75 [12673698.001]
  • [Cites] Cancer. 2003 Apr 15;97(8 Suppl):2083-9 [12673700.001]
  • [Cites] J Urol. 2003 Oct;170(4 Pt 1):1151-4 [14501713.001]
  • [Cites] Nature. 1993 Jun 10;363(6429):558-61 [8505985.001]
  • [Cites] Cancer Res. 1993 Dec 1;53(23):5620-3 [8242615.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Oct 11;91(21):9871-5 [7937908.001]
  • [Cites] Int J Cancer. 1996 Apr 22;69(2):142-5 [8608983.001]
  • [Cites] Am J Pathol. 1996 Jul;149(1):229-35 [8686747.001]
  • [Cites] Cancer Res. 1998 Dec 15;58(24):5835-41 [9865743.001]
  • (PMID = 15647110.001).
  • [ISSN] 1471-2490
  • [Journal-full-title] BMC urology
  • [ISO-abbreviation] BMC Urol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC545959
  •  go-up   go-down


45. Shinji S, Tajiri T, Ishiwata T, Seya T, Tanaka N, Naito Z: Different expression levels of lumican in human carcinoid tumor and neuroendocrine cell carcinoma. Int J Oncol; 2005 Apr;26(4):873-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Different expression levels of lumican in human carcinoid tumor and neuroendocrine cell carcinoma.
  • Lumican is a member of the small leucine-rich proteoglycan (SLRP) family and participates in the maintenance of tissue structures and tumor growth.
  • Neuroendocrine cell tumors (NETs) including carcinoid tumors and NE cell carcinomas (NECs) possess numerous neuroendocrine (NE) granules, and differences between these tumors are in terms of their biological and metastatic aggressiveness during tumor progression.
  • The purpose of this study was to examine the expression of lumican in NETs, and to determine whether the presence of lumican may be associated with the growth of NETs by comparing its expression between carcinoid tumors and NECs.
  • Immunohistochemically, the positivity rates of lumican expression in the cytoplasm of the tumor cells were 87.5% in carcinoid tumors and 37.5% in NECs.
  • Those of lumican expression in the stroma adjacent to the tumors were 90.1% in carcinoid tumors and 79.2% in NECs.
  • In situ hybridization analysis revealed the lumican mRNA expression in the cytoplasm of carcinoid tumor and NEC cells.
  • Ultrastructurally, the lumican protein was observed in the rough endoplasmic reticulum and NE granules of NETs and interspaces of collagen fibers.
  • These results indicate that the higher expression level of cytoplasmic lumican in carcinoid tumors than in NECs may play a role in the slow growth of these tumors.
  • [MeSH-major] Carcinoid Tumor / genetics. Carcinoid Tumor / pathology. Cell Proliferation. Chondroitin Sulfate Proteoglycans / biosynthesis. Gene Expression Profiling. Keratan Sulfate / biosynthesis. Neuroendocrine Tumors / genetics. Neuroendocrine Tumors / pathology
  • [MeSH-minor] Cytoplasm. Humans. Immunohistochemistry. RNA, Messenger / biosynthesis. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Carcinoid Tumor.
  • Genetic Alliance. consumer health - Pancreatic islet cell tumors.
  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15753980.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Chondroitin Sulfate Proteoglycans; 0 / RNA, Messenger; 0 / lumican; 9056-36-4 / Keratan Sulfate
  •  go-up   go-down


46. Agaram NP, Besmer P, Wong GC, Guo T, Socci ND, Maki RG, DeSantis D, Brennan MF, Singer S, DeMatteo RP, Antonescu CR: Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors. Clin Cancer Res; 2007 Jan 1;13(1):170-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors.
  • PURPOSE: Gastrointestinal stromal tumor (GIST) is the most common sarcoma of the intestinal tract.
  • Nearly all tumors express KIT protein, and most have an activating mutation in either KIT or PDGFRA.
  • Therapy with selective tyrosine kinase inhibitors achieves a partial response or stable disease in approximately 80% of patients with advanced GIST.
  • EXPERIMENTAL DESIGN: Forty-three tumor nodules from 28 patients were available for pathologic and molecular analysis, which included genotyping for primary and secondary KIT/PDGFRA-mutations, cell cycle alterations, and biochemical activation status of KIT and downstream targets.
  • The transcriptional changes of a subset of these tumors were compared with a group of imatinib-naive GISTs on a U133A Affymetrix expression platform.
  • Second-site KIT mutation was identified in only one tumor nodule.
  • Activation of KIT and downstream targets was consistent in all tumors analyzed.
  • Ultrastructurally, a subset of tumors showed a smooth muscle phenotype, which correlated with overexpression of genes involved in muscle differentiation and function.
  • Second-site KIT mutations are rare in imatinib-responsive GISTs compared with imatinib-resistant tumors.
  • [MeSH-major] Gastrointestinal Stromal Tumors / drug therapy. Piperazines / pharmacology. Protein Kinase Inhibitors / pharmacology. Proto-Oncogene Proteins c-kit / genetics. Pyrimidines / pharmacology
  • [MeSH-minor] Benzamides. Cell Proliferation. Cluster Analysis. DNA Mutational Analysis. Drug Resistance, Neoplasm. Exons. Genotype. Humans. Imatinib Mesylate. Microscopy, Electron. Mutation. Oligonucleotide Array Sequence Analysis. Protein-Tyrosine Kinases / antagonists & inhibitors. Sequence Analysis, DNA. Treatment Outcome

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17200352.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA102613; United States / NCI NIH HHS / CA / CA102774; United States / NIDDK NIH HHS / DK / HL/DK55748; United States / NCI NIH HHS / CA / P01 CA 47179
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


47. Puri A, Subin BS, Agarwal MG: Fibular centralisation for the reconstruction of defects of the tibial diaphysis and distal metaphysis after excision of bone tumours. J Bone Joint Surg Br; 2009 Feb;91(2):234-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fibular centralisation for the reconstruction of defects of the tibial diaphysis and distal metaphysis after excision of bone tumours.
  • We evaluated the results of fibular centralisation as a stand alone technique to reconstruct defects that occurred after resection of tumours involving the tibial diaphysis and distal metaphysis.
  • Between January 2003 and December 2006, 15 patients underwent excision of tumours of the tibial diaphysis or distal metaphysis and reconstruction by fibular centralisation.
  • Two patients were excluded; one died from the complications of chemotherapy and a second needed a below-knee amputation for a recurrent giant-cell tumour.
  • The mean Musculoskeletal Tumor Society Score was 24.7 (16 to 30).
  • [MeSH-major] Bone Neoplasms / surgery. Bone Transplantation / methods. Fracture Fixation, Internal / methods. Giant Cell Tumor of Bone / surgery. Osteosarcoma / surgery. Tibia
  • [MeSH-minor] Adolescent. Adult. Child. Diaphyses / transplantation. Disease-Free Survival. Female. Fibula / transplantation. Humans. Magnetic Resonance Imaging. Male. Time Factors. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Bone Grafts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19190060.001).
  • [ISSN] 0301-620X
  • [Journal-full-title] The Journal of bone and joint surgery. British volume
  • [ISO-abbreviation] J Bone Joint Surg Br
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


48. Compérat EV, Vasiliu V, Ferlicot S, Camparo P, Sibony M, Vieillefond A: [Tumors of the kidneys: new entities]. Ann Pathol; 2005 Apr;25(2):117-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Tumors of the kidneys: new entities].
  • [Transliterated title] Tumeurs du rein: les nouvelles entités.
  • Since 1998 new entities have surfaced in renal tumor classification and have been included in the WHO 2004 classification.
  • In this article, we will discuss the following entities: multilocular clear cell renal carcinoma, Xp11 translocation carcinoma, low grade mucinous tubular carcinoma, epithelioid angiomyolipoma, benign mixed epithelial and stromal tumor.
  • We will investigate new concepts of hybrid oncocytoma and chromophobe renal cell carcinoma and the syndrome of Birt-Hogg-Dube which is associated to kidney tumors.
  • At least, we will touch on new elements in the Bellini carcinoma definition.
  • [MeSH-major] Kidney Neoplasms / classification. Kidney Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16142163.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 77
  •  go-up   go-down


49. D'Amato A, Pezzoli F, Caterino S, Cavallini M, Balducci G, Bocchetti T, Ziparo V: [GIST: a clinical case as a model of surgical and pharmacological therapy of solid tumours]. Chir Ital; 2005 Jul-Aug;57(4):509-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [GIST: a clinical case as a model of surgical and pharmacological therapy of solid tumours].
  • [Transliterated title] GIST: un caso clinico come modello della terapia chirurgica e farmacologica dei tumori solidi.
  • Gastrointestinal stromal tumour: report of a case as a model of surgical and pharmacological therapy of solid tumours. mutation of this protein is present in most of these tumours.
  • Gastrointestinal stromal tumours are notoriously unresponsive to chemotherapy and radiotherapy and prior to the recent introduction of the kit inhibitor imatinib, there was no effective therapy for advanced, metastatic disease.
  • We report a case of metastatic gastrointestinal stromal tumour located primarily in the ileum and examine it in detail in order to contribute both to identifying factors capable of predicting its clinical course and evaluating the efficacy of imatinib as adjuvant therapy for this rare type of tumour.
  • We share the opinion that, given the present state of the art, surgical resection remains the gold standard of treatment for these tumours and imatinib is a valid systemic therapy for metastastic and locally unresectable gastrointestinal stromal tumours.
  • [MeSH-major] Gastrointestinal Stromal Tumors / drug therapy. Gastrointestinal Stromal Tumors / surgery

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16060192.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


50. Alagaratnam S, Hardy JR, Lothe RA, Skotheim RI, Byrne JA: TPD52, a candidate gene from genomic studies, is overexpressed in testicular germ cell tumours. Mol Cell Endocrinol; 2009 Jul 10;306(1-2):75-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TPD52, a candidate gene from genomic studies, is overexpressed in testicular germ cell tumours.
  • Several genomic regions are recurrently over- or underrepresented in testicular germ cell tumours (TGCTs), but only a fraction of their genes change their expression accordingly.
  • We performed immunohistochemical analysis of TPD52 on a tissue microarray, which showed complete absence of TPD52 protein in normal germ cells and most intratubular germ cell neoplasias.
  • TPD52 was expressed in two-thirds of seminomas and embryonal carcinomas, and at intermediate frequencies in the more differentiated non-seminomas.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Genome, Human / genetics. Genomics. Neoplasm Proteins / genetics. Neoplasms, Germ Cell and Embryonal / genetics. Testicular Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19041365.001).
  • [ISSN] 1872-8057
  • [Journal-full-title] Molecular and cellular endocrinology
  • [ISO-abbreviation] Mol. Cell. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / TPD52 protein, human
  •  go-up   go-down


51. Pasquali C, Sperti C, Baratella P, Liessi G, Pedrazzoli S: [Enucleation-resection of pancreatic neuroendocrine tumors: 25 years of experience]. Suppl Tumori; 2005 May-Jun;4(3):S59-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Enucleation-resection of pancreatic neuroendocrine tumors: 25 years of experience].
  • [Transliterated title] Enucleoresezione di tumori neuroendocrini pancreatici venticinque anni di esperienza.
  • From 1980 to 2004, out of 109 patients who underwent surgery for neuroendocrine pancreatic tumor, 33 had a simple tumor excision.
  • Age, sex, site and size of the tumor, associated diseases, hospital stay and complications were retrospectively reviewed by the clinical records.
  • Mean size of the tumor was 1.7 cm and 54.5% were in the pancreatic head; 78.8% of cases had medical associated diseases.
  • [MeSH-major] Neuroendocrine Tumors / surgery. Pancreatectomy / methods. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16437904.001).
  • [ISSN] 2283-5423
  • [Journal-full-title] I supplementi di Tumori : official journal of Società italiana di cancerologia ... [et al.]
  • [ISO-abbreviation] Suppl Tumori
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


52. Helland SK, Prøsch AM, Viste A: Carcinoid tumours in the gastrointestinal tract--a population-based study from Western Norway. Scand J Surg; 2006;95(3):158-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoid tumours in the gastrointestinal tract--a population-based study from Western Norway.
  • OBJECTIVE: To analyze population-based incidence, anatomic distribution and patient characteristics of gastrointestinal carcinoid tumours.
  • BACKGROUND: Neuroendocrine carcinomas (NE, carcinoid tumours) arise from neuroendocrine cells and are most commonly found in gastrointestinal tract and lungs.
  • Previous studies on carcinoids report varying incidence rates, location of tumours and patient survival rates.
  • Patient and tumour characteristics, treatment and survival were analyzed in a sub-group of 51 patients treated at Haukeland University Hospital.
  • The tumours were located in the small bowel in 53%, appendix 18%, colon 4%, rectum 4%, stomach 8% and duodenum 10%.
  • Five-year survival rate was 50% in stomach, 80% in duodenum, 43% in the small bowel, 100% for tumours in appendix, 40% in colon and 100% in rectum.
  • CONCLUSION: Carcinoid tumours are relatively uncommon neoplasms and most of them are found in the small bowel.
  • Tumours in the appendix are found at lower age and in an early stage.
  • [MeSH-major] Carcinoid Tumor / epidemiology. Gastrointestinal Neoplasms / epidemiology. Population Surveillance

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17066609.001).
  • [ISSN] 1457-4969
  • [Journal-full-title] Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society
  • [ISO-abbreviation] Scand J Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


53. Schrofer C, Villiger P, Cathomas R: [Multiple primary neoplasms - coincidence or tumor syndrom?]. Praxis (Bern 1994); 2009 Sep 9;98(18):1027-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multiple primary neoplasms - coincidence or tumor syndrom?].
  • BACKGROUND: Multiple primary neoplasms occur either by hazard or in the context of hereditary cancer syndromes, after chronic toxic exposition, in immunodeficiency or as secondary malignancies after radio- and/or chemotherapy.
  • CASE REPORT: We present the history of an actually asymptomatic female patient with four different malignancies within 30 years: malignant melanoma (1976), liposarcoma (1983), carcinoma of the appendix (2006) and lymphoma (2006).
  • DISCUSSION: There is not only a remarkable variety of malignant tumors but also an extraordinary long survival without recurrence of the generalised malignomas of the skin and soft tissue (malignant melanoma and liposarcoma).
  • It is difficult to explain the entire restitution with the implemented treatments (several tumor resections, chemotherapy with Ifosfamide).
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Appendiceal Neoplasms / diagnosis. Ileal Neoplasms / diagnosis. Liposarcoma / diagnosis. Lymphoma, Follicular / diagnosis. Melanoma / diagnosis. Neoplasms, Second Primary / diagnosis. Skin Neoplasms / diagnosis. Soft Tissue Neoplasms / diagnosis
  • [MeSH-minor] Aged. Combined Modality Therapy. Female. Humans. Lymph Nodes / pathology. Neoplasm Staging. Syndrome

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19739050.001).
  • [ISSN] 1661-8157
  • [Journal-full-title] Praxis
  • [ISO-abbreviation] Praxis (Bern 1994)
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


54. Kotoula V, Cheva A, Barbanis S, Papadimitriou CS, Karkavelas G: hTERT immunopositivity patterns in the normal brain and in astrocytic tumors. Acta Neuropathol; 2006 Jun;111(6):569-78
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] hTERT immunopositivity patterns in the normal brain and in astrocytic tumors.
  • Accumulating data about the impact of hTERT in astrocytic tumor carcinogenesis and recent evidence about its association with disease outcome prompt the evaluation of this molecule with methods applicable in routine pathology practice.
  • In this study, we investigated hTERT protein expression with immunohistochemistry (IHC) and the NCL-hTERT antibody in 49 astrocytic tumors.
  • Low- and high-grade astrocytic tumors were found positive for hTERT in 74 and 85% of cases, respectively.
  • Heterogeneity in the distribution of hTERT-positive cells was observed in all tumors.
  • The prevailing nuclear IPs differed significantly between pilocytic astrocytomas (pattern As) and the rest of histologic types up to glioblastoma (patterns Am and B) (P<0.0001).
  • The described nuclear IPs were also observed in non-neoplastic cells.
  • Positive endothelial cells were found in astrocytic tumors of all grades, even when tumor cells showed no hTERT immunoreactivity.
  • The nuclear hTERT IPs described here may reflect the functional status of non-neoplastic brain and neoplastic astrocytic cells and support the model of a continuum in the development of glioblastomas from diffuse fibrillary astrocytomas.
  • [MeSH-major] Astrocytes / metabolism. Astrocytoma / metabolism. Brain Chemistry / physiology. Brain Neoplasms / metabolism. Telomerase / genetics. Telomerase / metabolism
  • [MeSH-minor] Adult. Aged. Child. Endothelial Cells / pathology. Female. Fixatives. Formaldehyde. Humans. Immunohistochemistry. In Situ Hybridization. Male. Middle Aged. Paraffin Embedding. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. RNA, Neoplasm / biosynthesis. RNA, Neoplasm / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. FORMALDEHYDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16614861.001).
  • [ISSN] 0001-6322
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Fixatives; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 1HG84L3525 / Formaldehyde; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


55. Murphy AM, Gilbert SM, Katz AE, Goluboff ET, Sawczuk IS, Olsson CA, Benson MC, McKiernan JM: Re-evaluation of the Tumour-Node-Metastasis staging of locally advanced renal cortical tumours: absolute size (T2) is more significant than renal capsular invasion (T3a). BJU Int; 2005 Jan;95(1):27-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Re-evaluation of the Tumour-Node-Metastasis staging of locally advanced renal cortical tumours: absolute size (T2) is more significant than renal capsular invasion (T3a).
  • Authors from Iowa City report on the incidence of RCC; they compared the rate of these tumours at autopsy and felt that the decrease found was a result of better antemortem detection, and an increase with time in the frequency of clinically detected renal cancer.
  • A study from New York attempted to determine whether size, or transcapsular extension irrespective of size, was more likely to produce an adverse outcome.
  • They analysed their database of 717 such tumours between 1988 and 2002, and found that absolute tumour size was the more significant of the two findings.
  • OBJECTIVE: To determine which factor was more predictive of adverse outcome in our institutional experience with T2N0M0 and T3N0M0 renal cortical tumours (RCTs) treated surgically, as the current Tumour-Node-Metastasis (TNM) staging system for RCTs differentiates between tumours of >7.0 cm but confined to the renal capsule (T2) and tumours that extend through the renal capsule regardless of size (T3a).
  • MATERIALS AND METHODS: We analysed our institutional database of surgical urological oncology for all patients with T2N0M0 and T3aN0M0 RCT treated with partial or radical nephrectomy from 1988 to 2002.
  • All patients with preoperative metastasis, bilateral or multifocal tumours, nonsporadic disease or benign histology were excluded from analysis.
  • After exclusion criteria were applied, 21 patients with T2N0M0 and 97 with T3aN0M0 tumours were eligible; the median (mean, range) age was 63 (16.6-88.3) years and follow-up 30.5 (40.8, 6-162) months.
  • The estimated 5-year disease-free survival was 68% and 85% for T2N0M0 and T3aN0M0 RCT, respectively (P = 0.002).
  • The 5-year disease-specific survival was 81% and 94% for the T2N0M0 and T3aN0M0 groups, respectively (P = 0.085).
  • CONCLUSION: Patients with T3aN0M0 tumours appear to have better disease-free and disease-specific survival than those with T2N0M0 disease, which suggests that tumour invasion through the renal capsule is not as significant as the absolute tumour size.
  • [MeSH-major] Kidney Cortex. Kidney Neoplasms / pathology. Kidney Neoplasms / surgery. Lymphatic Metastasis / pathology
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] BJU Int. 2005 Jun;95(9):1369-70 [15892836.001]
  • (PMID = 15638890.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


56. Muszyńska-Rosłan K, Krawczuk-Rybak M, Protas P, Siedlecka E, Wiśniewska M, Wołczyński S: [Biochemical markers of bone formation activity in children with neoplasms]. Wiad Lek; 2005;58(1-2):29-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Biochemical markers of bone formation activity in children with neoplasms].
  • The aim of the study was the analysis of biochemical markers of bone turnover in children with neoplasms comparing with the group of healthy children.
  • We explored the relationships between sex, pubertal development and type of neoplastic disease.
  • 85 children (53 boys) with newly diagnosed neoplasms: 48 with acute lymphoblastic leukaemia (ALL), 13 with Hodgkin's disease and 22 with solid tumors (group I) and 111 healthy children (group II) were studied.
  • In the group of boys with neoplasms osteocalcin and BALP values were lower than in healthy boys: OST 51.2 ng/ml +/- 35.3 vs 85.8 ng/ml +/- 35.96, p < 0.0001, BALP 105.6 U/L +/- 56.8, p < 0.0001.
  • The girls had lowered values of osteocalcin (45.55 ng/ml +/- 40.9 vs 71.94 ng/ml +/- 28.75, p < 0.0008) and ICTP (11.25 U/L +/- 3.38 vs 15,47 U/L +/- 5.33, p < 0.0016).
  • 2. The values of OST and BALP were lower in children with ALL than in the children with solid tumours (p < 0.01).
  • The values of ICTP did not depend on the type of disease, sex and pubertal stage, except the children before puberty.
  • CONCLUSIONS: The markers of bone turnover are decreased in children with newly diagnosed neoplasms, especially with ALL.
  • [MeSH-major] Biomarkers / blood. Bone Remodeling. Bone and Bones / metabolism. Neoplasms / blood

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15991550.001).
  • [ISSN] 0043-5147
  • [Journal-full-title] Wiadomości lekarskie (Warsaw, Poland : 1960)
  • [ISO-abbreviation] Wiad. Lek.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Collagen Type I; 0 / Parathyroid Hormone; 0 / Peptide Fragments; 0 / Peptides; 0 / Procollagen; 0 / collagen type I trimeric cross-linked peptide; 104982-03-8 / Osteocalcin; EC 3.1.3.1 / Alkaline Phosphatase
  •  go-up   go-down


57. Speight PM, Barrett AW: Prognostic factors in malignant tumours of the salivary glands. Br J Oral Maxillofac Surg; 2009 Dec;47(8):587-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in malignant tumours of the salivary glands.
  • Salivary gland tumours are a relatively rare group of lesions best managed in specialist centres.
  • Even high grade neoplasms may do well when they are small.
  • [MeSH-major] Salivary Gland Neoplasms / pathology
  • [MeSH-minor] Carcinoma / classification. Carcinoma / pathology. Carcinoma / secondary. Humans. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Risk Factors. Survival Rate

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Oral Maxillofac Surg. 2010 Jul;48(5):397-8 [20153096.001]
  • [CommentIn] Br J Oral Maxillofac Surg. 2010 Jul;48(5):398 [20206423.001]
  • (PMID = 19409681.001).
  • [ISSN] 1532-1940
  • [Journal-full-title] The British journal of oral & maxillofacial surgery
  • [ISO-abbreviation] Br J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Scotland
  • [Number-of-references] 53
  •  go-up   go-down


58. Hayakawa Y, Smyth MJ: Innate immune recognition and suppression of tumors. Adv Cancer Res; 2006;95:293-322
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Innate immune recognition and suppression of tumors.
  • We then focused the remainder of the chapter on methods of tumor recognition that contribute to natural host immune suppression of tumors.
  • NKG2D binds to family of ligands with structural homology to major histocompatibility complex (MHC) class I, however, NKG2D ligands often display upregulated surface expression on stressed cells and are frequently overexpressed by tumors unlike conventional MHC class I molecules.
  • Evidence clearly implicate that NKG2D recognition plays an important role in tumor immune surveillance.
  • [MeSH-major] Immunity, Innate / physiology. Immunotherapy / methods. Neoplasms / immunology. Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Cancer Immunotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16860661.001).
  • [ISSN] 0065-230X
  • [Journal-full-title] Advances in cancer research
  • [ISO-abbreviation] Adv. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / KLRK1 protein, human; 0 / Klrk1 protein, mouse; 0 / Ligands; 0 / NK Cell Lectin-Like Receptor Subfamily K; 0 / Receptors, Immunologic; 0 / Receptors, Natural Killer Cell
  • [Number-of-references] 165
  •  go-up   go-down


59. Schubert GA, Barth M, Thomé C: The use of indocyanine green videography for intraoperative localization of intradural spinal tumors. Spine (Phila Pa 1976); 2010 Mar 15;35(6):E212-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of indocyanine green videography for intraoperative localization of intradural spinal tumors.
  • OBJECTIVE: To characterize the role of indocyanine-green videography in the intraoperative localization of intradural spinal tumors.
  • SUMMARY OF BACKGROUND DATA: Correct intraoperative localization of intradural spinal tumors as well as tailored dural opening is essential in surgery and can be demanding in some instances.
  • We investigated the role of indocyanine green (ICG) videography to correctly localize intradural, spinal tumors.
  • METHODS: We report a series of 30 patients with intradural spinal tumors, in which (hemi-)laminectomy or extended laminotomy was followed by ICG videography to determine intradural tumor margins (injection of intravenous ICG, visualization with operating microscope in combination with an additional, fluorescent light source).
  • Tumor projection was verified after dural opening, and surgical resection was continued thereafter.
  • Identification of the tumor margins before dural opening was achieved in 28 cases (93%), either by tumor enhancement or absence of ICG uptake in relation to the surrounding spinal cord or nerve roots.
  • CONCLUSION: ICG videography represents a helpful tool to localize the position of intraspinal, intradural tumors, which are lateral or dorsal to the spinal cord or nerve roots.
  • [MeSH-major] Dura Mater / pathology. Indocyanine Green. Monitoring, Intraoperative / methods. Spinal Cord Neoplasms / diagnosis. Video Recording / methods

  • Hazardous Substances Data Bank. INDOCYANINE GREEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20195202.001).
  • [ISSN] 1528-1159
  • [Journal-full-title] Spine
  • [ISO-abbreviation] Spine
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Coloring Agents; IX6J1063HV / Indocyanine Green
  •  go-up   go-down


60. Menichetti L, Cionini L, Sauerwein WA, Altieri S, Solin O, Minn H, Salvadori PA: Positron emission tomography and [18F]BPA: a perspective application to assess tumour extraction of boron in BNCT. Appl Radiat Isot; 2009 Jul;67(7-8 Suppl):S351-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Positron emission tomography and [18F]BPA: a perspective application to assess tumour extraction of boron in BNCT.
  • The recent physical integration of PET and computed tomography (CT) in hybrid PET/CT scanners allows a combined anatomical and functional imaging: nowadays PET molecular imaging is emerging as powerful pharmacological tool in oncology, neurology and for treatment planning as guidance for radiation therapy.
  • The added value of the use of L-[(18)F]FBPA and PET/CT in BNCT is to provide key data on the tumour extraction of (10)B-BPA versus normal tissue and to predict the efficacy of the treatment based on a single-study patient analysis.
  • Due to the complexity of a binary treatment like BNCT, the role of PET/CT is currently to design new criteria for patient enrolment in treatment protocols: the L-[(18)F]BPA/PET methodology could be considered as an important tool in newly designed clinical trials to better estimate the concentration ratio of BPA in the tumour as compared to neighbouring normal tissues.
  • Based on these values for individual patients the decision could be made whether BNCT treatment could be advantageous due to a selective accumulation of BPA in an individual tumour.
  • This approach, applicable in different tumour entities like melanoma, glioblastoma and head and neck malignancies, make this methodology as reliable prognostic and therapeutic indicator for patient undergoing BNCT.
  • [MeSH-major] Boron / pharmacokinetics. Boron / therapeutic use. Boron Compounds. Boron Neutron Capture Therapy / methods. Neoplasms / radionuclide imaging. Neoplasms / radiotherapy. Phenylalanine / analogs & derivatives. Positron-Emission Tomography / methods

  • Hazardous Substances Data Bank. BORON COMPOUNDS .
  • Hazardous Substances Data Bank. (L)-Phenylalanine .
  • Hazardous Substances Data Bank. BORON, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19410471.001).
  • [ISSN] 1872-9800
  • [Journal-full-title] Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine
  • [ISO-abbreviation] Appl Radiat Isot
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Boron Compounds; 0 / Fluorine Radioisotopes; 0 / Isotopes; 0 / Radiation-Sensitizing Agents; 133921-60-5 / 4-borono-2-fluorophenylalanine; 47E5O17Y3R / Phenylalanine; N9E3X5056Q / Boron
  •  go-up   go-down


61. Zhou PH, Yao LQ, Xu MD, Chen WF, Zhong YS, Gao WD, He GJ, Qin XY: [Endoscopic submucosal dissection for rectal carcinoid tumors]. Zhonghua Wei Chang Wai Ke Za Zhi; 2007 Jul;10(4):319-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Endoscopic submucosal dissection for rectal carcinoid tumors].
  • OBJECTIVE: To assess the clinical value of endoscopic submucosal dissection(ESD)for rectal carcinoid tumors.
  • METHODS: Endoscopic miniprobe ultrasonography was performed in patients with rectal submucosal tumors under colonoscope.
  • All rectal carcinoid tumors were verified by pathological examination with lateral and basal resection margins free of tumor.
  • Minor bleeding occurred in all of the tumors, and none of patients had massive hemorrhage requiring blood transfusion or emergency colonoscopy due to hematochezia after ESD.
  • Rectal carcinoid tumors can now be treated by ESD to achieve the same therapeutic effect as operation.
  • [MeSH-major] Carcinoid Tumor / surgery. Intestinal Mucosa / surgery. Rectal Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17659452.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


62. Hall NC, Povoski SP, Murrey DA, Knopp MV, Martin EW Jr: Combined approach of perioperative 18F-FDG PET/CT imaging and intraoperative 18F-FDG handheld gamma probe detection for tumor localization and verification of complete tumor resection in breast cancer. World J Surg Oncol; 2007;5:143
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined approach of perioperative 18F-FDG PET/CT imaging and intraoperative 18F-FDG handheld gamma probe detection for tumor localization and verification of complete tumor resection in breast cancer.
  • BACKGROUND: 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) has become an established method for detecting hypermetabolic sites of known and occult disease and is widely used in oncology surgical planning.
  • Intraoperatively, it is often difficult to localize tumors and verify complete resection of tumors that have been previously detected on diagnostic PET/CT at the time of the original evaluation of the cancer patient.
  • Therefore, we propose an innovative approach for intraoperative tumor localization and verification of complete tumor resection utilizing 18F-FDG for perioperative PET/CT imaging and intraoperative gamma probe detection.
  • Intraoperatively, tumors were localized and resected with the assistance of a handheld gamma probe.
  • Resected tumors were scanned with specimen PET/CT prior to pathologic processing.
  • RESULTS: One patient had primary carcinoma of breast and a metastatic axillary lymph node.
  • Such perioperative PET/CT imaging, along with intraoperative gamma probe detection and specimen PET/CT, can be used to verify complete tumor resection.
  • This innovative approach demonstrates promise for assisting the oncologic surgeon in localizing and verifying resection of 18F-FDG positive tumors and may ultimately positively impact upon long-term patient outcomes.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg Oncol. 2007;5:65 [17555587.001]
  • [Cites] Ann Nucl Med. 2007 Jan;21(1):33-8 [17373334.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Cancer. 2006 Dec 1;107(11):2545-51 [17063499.001]
  • [Cites] Ann Thorac Surg. 2006 Nov;82(5):1815-20; discussion 1820 [17062254.001]
  • [Cites] Nuklearmedizin. 2006;45(4):153-9 [16964340.001]
  • [Cites] Arch Surg. 2006 Aug;141(8):783-8; discussion 788-9 [16924086.001]
  • [Cites] Ann Surg Oncol. 2006 May;13(5):677-84 [16538409.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2006 Mar;33(3):254-62 [16258765.001]
  • [Cites] Nucl Med Commun. 2006 Mar;27(3):231-6 [16479242.001]
  • [Cites] Clin Nucl Med. 2005 Dec;30(12):787-91 [16319633.001]
  • [Cites] Curr Probl Surg. 2004 Nov;41(11):882-935 [15717717.001]
  • [Cites] J Natl Cancer Inst. 1996 Sep 4;88(17):1204-9 [8780629.001]
  • [Cites] Cancer Invest. 1996;14(6):560-71 [8951360.001]
  • [Cites] Q J Nucl Med Mol Imaging. 2004 Jun;48(2):109-18 [15243412.001]
  • [Cites] Ann Nucl Med. 2004 Apr;18(2):105-14 [15195757.001]
  • [Cites] Cancer J. 2002 Mar-Apr;8(2):100-8 [11999944.001]
  • [Cites] J Surg Res. 2001 May 1;97(1):9-13 [11319873.001]
  • [Cites] Eur J Nucl Med. 2001 Mar;28(3):351-8 [11315604.001]
  • [Cites] J Surg Res. 2001 Mar;96(1):120-6 [11181005.001]
  • [Cites] Q J Nucl Med Mol Imaging. 2008 Mar;52(1):37-49 [17657203.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2007 Oct;34(10):1534-44 [17431612.001]
  • [Cites] World J Surg Oncol. 2007;5:80 [17634125.001]
  • (PMID = 18154677.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2235860
  •  go-up   go-down


63. Wegert J, Wittmann S, Leuschner I, Geissinger E, Graf N, Gessler M: WTX inactivation is a frequent, but late event in Wilms tumors without apparent clinical impact. Genes Chromosomes Cancer; 2009 Dec;48(12):1102-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] WTX inactivation is a frequent, but late event in Wilms tumors without apparent clinical impact.
  • Wilms tumor (WT) is one of the most common solid tumors in childhood.
  • We determined the mutation status of WTX, CTNNB1, and WT1 in a large set of 429 tumors.
  • An additional 11.5% of tumor samples lacked expression of WTX mRNA.
  • However, we could not find a significant correlation between WTX deletion status or expression level and clinical parameters suggesting that WTX mutations apparently have little direct impact on tumor behavior and presentation.
  • Incomplete deletions of WTX in several cases suggested heterogeneity in tumors.
  • In a small number of cases, we could analyze separate tumor fragments or microdissected regions with different histology of tumors with heterozygous point mutations.
  • [MeSH-major] Kidney Neoplasms / genetics. Tumor Suppressor Proteins / genetics. Wilms Tumor / genetics

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19760609.001).
  • [ISSN] 1098-2264
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AMER1 protein, human; 0 / Adaptor Proteins, Signal Transducing; 0 / CTNNB1 protein, human; 0 / Tumor Suppressor Proteins; 0 / WT1 Proteins; 0 / beta Catenin
  •  go-up   go-down


64. Cárdenas-Navia LI, Mace D, Richardson RA, Wilson DF, Shan S, Dewhirst MW: The pervasive presence of fluctuating oxygenation in tumors. Cancer Res; 2008 Jul 15;68(14):5812-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The pervasive presence of fluctuating oxygenation in tumors.
  • Tumor hypoxia is a persistent obstacle for traditional therapies in solid tumors.
  • Strategies for mitigating the effects of hypoxic tumor cells have been developed under the assumption that chronically hypoxic tumor cells were the central cause of treatment resistance.
  • In this study, we show that instabilities in tumor oxygenation are a prevalent characteristic of three tumor lines and previous characterization of tumor hypoxia as being primarily diffusion-limited does not accurately portray the tumor microenvironment.
  • Phosphorescence lifetime imaging was used to measure fluctuations in vascular pO(2) in rat fibrosarcomas, 9L gliomas, and R3230 mammary adenocarcinomas grown in dorsal skin-fold window chambers (n = 6 for each tumor type) and imaged every 2.5 minutes for a duration of 60 to 90 minutes.
  • O(2) delivery to tumors is constantly changing in all tumors, resulting in continuous reoxygenation events throughout the tumor.
  • The fluctuations in oxygenation occur with a common periodicity within and between tumors, suggesting a common mechanism, but have tumor type-dependent spatial patterns.
  • The widespread presence of fluctuations in tumor oxygenation has broad ranging implications for tumor progression, stress response, and signal transduction, which are altered by oxygenation/reoxygenation events.
  • [MeSH-major] Anoxia. Cell Hypoxia. Neoplasms / pathology. Oxygen / metabolism
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Respiration. Female. Fibrosarcoma. Mammary Neoplasms, Animal / metabolism. Mammary Neoplasms, Animal / pathology. Mammary Neoplasms, Experimental. Models, Biological. Oxygen Consumption. Rats. Rats, Inbred F344

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. OXYGEN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18632635.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA40355
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] S88TT14065 / Oxygen
  •  go-up   go-down


65. Burzynski SR: Treatments for astrocytic tumors in children: current and emerging strategies. Paediatr Drugs; 2006;8(3):167-78
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatments for astrocytic tumors in children: current and emerging strategies.
  • Despite these accomplishments, CNS tumors remain the leading cause of death in pediatric oncology.
  • Astrocytic tumors form the most common histologic group among childhood brain tumors.
  • Careful follow-up without any treatment is indicated for a small percentage of patients diagnosed with LGA with an indolent course including children with neurofibromatosis type 1 (NF1).
  • Radiation therapy is generally recommended for children with progressive LGA, or after failure of chemotherapy, accomplishing tumor control at 10 years in over 60% of patients.
  • The introduction of temozolomide has allowed better responses, including a 24% complete response rate compared with 0-5% complete response rates with the previous regimens.
  • OPG is the most common type of brain tumor associated with NF1.
  • Tumor growth in some of these patients is slow with no treatment recommended for an extended period of time.
  • Combination chemotherapy before or after radiation, including cisplatin, carmustine, cyclophosphamide, and vincristine or carboplatin, ifosfamide, cyclophosphamide, and etoposide has provided disappointing results.
  • Diffuse intrinsic BSG are among the most difficult-to-treat brain tumors.
  • None of the numerous chemotherapy regimens, including temozolomide, has provided a significant response rate or an improvement in survival.
  • Careful evaluation of histology, location of the tumor, patient age, and consideration of treatment-related morbidity play an important part in selecting between clinical observation, surgery, radiation, chemotherapy, or investigational agents.
  • The goals of treatment for astrocytic tumors should extend well beyond objective responses and increased survival.
  • [MeSH-major] Astrocytoma / therapy. Central Nervous System Neoplasms / therapy

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Probl Pediatr. 1992 Feb;22(2):66-106; discussion 107 [1576827.001]
  • [Cites] Exp Mol Pathol. 1979 Feb;30(1):1-11 [421860.001]
  • [Cites] J Neurosurg. 1998 Jul;89(1):52-9 [9647172.001]
  • [Cites] Cancer Treat Rep. 1985 Feb;69(2):149-51 [3971390.001]
  • [Cites] J Neurosurg. 1997 May;86(5):747-54 [9126887.001]
  • [Cites] Klin Padiatr. 2004 Nov-Dec;216(6):331-42 [15565548.001]
  • [Cites] Curr Neurol Neurosci Rep. 2001 Mar;1(2):137-43 [11898509.001]
  • [Cites] J Pediatr Hematol Oncol. 2003 May;25(5):372-8 [12759623.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jun 1;47(3):561-4 [10837936.001]
  • [Cites] Arch Ophthalmol. 1982 Nov;100(11):1766-72 [7138345.001]
  • [Cites] Med Pediatr Oncol. 1989;17(2):92-6 [2704342.001]
  • [Cites] Anticancer Res. 1999 Jul-Aug;19(4C):3569-74 [10629654.001]
  • [Cites] Curr Opin Neurol. 2001 Dec;14(6):711-5 [11723378.001]
  • [Cites] Cancer. 1980 Mar 15;45(6):1467-71 [7357527.001]
  • [Cites] Semin Radiat Oncol. 2001 Apr;11(2):138-44 [11285551.001]
  • [Cites] Eur Radiol. 2001;11(12):2638-40 [11734972.001]
  • [Cites] Radiother Oncol. 2000 Mar;54(3):239-45 [10738082.001]
  • [Cites] Ann Neurol. 1987 Sep;22(3):355-64 [2823687.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jan 15;40(2):265-71 [9457808.001]
  • [Cites] Cancer Treat Rep. 1976 Sep;60(9):1257-61 [1071015.001]
  • [Cites] Strahlenther Onkol. 2003 Aug;179(8):509-20 [14509949.001]
  • [Cites] J Pediatr Hematol Oncol. 2000 May-Jun;22(3):247-51 [10864056.001]
  • [Cites] Med Pediatr Oncol. 1986;14 (4):238-41 [3747943.001]
  • [Cites] Cancer Treat Rep. 1979 Sep-Oct;63(9-10):1527-31 [387223.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1969 Jan;105(1):43-62 [5774280.001]
  • [Cites] Cancer J. 2005 Jul-Aug;11(4):283-93 [16197718.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(6):1246-53 [10715294.001]
  • [Cites] Cancer. 1977 Oct;40(4 Suppl):1903-11 [198110.001]
  • [Cites] Cancer. 1988 Mar 1;61(5):896-902 [3338054.001]
  • [Cites] Radiology. 1992 Oct;185(1):71-6 [1523337.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):325-32 [11872277.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4684-91 [12488414.001]
  • [Cites] Cancer. 1972 Feb;29(2):498-500 [5013552.001]
  • [Cites] Cancer. 1996 Feb 1;77(3):555-62 [8630965.001]
  • [Cites] Cancer. 1986 Apr 1;57(7):1276-80 [3948112.001]
  • [Cites] J Neurosurg. 1985 Dec;63(6):862-6 [4056900.001]
  • [Cites] J Neuropathol Exp Neurol. 1993 Sep;52(5):507-15 [8103086.001]
  • [Cites] N Engl J Med. 1974 Jul 18;291(3):127-33 [4365666.001]
  • [Cites] Br J Cancer. 1987 Sep;56(3):339-47 [2822073.001]
  • [Cites] Ann Neurol. 1988 Jan;23 (1):79-85 [3345069.001]
  • [Cites] Hum Pathol. 1999 Nov;30(11):1284-90 [10571506.001]
  • [Cites] N Engl J Med. 1985 Aug 29;313(9):579 [3894973.001]
  • [Cites] Neuro Oncol. 2003 Jul;5(3):153-60 [12816721.001]
  • [Cites] Integr Cancer Ther. 2006 Mar;5(1):40-7 [16484713.001]
  • [Cites] Br J Cancer. 1998 Sep;78(5):652-61 [9744506.001]
  • [Cites] J Clin Oncol. 2002 Oct 15;20(20):4209-16 [12377964.001]
  • [Cites] Pediatr Neurosurg. 2000 Jan;32(1):24-9 [10765135.001]
  • [Cites] J Neurooncol. 1989 Jul;7(2):165-77 [2550594.001]
  • [Cites] N Z Med J. 1987 Feb 11;100(817):81 [3469552.001]
  • [Cites] J Clin Oncol. 1991 Apr;9(4):592-9 [2066756.001]
  • [Cites] J Neurooncol. 1986;3(4):297-314 [3958776.001]
  • [Cites] J Neurosurg. 1982 Oct;57(4):452-8 [7108594.001]
  • [Cites] Haematologica. 1987 Mar-Apr;72(2):184-5 [3114078.001]
  • [Cites] J Clin Oncol. 1986 Apr;4(4):614 [3958773.001]
  • [Cites] J Clin Oncol. 2002 Aug 15;20(16):3431-7 [12177103.001]
  • [Cites] Ophthalmology. 1984 Aug;91(8):929-35 [6436764.001]
  • [Cites] JAMA. 1988 Apr 8;259(14):2123-5 [3162285.001]
  • [Cites] Cancer. 1994 Sep 15;74(6):1827-34 [8082086.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 15;50(4):929-35 [11429220.001]
  • [Cites] Pediatr Res. 1989 Jun;25(6):561-7 [2662128.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):1036-8 [15758016.001]
  • [Cites] J Clin Oncol. 2003 Feb 15;21(4):646-51 [12586801.001]
  • [Cites] Cancer. 2005 Jun 15;103(12):2636-42 [15861409.001]
  • [Cites] Cancer Res. 1965 Dec;25(11):1876-81 [5858571.001]
  • [Cites] J Clin Oncol. 1995 Jan;13(1):112-23 [7799011.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Jan 15;25(2):193-207 [8380567.001]
  • [Cites] J Neurosurg. 1990 Nov;73(5):661-7 [2213155.001]
  • [Cites] N Engl J Med. 2004 Dec 30;351(27):2865-7 [15591336.001]
  • [Cites] J Clin Neuroophthalmol. 1981 Dec;1(4):261-4 [6213670.001]
  • [Cites] Br J Cancer. 1987 Sep;56(3):331-8 [3478072.001]
  • [Cites] J Clin Oncol. 1998 Sep;16(9):3037-43 [9738573.001]
  • [Cites] Cancer. 1990 Jun 15;65(12):2771-8 [2160318.001]
  • [Cites] Cancer. 1994 Jun 15;73(12):3029-36 [8200000.001]
  • [Cites] Cancer Chemother Pharmacol. 1986;18(1):69-73 [2875808.001]
  • [Cites] J Neurosurg. 1983 Apr;58(4):543-52 [6827349.001]
  • [Cites] Neuro Oncol. 2005 Oct;7(4):485-94 [16212813.001]
  • [Cites] J Clin Oncol. 1989 Oct;7(10):1457-61 [2476531.001]
  • [Cites] J Pharmacol Exp Ther. 1980 Jun;213(3):551-6 [7193726.001]
  • [Cites] Childs Nerv Syst. 1999 Nov;15(11-12):758-63 [10603019.001]
  • [Cites] J Neurooncol. 1999 Aug;44(1):77-83 [10582673.001]
  • [Cites] Semin Oncol. 1992 Feb;19(1 Suppl 2):155-63 [1411627.001]
  • [Cites] J Neurooncol. 1992 Oct;14(2):151-8 [1432038.001]
  • [Cites] Cancer. 2000 Feb 1;88(3):685-92 [10649264.001]
  • [Cites] Cancer. 1997 Aug 1;80(3):497-504 [9241084.001]
  • [Cites] Cancer. 1985 Oct 15;56(8):1934-9 [4040801.001]
  • [Cites] Curr Neurol Neurosci Rep. 2001 Mar;1(2):162-7 [11898512.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Mar 15;43(5):959-64 [10192340.001]
  • [Cites] AJNR Am J Neuroradiol. 1988 May-Jun;9(3):517-22 [3132825.001]
  • [Cites] J Clin Neurosci. 2002 Sep;9(5):549-52 [12383413.001]
  • [Cites] Cancer Chemother Pharmacol. 1989;25(1):62-4 [2556219.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1980 Sep;6(9):1215-28 [7007303.001]
  • [Cites] J Pediatr. 1986 Feb;108(2):219-23 [3944706.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):43-51 [12007940.001]
  • [Cites] Oncologist. 2004;9(2):197-206 [15047924.001]
  • [Cites] J Neurosurg. 1980 Nov;53(5):618-26 [7431071.001]
  • [Cites] Cancer J. 2005 Jul-Aug;11(4):340-54 [16197724.001]
  • [Cites] N Engl J Med. 1993 Jun 17;328(24):1725-31 [8388548.001]
  • [Cites] Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3620-4 [14506149.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):374-9 [15667955.001]
  • [Cites] Neurology. 1996 Jun;46(6):1652-60 [8649565.001]
  • [Cites] J Neurosurg. 1991 May;74(5):701-8 [1901597.001]
  • [Cites] N Engl J Med. 1994 Dec 1;331(22):1500-7 [7969301.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Nov 1;51(3):704-10 [11597812.001]
  • [Cites] Semin Oncol. 1988 Aug;15(4):345-50 [3043669.001]
  • [Cites] Expert Rev Neurother. 2004 Nov;4(6):1005-14 [15853527.001]
  • [Cites] Cancer. 1995 Feb 15;75(4):1051-9 [7842408.001]
  • [Cites] J Neurooncol. 1989 Sep;7(3):269-81 [2795121.001]
  • [Cites] Clin Endocrinol Metab. 1986 Aug;15(3):591-606 [2429795.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1981 Feb;7(2):243-52 [6260715.001]
  • [Cites] Cancer. 2005 Jan 1;103(1):133-9 [15565574.001]
  • [Cites] Childs Nerv Syst. 1999 Oct;15(10):545-53 [10550585.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Nov 15;30(4):755-63 [7960976.001]
  • [Cites] Cancer. 1986 Apr 15;57(8):1473-82 [3948128.001]
  • [Cites] CA Cancer J Clin. 2004 Jul-Aug;54(4):208-36 [15253918.001]
  • [Cites] Cancer Treat Rep. 1976 Nov;60(11):1691-4 [1021241.001]
  • [Cites] Nat Rev Cancer. 2005 Jul;5(7):557-64 [16069817.001]
  • [Cites] Cancer. 1991 Jun 1;67(11):2772-5 [1851047.001]
  • [Cites] Drugs R D. 2003;4(2):91-101 [12718563.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Dec;17(6):1129-39 [2557303.001]
  • [Cites] Childs Nerv Syst. 1989 Apr;5(2):107-10 [2736547.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • [Cites] N Engl J Med. 1991 Nov 7;325(19):1330-6 [1922234.001]
  • [Cites] J Neurosurg. 1994 Apr;80(4):681-8 [8151347.001]
  • [Cites] Cancer. 1999 Sep 15;86(6):1064-9 [10491535.001]
  • [Cites] Am J Med. 1981 Oct;71(4):552-6 [7282743.001]
  • (PMID = 16774296.001).
  • [ISSN] 1174-5878
  • [Journal-full-title] Paediatric drugs
  • [ISO-abbreviation] Paediatr Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 155
  •  go-up   go-down


66. Raghavendra Babu YP, Vikram P, Arun M, Pradeep Kumar G, Lakshmi R: Sudden death due to dysembryoplastic neuroepithelial tumor. J Forensic Leg Med; 2010 Nov;17(8):432-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sudden death due to dysembryoplastic neuroepithelial tumor.
  • The neoplasms of neuroepithelial origin account for 3 percent of these cases.
  • A cystic swelling of the right frontal lobe was present at autopsy, histopathological examination of the swelling revealed to be Dysembryoplastic Neuroepithelial Tumour (DNT).
  • DNT is a rare neurological tumor characterized by presence of neurons, astrocytes and oligodendrocytes presenting with complex partial seizures.
  • [MeSH-major] Brain Neoplasms / pathology. Death, Sudden / etiology. Frontal Lobe / pathology. Neoplasms, Neuroepithelial / pathology

  • Genetic Alliance. consumer health - Dysembryoplastic Neuroepithelial Tumor.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd and Faculty of Forensic and Legal Medicine. All rights reserved.
  • (PMID = 21056878.001).
  • [ISSN] 1878-7487
  • [Journal-full-title] Journal of forensic and legal medicine
  • [ISO-abbreviation] J Forensic Leg Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


67. Strother D: Atypical teratoid rhabdoid tumors of childhood: diagnosis, treatment and challenges. Expert Rev Anticancer Ther; 2005 Oct;5(5):907-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical teratoid rhabdoid tumors of childhood: diagnosis, treatment and challenges.
  • Atypical teratoid rhabdoid tumor of the brain was described as a unique entity in the late 1980s.
  • It occurs primarily in early childhood but the true incidence of the disease is not yet known.
  • At presentation, the differential diagnosis includes medulloblastoma, primitive neuroectodermal tumor, ependymoma and choroid plexus carcinoma.
  • Atypical teratoid rhabdoid tumor behaves in a very aggressive manner and while cure is possible for a small minority of patients, no standard or effective therapy has been defined for most patients.
  • Since its first description, considerable pathologic, cytogenetic and molecular characterizations, as described in this review, have been accomplished that provide insight into the possible molecular etiology of the disease and of malignant rhabdoid tumors that occur outside the CNS.
  • Co-operative group clinical trials that focus solely on atypical teratoid rhabdoid tumor are needed that incorporate biologic studies along with evaluations of aggressive treatment approaches.
  • The goal of these trials should be to increase the cure rate for children with atypical teratoid rhabdoid tumor and further increase our understanding not only of atypical teratoid rhabdoid tumor, but also of other pediatric brain tumors.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / therapy. Rhabdoid Tumor / diagnosis. Rhabdoid Tumor / therapy. Teratoma / diagnosis. Teratoma / therapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16221059.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 69
  •  go-up   go-down


68. Kim TH, Mount CW, Gombotz WR, Pun SH: The delivery of doxorubicin to 3-D multicellular spheroids and tumors in a murine xenograft model using tumor-penetrating triblock polymeric micelles. Biomaterials; 2010 Oct;31(28):7386-97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The delivery of doxorubicin to 3-D multicellular spheroids and tumors in a murine xenograft model using tumor-penetrating triblock polymeric micelles.
  • Doxorubicin (DOX) is an effective chemotherapeutic against a wide range of solid tumors.
  • However, its clinical use is limited by severe side effects such as cardiotoxicity as well as inherent and acquired drug resistance of tumors.
  • DOX encapsulation within self-assembled polymeric micelles has the potential to decrease the systemic distribution of free drug and enhance the drug accumulation in the tumor via the enhanced permeability and retention (EPR).
  • To evaluate DOX activity, micelles were tested in both monolayer cell cultures and three-dimensional (3-D) multicellular spheroids (MCS) that mimic solid tumors.
  • Antitumor activity in vivo was further studied with tumor-bearing mice.
  • Finally, DOX-loaded micelles mediate efficient tumor delivery from tail vein injections to tumor-bearing mice with much less toxicity compared with free DOX.
  • [MeSH-minor] Animals. Apoptosis. Biocompatible Materials / chemistry. Biocompatible Materials / metabolism. Cell Line. Cell Line, Tumor. Drug Compounding. Drug Delivery Systems. Humans. Male. Materials Testing. Mice. Mice, Nude. Molecular Structure

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20598741.001).
  • [ISSN] 1878-5905
  • [Journal-full-title] Biomaterials
  • [ISO-abbreviation] Biomaterials
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Biocompatible Materials; 0 / Micelles; 0 / Polymers; 0 / poly(ethylene oxide)-poly(3-hydroxybutyrate)-poly(ethylene oxide); 30IQX730WE / Polyethylene Glycols; 80168379AG / Doxorubicin
  •  go-up   go-down


69. Falchetti A, Marini F, Tonelli F, Brandi ML: Lessons from genes mutated in multiple endocrine neoplasia (MEN) syndromes. Ann Endocrinol (Paris); 2005 Jun;66(3):195-205
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lessons from genes mutated in multiple endocrine neoplasia (MEN) syndromes.
  • Multiple endocrine neoplasia (MEN) types 1 and 2 syndromes are rare hereditary cancer syndromes expressing a variety of endocrine and non-endocrine neoplasias and lesions.
  • The MEN1 gene, a tumour suppressor gene, is responsible of MEN1 syndrome, and is probably involved in the regulation of several cell functions, including DNA replication and repair and transcriptional machinery.
  • Consequently, the combination of new genetic and diagnostic tools could permit a precocious detection of MEN-associated neoplasms, and in particular the identification of a strong genotype-phenotype correlations in MEN2 syndrome demonstrates an improving outcome and quality of life for affected subjects.
  • [MeSH-major] Multiple Endocrine Neoplasia Type 1 / genetics. Multiple Endocrine Neoplasia Type 2a / genetics. Mutation
  • [MeSH-minor] Humans. Hyperparathyroidism / genetics. Insulinoma / genetics. Oncogene Proteins / genetics. Pancreatic Neoplasms / genetics. Proto-Oncogene Proteins c-ret. Receptor Protein-Tyrosine Kinases / genetics

  • Genetic Alliance. consumer health - Multiple Endocrine Neoplasia.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15988380.001).
  • [ISSN] 0003-4266
  • [Journal-full-title] Annales d'endocrinologie
  • [ISO-abbreviation] Ann. Endocrinol. (Paris)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Oncogene Proteins; EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.10.1 / RET protein, human; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases
  • [Number-of-references] 92
  •  go-up   go-down


70. Fléchon A, Rivoire M, Droz JP: Management of advanced germ-cell tumors of the testis. Nat Clin Pract Urol; 2008 May;5(5):262-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of advanced germ-cell tumors of the testis.
  • Advanced tumors of the testis are curable.
  • Standard treatment includes chemotherapy with a combination of bleomycin, etoposide and cisplatin, followed by surgical resection of residual tumor.
  • The number of cycles of chemotherapy needed depends on prognostic factors such as the primary site, histology, presence of visceral metastases, and serum levels of tumor markers.
  • After chemotherapy, resection of all residual local disease and systematic retroperitoneal dissection of bulky lymph-node disease are mandatory for patients with nonseminoma germ-cell tumors.
  • In patients with seminoma, surgery is required when residual disease is either bulky or functional on (18)fluorodeoxyglucose-PET scan.
  • Secondary malignancies are reported, as well as contralateral germ-cell tumors.
  • Owing to the complexity of treatment and the multidisciplinary approach required, patients with advanced germ-cell tumors should be managed in high-volume centers with experience of treating large numbers of patients.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal / therapy. Testicular Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Biomarkers, Tumor. Humans. Lymphatic Metastasis. Male. Neoplasm Staging. Neoplasm, Residual / surgery. Prognosis. Risk Assessment

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18398406.001).
  • [ISSN] 1743-4289
  • [Journal-full-title] Nature clinical practice. Urology
  • [ISO-abbreviation] Nat Clin Pract Urol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor
  • [Number-of-references] 97
  •  go-up   go-down


71. Jiang L, Lv Y, Liu XG, Ma QJ, Wei F, Dang GT, Liu ZJ: Results of surgical treatment of cervical dumbbell tumors: surgical approach and development of an anatomic classification system. Spine (Phila Pa 1976); 2009 May 20;34(12):1307-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of surgical treatment of cervical dumbbell tumors: surgical approach and development of an anatomic classification system.
  • STUDY DESIGN: A retrospective study of a new classification and surgical approach of cervical dumbbell tumors.
  • METHODS: PUTH classification for cervical dumbbell tumors includes 7 categories (types 1-7) and 2 foraminal modifiers.
  • Posterior approach is appropriate for type 1, 2 and 5 tumors, anterior and anterolateral approach is an ideal choice for type 4 and 6 tumors.
  • Type 7 tumors need combined anterior and posterior approach.
  • RESULTS: Forty-four consecutive patients with cervical dumbbell tumor were surgically treated.
  • Tumors were unilateral in 41 cases, and bilateral in 3 cases.
  • Five were tumor revision cases.
  • Tumors involved nerve roots were transected in 12 cases.
  • The complications included cerebrospinal fluid leakage in 18 cases, esophagus injury in 1, Horner syndrome in 1, dysphagia in 2, dyspnea in 1 and deep infection in 1.
  • CONCLUSION: PUTH classification covers all tumor types and is easier to remember.
  • The recurrence rate decreases significantly after radial tumor resection.
  • [MeSH-major] Cervical Vertebrae / surgery. Neurilemmoma / surgery. Neurofibroma / surgery. Neurosurgical Procedures / methods. Peripheral Nervous System Neoplasms / surgery. Spinal Nerve Roots / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Decompression, Surgical / methods. Female. Ganglioneuroma / classification. Ganglioneuroma / pathology. Ganglioneuroma / surgery. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local / prevention & control. Postoperative Complications / etiology. Postoperative Complications / physiopathology. Postoperative Complications / prevention & control. Reoperation. Retrospective Studies. Spinal Canal / anatomy & histology. Spinal Canal / pathology. Spinal Canal / surgery. Spinal Curvatures / etiology. Spinal Curvatures / radiography. Spinal Curvatures / surgery. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Neck Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19455006.001).
  • [ISSN] 1528-1159
  • [Journal-full-title] Spine
  • [ISO-abbreviation] Spine
  • [Language] eng
  • [Publication-type] Case Reports; Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Chow SP, Nastri A, Hardy T: Infratemporal inflammatory myofibroblastic tumour with orbital extension. Clin Exp Ophthalmol; 2010 Oct;38(7):727-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infratemporal inflammatory myofibroblastic tumour with orbital extension.
  • Inflammatory myofibroblastic tumour (IMT) is a rare distinctive neoplasm of intermediate biological potential with a predilection for the abdominopelvic region and lung of children and young adults.
  • [MeSH-major] Neoplasms, Muscle Tissue / diagnosis. Orbit / pathology. Skull Base Neoplasms / diagnosis
  • [MeSH-minor] Adrenal Cortex Hormones / therapeutic use. Adult. Cranial Fossa, Middle / pathology. Cranial Fossa, Middle / surgery. Female. Humans. Magnetic Resonance Imaging. Neoplasm Invasiveness. Osteotomy / methods. Pterygopalatine Fossa / pathology. Pterygopalatine Fossa / surgery. Radiotherapy, Adjuvant. Tomography, X-Ray Computed. Zygoma / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. Journal compilation © 2010 Royal Australian and New Zealand College of Ophthalmologists.
  • (PMID = 20497435.001).
  • [ISSN] 1442-9071
  • [Journal-full-title] Clinical & experimental ophthalmology
  • [ISO-abbreviation] Clin. Experiment. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones
  •  go-up   go-down


73. Burch S, London C, Seguin B, Rodriguez C, Wilson BC, Bisland SK: Treatment of canine osseous tumors with photodynamic therapy: a pilot study. Clin Orthop Relat Res; 2009 Apr;467(4):1028-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of canine osseous tumors with photodynamic therapy: a pilot study.
  • Photodynamic therapy uses nonthermal coherent light delivered via fiber optic cable to locally activate a photosensitive chemotherapeutic agent that ablates tumor tissue.
  • Owing to the limitations of light penetration, it is unknown whether photodynamic therapy can treat large osseous tumors.
  • We determined whether photodynamic therapy can induce necrosis in large osseous tumors, and if so, to quantify the volume of treated tissue.
  • Tumors were imaged with MRI before and 48 hours after treatment, and the volumes of hypointense regions were compared.
  • We identified tumor necrosis histologically; the regions of necrosis corresponded anatomically to hypointense tissue on MRI.
  • These pilot data suggest photodynamic therapy penetrates relatively large canine osseous tumors and may be a useful adjunct for treatment of bone tumors.
  • [MeSH-major] Bone Neoplasms / veterinary. Osteosarcoma / veterinary. Photochemotherapy / veterinary. Photosensitizing Agents / therapeutic use
  • [MeSH-minor] Animals. Dogs. Magnetic Resonance Imaging / veterinary. Necrosis / pathology. Necrosis / radionuclide imaging. Neoplasm Staging / veterinary. Pilot Projects

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acad Radiol. 2000 Feb;7(2):83-93 [10730163.001]
  • [Cites] Photochem Photobiol. 1996 Feb;63(2):229-37 [8657737.001]
  • [Cites] Res Exp Med (Berl). 2000 Jun;199(6):341-57 [10945652.001]
  • [Cites] Ann Surg Oncol. 2001 Jan-Feb;8(1):65-71 [11206227.001]
  • [Cites] Int J Cancer. 2001 Sep 1;93(5):720-4 [11477585.001]
  • [Cites] Radiother Oncol. 2001 Sep;60(3):281-8 [11514008.001]
  • [Cites] Mayo Clin Proc. 1997 Jul;72(7):595-602 [9212759.001]
  • [Cites] Cancer. 1997 Oct 15;80(8 Suppl):1668-73 [9362434.001]
  • [Cites] Ann Surg Oncol. 1997 Dec;4(8):628-33 [9416409.001]
  • [Cites] Photochem Photobiol. 1997 Dec;66(6):847-52 [9421970.001]
  • [Cites] Radiology. 1998 Jan;206(1):227-35 [9423677.001]
  • [Cites] Ann Thorac Surg. 1997 Dec;64(6):1611-8 [9436544.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5425-31 [9850075.001]
  • [Cites] Br J Cancer. 1999 Apr;79(11-12):1702-8 [10206280.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1999 May;66(5):623-7 [10209174.001]
  • [Cites] J Clin Pathol. 1964 Jul;17:448-57 [14195633.001]
  • [Cites] J Orthop Res. 2005 Sep;23(5):995-1003 [16140186.001]
  • [Cites] J Biomed Opt. 2005 May-Jun;10(3):034011 [16229655.001]
  • [Cites] Clin Orthop Relat Res. 2007 Jan;454:230-6 [16924176.001]
  • [Cites] J Neurosci Nurs. 2001 Dec;33(6):296-300 [11776711.001]
  • [Cites] BJU Int. 2002 May;89(7):665-70 [11966622.001]
  • [Cites] Neurology. 2002 May 14;58(9):1360-6 [12011281.001]
  • [Cites] Int J Cancer. 2003 Mar 1;103(6):829-32 [12516106.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):1025-33 [12615718.001]
  • [Cites] Cell Mol Biol (Noisy-le-grand). 2002 Dec;48(8):931-7 [12699253.001]
  • [Cites] Cancer. 2003 Jun 1;97(11):2783-90 [12767091.001]
  • [Cites] Technol Cancer Res Treat. 2003 Aug;2(4):311-7 [12892513.001]
  • [Cites] Lung Cancer. 2003 Oct;42(1):103-11 [14512194.001]
  • [Cites] Cancer. 2003 Oct 15;98(8):1767-71 [14534895.001]
  • [Cites] Eur Spine J. 2003 Oct;12 Suppl 2:S202-13 [14505120.001]
  • [Cites] Dermatol Surg. 2004 Feb;30(2 Pt 2):264-71 [14871220.001]
  • [Cites] Ann Surg Oncol. 2004 Mar;11(3):322-7 [14993029.001]
  • [Cites] J Clin Laser Med Surg. 2004 Feb;22(1):3-8 [15117480.001]
  • [Cites] Neoplasia. 2004 May-Jun;6(3):224-33 [15153334.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2192-201 [15169808.001]
  • [Cites] Lancet Oncol. 2004 Aug;5(8):497-508 [15288239.001]
  • [Cites] Clin Orthop Relat Res. 1980 Nov-Dec;(153):106-20 [7449206.001]
  • [Cites] Instr Course Lect. 1988;37:3-10 [3047253.001]
  • [Cites] Jpn J Cancer Res. 2000 Apr;91(4):439-45 [10804293.001]
  • (PMID = 19159117.001).
  • [ISSN] 1528-1132
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents
  • [Other-IDs] NLM/ PMC2650069
  •  go-up   go-down


74. Muela Molinero A, Jorquera Plaza F, Ribas Ariño T, Malagón Rojo R, Santos Calderón JA, Espinel Díez V, Olcoz Goñi JL, Quiroga Prado L: [Analysis of the characteristics of patients with bladder cancer diagnosed of multiple neoplasms in the health district of León (Spain)]. Rev Clin Esp; 2006 Oct;206(9):422-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of the characteristics of patients with bladder cancer diagnosed of multiple neoplasms in the health district of León (Spain)].
  • [Transliterated title] Análisis de las características de los pacientes con cáncer vesical diagnosticados de neoplasias múltiples en el área sanitaria de León.
  • OBJECTIVE: We analyzed the characteristics of the patients with bladder neoplasms who developed a multiple malignant primary neoplasm (MMPN) in the health district of León, the impact on survival and the prognostic variables.
  • MATERIAL AND METHODS: We have used the data from the Tumor Registry of the Hospital of León and selected all those patients who were diagnosed of a bladder tumor between 1993 and 2002.
  • They were classified into two groups: the first with 71 patients with MMPN and a second group with 159 patients with single bladder tumors diagnosed between 1996 and 1997.
  • The second most frequently diagnosed neoplasms were urologic, followed by gastrointestinal and respiratory.
  • Survival of patients with MMPN was 21 percent lower than single neoplasms.
  • Variables with prognosis significance were the stage of the second neoplasm, diagnosis of a second urologic neoplasm and surgery treatment for the second tumor.
  • CONCLUSIONS: MMPN in patients with bladder tumors are frequent in our geographic area.
  • Prognosis of MMPN patients is worse than single tumors patients, but no differences were observed regarding prognosis in patients with synchronous or metachronous MMPN.
  • [MeSH-major] Neoplasms, Multiple Primary / epidemiology. Urinary Bladder Neoplasms / epidemiology

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17042983.001).
  • [ISSN] 0014-2565
  • [Journal-full-title] Revista clínica española
  • [ISO-abbreviation] Rev Clin Esp
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


75. Werther M, Schmelz HU, Schwerer M, Sparwasser C: [Sclerosing Sertoli cell tumor of the testis: a rare tumor. Case report and review of the literature on the subtypes of Sertoli-cell tumor]. Urologe A; 2007 Nov;46(11):1551-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Sclerosing Sertoli cell tumor of the testis: a rare tumor. Case report and review of the literature on the subtypes of Sertoli-cell tumor].
  • [Transliterated title] Sklerosierender Sertoli-Zell-Tumor des Hodens - ein seltener Tumor : Fallvorstellung und Literaturübersicht über die Subtypen des Sertoli-Zell-Tumors.
  • Sertoli cell tumors of the testis are extremely rare (0.4-1.5% of all testicular neoplasms) and have a heterogeneous pathology.
  • Histopathologically classic, large cell calcifying and sclerosing subtypes are differentiated.Up to now, 14 cases of sclerosing Sertoli cell tumor are known.
  • This article presents a new case and compares the three subtypes.
  • The subtypes differ in particular in age of onset, malignant potential, prognosis, and therapy.
  • While no cases of sclerosing Sertoli cell tumor with a malignant course have been reported, both other subtypes have been found to be potentially malignant.
  • In the case of malignancy the prognosis is very poor, and it is difficult to select the best treatment because there is so little experience with this type of tumor.
  • Once the diagnosis of a Sertoli cell tumor has been confirmed, exact determination of the histological subtype is essential to allow appropriate risk-adapted therapy.
  • [MeSH-major] Sertoli Cell Tumor / diagnosis. Testicular Neoplasms / diagnosis
  • [MeSH-minor] Adult. Biomarkers, Tumor / blood. Biopsy. Diagnosis, Differential. Fatty Liver, Alcoholic / blood. Humans. Male. Neoplasm Staging. Sclerosis. Testis / pathology. Ultrasonography. alpha-Fetoproteins

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Surg Oncol. 1990 Jun;44(2):129-31 [2355742.001]
  • [Cites] Cancer. 2003 Aug 15;98(4):753-7 [12910519.001]
  • [Cites] J Coll Physicians Surg Pak. 2005 Jul;15(7):437-8 [16197877.001]
  • [Cites] AJR Am J Roentgenol. 1994 Aug;163(2):373-5 [8037034.001]
  • [Cites] Medicine (Baltimore). 1985 Jul;64(4):270-83 [4010501.001]
  • [Cites] Am J Surg Pathol. 1998 Jun;22(6):709-21 [9630178.001]
  • [Cites] Urol Int. 2005;75(4):365-7 [16327308.001]
  • [Cites] Am J Surg Pathol. 1995 Jan;19(1):50-8 [7802138.001]
  • [Cites] Int Urol Nephrol. 2003;35(4):515-6 [15198158.001]
  • [Cites] Scand J Urol Nephrol. 1999 Jun;33(3):197-9 [10452297.001]
  • [Cites] J Am Osteopath Assoc. 1996 Oct;96(10):612-4 [8936931.001]
  • [Cites] Am J Surg Pathol. 1997 Nov;21(11):1271-80 [9351565.001]
  • [Cites] Br J Urol. 1988 May;61(5):456-7 [3134972.001]
  • [Cites] J Urol. 1995 Nov;154(5):1756-8 [7563340.001]
  • [Cites] Urol Int. 2003;70(3):205-10 [12660458.001]
  • [Cites] Acta Oncol. 1990;29(7):946-9 [2261213.001]
  • [Cites] Am J Surg Pathol. 1991 Sep;15(9):829-34 [1719830.001]
  • [Cites] Histopathology. 1995 Mar;26(3):255-9 [7541015.001]
  • (PMID = 17898983.001).
  • [ISSN] 0340-2592
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / alpha-Fetoproteins
  • [Number-of-references] 20
  •  go-up   go-down


76. Perez EA, Livingstone AS, Franceschi D, Rocha-Lima C, Lee DJ, Hodgson N, Jorda M, Koniaris LG: Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors. J Am Coll Surg; 2006 Apr;202(4):623-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors.
  • BACKGROUND: Gastrointestinal stromal tumors (GISTs) have been recognized as the most common mesenchymal tumors of the gastrointestinal tract.
  • The most effective treatment for unresectable tumors is imatinib mesylate, based on two phase II trials.
  • STUDY DESIGN: The 13-center cumulative tumor registry (April 2005 release) from the Surveillance, Epidemiology, and End Results (SEER) database was queried from 1992 to 2002 to determine incidence and associated outcomes for patients diagnosed with GIST.
  • This increase is mostly because smooth-muscle tumors have been reclassified as GISTs, but it also represents a 50% increase in population- and age-adjusted gastrointestinal mesenchymal tumor diagnosis since 1992.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Gastrointestinal Stromal Tumors / drug therapy. Gastrointestinal Stromal Tumors / epidemiology. Piperazines / therapeutic use. Protein Kinase Inhibitors / therapeutic use. Pyrimidines / therapeutic use

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16571433.001).
  • [ISSN] 1072-7515
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


77. Seo SH, Shin DH, Kang HJ, Choi KU, Kim JY, Park DY, Lee CH, Sol MY, Lee JC: Reticulated myxoid tumor of the tongue: 2 cases supporting an expanded clinical and immunophenotypic spectrum of ectomesenchymal chondromyxoid tumor of the tongue. Am J Dermatopathol; 2010 Oct;32(7):660-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reticulated myxoid tumor of the tongue: 2 cases supporting an expanded clinical and immunophenotypic spectrum of ectomesenchymal chondromyxoid tumor of the tongue.
  • An ectomesenchymal chondromyxoid tumor (ECMT) is a rare neoplasm that exclusively occurs in the anterior dorsum of the tongue.
  • The tumor consists of small round to fusiform or spindle cells with myxoid or chondroid stroma.
  • The tumor consistently shows a positive reaction with glial fibrillary acidic protein antibodies, especially polyclonal antibodies.
  • We report 2 cases of reticulated myxoid tumors arising in the tongue.
  • One tumor occurred in the posterior dorsum of the tongue and another in the anterior.
  • Both tumors showed characteristic morphology of ECMT; however, both were negative for reactions with monoclonal and polyclonal glial fibrillary acidic protein antibodies.
  • [MeSH-major] Biomarkers, Tumor / analysis. Myxoma / pathology. Tongue Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20661118.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glial Fibrillary Acidic Protein
  •  go-up   go-down


78. Wilzén A, Nilsson S, Sjöberg RM, Kogner P, Martinsson T, Abel F: The Phox2 pathway is differentially expressed in neuroblastoma tumors, but no mutations were found in the candidate tumor suppressor gene PHOX2A. Int J Oncol; 2009 Mar;34(3):697-705
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Phox2 pathway is differentially expressed in neuroblastoma tumors, but no mutations were found in the candidate tumor suppressor gene PHOX2A.
  • Neuroblastoma (NB), a tumor of the sympathetic nervous system, is the most common solid tumor in childhood.
  • By microarray expression analysis (Affymetrix HU133A) important players in the noradrenalin biosynthesis pathway (DBH, DDC, GATA2, GATA3, PHOX2A, PHOX2B, SLC6A2 SLC18A1 and TH) were found to be among the top ranked genes in showing lower expression in unfavorable NB tumor types as compared to favorable ones.
  • By quantitative PCR with TaqMan, this result was significantly verified for all transcripts (p<0.05, one-tailed) in a new set of 11 primary NB tumors (5 favorable vs. 6 unfavorable).
  • Since the PHOX2A gene is localized in a tumor suppressor candidate region at 11q, we screened this gene for mutations by DNA sequencing in 47 tumors of different stages.
  • However, no critical changes were found that could support its role in tumor development or progression.
  • Overall, the findings in this study either suggest that expression of this pathway could be a predictive differentiation marker of NB tumors, or our results could also imply that the noradrenalin biosynthesis pathway is involved in tumor pathogenesis.
  • [MeSH-major] Genes, Tumor Suppressor. Homeodomain Proteins / biosynthesis. Neuroblastoma / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Base Sequence. Cell Line, Tumor. Child. Child, Preschool. DNA Mutational Analysis. Female. Gene Expression Regulation, Neoplastic. Humans. Infant. Infant, Newborn. Male. Microarray Analysis. Middle Aged. Molecular Sequence Data. Reverse Transcriptase Polymerase Chain Reaction / methods. Young Adult

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19212675.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / PHOX2A protein, human
  •  go-up   go-down


79. Robinson J, Nye E, Stamp G, Silver A: Osteogenic tumours in Lkb1-deficient mice. Exp Mol Pathol; 2008 Dec;85(3):223-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteogenic tumours in Lkb1-deficient mice.
  • Germline mutation in LKB1 is the cause of Peutz-Jeghers Syndrome in humans, a rare disorder predisposing to cancer and multiple gastrointestinal hamartomous polyps.
  • Mice harboring a germline inactivating Lkb1 mutation develop similar gastrointestinal polyps and liver neoplasia.
  • Stepped serial sectioning of the whole spinal column found multiple osteogenic tumours that were lobulated, showed osteoid formation and had an infiltrative growth pattern, which extended into the surrounding muscle.
  • Osteogenic tumours were also present in asymptomatic Lkb1(+/-) mice (n=12) in the lateral spinous processes, spinous vertebral bodies and the bodies of sacral tail vertebrae.
  • This is the first report of multifocal osteoblastic tumours in Lkb1(+/-) mice and our observations indicate that Lkb1, like Pten, may have a distinct role in controlling osteoblast proliferation in the mouse.
  • [MeSH-major] Bone Neoplasms / enzymology. Protein-Serine-Threonine Kinases / deficiency


80. Triponez F, Dosseh D, Goudet P, Cougard P, Bauters C, Murat A, Cadiot G, Niccoli-Sire P, Chayvialle JA, Calender A, Proye CA: Epidemiology data on 108 MEN 1 patients from the GTE with isolated nonfunctioning tumors of the pancreas. Ann Surg; 2006 Feb;243(2):265-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiology data on 108 MEN 1 patients from the GTE with isolated nonfunctioning tumors of the pancreas.
  • OBJECTIVE: To analyze the penetrance and clinical course of isolated nonfunctioning tumors of the pancreas (NFTP) in MEN 1 patients, and to propose a strategy for managing them.
  • SUMMARY BACKGROUND DATA: Pancreaticoduodenal tumors develop in a majority of MEN 1 patients and are a major cause of death.
  • METHODS: Data on 108 patients with isolated NFTP among 579 MEN 1 patients from the French Endocrine Tumor Study Group (GTE) were analyzed.
  • RESULTS: The penetrance of NFTP was 34% at age 50, making it the most frequent pancreaticoduodenal tumor in MEN 1 patients.
  • Average life expectancy for patients with NFTP was shorter than that for MEN 1 patients who did not have pancreaticoduodenal tumors.
  • Tumor size was correlated with the risks of metastasis and death.
  • These risks were low for patients with tumors<or=20 mm.
  • CONCLUSIONS: NFTP are currently the most common tumors of the pancreaticoduodenal region in patients with MEN 1.
  • Prevention of tumor spread by surgery should be balanced with potential operative mortality and morbidity.
  • [MeSH-major] Multiple Endocrine Neoplasia Type 1 / epidemiology. Pancreatic Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Chir. 2002 Oct;127(8):591-9 [12491633.001]
  • [Cites] Am J Gastroenterol. 2000 Sep;95(9):2271-7 [11007228.001]
  • [Cites] Am J Clin Oncol. 2003 Jun;26(3):270-2 [12796599.001]
  • [Cites] Br J Surg. 2003 Jun;90(6):748-54 [12808627.001]
  • [Cites] Surg Oncol. 2003 Aug;12(2):135-43 [12946484.001]
  • [Cites] Surg Endosc. 2003 Oct;17(10):1658-62 [12915965.001]
  • [Cites] Medicine (Baltimore). 2004 Jan;83(1):43-83 [14747767.001]
  • [Cites] Ann Chir. 2004 Apr;129(3):149-55 [15142812.001]
  • [Cites] Ann Surg. 2004 Nov;240(5):757-73 [15492556.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2004 Oct;18(5):947-55 [15494288.001]
  • [Cites] Surgery. 1979 Sep;86(3):475-84 [38521.001]
  • [Cites] World J Surg. 1984 Aug;8(4):561-74 [6207668.001]
  • [Cites] Nature. 1988 Mar 3;332(6159):85-7 [2894610.001]
  • [Cites] N Engl J Med. 1990 Mar 29;322(13):898-903 [2179721.001]
  • [Cites] J Clin Endocrinol Metab. 1991 Aug;73(2):281-7 [1677362.001]
  • [Cites] Arch Surg. 1991 Aug;126(8):935-52 [1677802.001]
  • [Cites] N Engl J Med. 1992 Jun 25;326(26):1721-6 [1317506.001]
  • [Cites] Arch Surg. 1993 Jun;128(6):683-90 [8099273.001]
  • [Cites] Gastroenterology. 1995 Jun;108(6):1637-49 [7768367.001]
  • [Cites] World J Surg. 1996 Sep;20(7):872-6; discussion 877 [8678965.001]
  • [Cites] Gastroenterology. 1996 Oct;111(4):845-54 [8831579.001]
  • [Cites] Am J Surg Pathol. 1996 Nov;20(11):1378-84 [8898842.001]
  • [Cites] Science. 1997 Apr 18;276(5311):404-7 [9103196.001]
  • [Cites] Surgery. 1997 Dec;122(6):1012-9; discussion 1019-20 [9426414.001]
  • [Cites] World J Surg. 1998 Mar;22(3):309-18 [9494425.001]
  • [Cites] World J Surg. 1998 Jun;22(6):581-6; discussion 586-7 [9597932.001]
  • [Cites] World J Surg. 1998 Jul;22(7):673-7; discussion 667-8 [9606280.001]
  • [Cites] J Intern Med. 1998 Jun;243(6):477-88 [9681846.001]
  • [Cites] J Intern Med. 1998 Jun;243(6):495-500 [9681848.001]
  • [Cites] Am J Hum Genet. 1998 Aug;63(2):455-67 [9683585.001]
  • [Cites] Surgery. 1998 Dec;124(6):1037-42 [9854580.001]
  • [Cites] Surgery. 1998 Dec;124(6):1043-8, discussion 1048-9 [9854581.001]
  • [Cites] Surgery. 1998 Dec;124(6):1134-43; discussion 1143-4 [9854595.001]
  • [Cites] Gastroenterology. 1999 Feb;116(2):286-93 [9922308.001]
  • [Cites] N Engl J Med. 1999 Aug 26;341(9):635-44 [10460814.001]
  • [Cites] Am J Med. 1954 Mar;16(3):363-71 [13138607.001]
  • [Cites] World J Surg. 2004 Dec;28(12):1317-22 [15517479.001]
  • [Cites] World J Surg. 2004 Dec;28(12):1248-60 [15517487.001]
  • [Cites] Gastroenterol Clin Biol. 2004 Nov;28(11):1075-81 [15657529.001]
  • [Cites] Surgery. 2004 Dec;136(6):1205-11 [15657577.001]
  • [Cites] World J Surg. 2000 Nov;24(11):1437-41 [11038219.001]
  • [Cites] Surgery. 2000 Dec;128(6):958-66 [11114630.001]
  • [Cites] World J Surg. 2001 Apr;25(4):452-60 [11344398.001]
  • [Cites] Ann Surg. 2001 Oct;234(4):495-505; discussion 505-6 [11573043.001]
  • [Cites] Br J Radiol. 2001 Oct;74(886):968-73 [11675319.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Dec;86(12):5658-71 [11739416.001]
  • [Cites] Langenbecks Arch Surg. 2002 Mar;386(8):558-69 [11914931.001]
  • [Cites] N Engl J Med. 2002 Apr 11;346(15):1128-37 [11948273.001]
  • [Cites] Ann Surg. 2000 Jun;231(6):909-18 [10816635.001]
  • [Cites] J Intern Med. 2003 Jun;253(6):590-8 [12755954.001]
  • (PMID = 16432361.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1448903
  •  go-up   go-down


81. Arteaga-Gómez AC, Aranda-Flores C, Márquez-Acosta G, Colín-Valenzuela A: [Adnexal tumor and pregnancy: diagnosis and treatment]. Ginecol Obstet Mex; 2010 Mar;78(3):160-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adnexal tumor and pregnancy: diagnosis and treatment].
  • [Transliterated title] Tumor anexial y embarazo: diagnóstico y tratamiento.
  • BACKGROUND: The finding of adnexal masses during pregnancy is an exceptional event.
  • The diagnosis was established by ultrasound (USG) in 95% of cases, 48% had cystic characteristics, the mean diameter of the tumor was 99 +/- 42 mm.
  • The mean tumor size was 118 mm (range 2 a 40 mm), weight 1,370 g (range 10 a 5,800 g).
  • The most frequent histological diagnosis were serous cyst (40%), mature teratoma (28%), mucinous (6%), malignancy (4%).
  • Tumor markers (CA-125, AFP, GCH-B,DHL, ACE), are not useful during pregnancy.
  • If the tumor doesn't achieve surgical criteria the recommended follow up is clinical observation and USG.
  • If surgery is decided, it should be performed between 16 a 23 weeks of pregnancy, and it's recommended to send the tumor to histological diagnosis, in case of malignancy the surgery will continue according to the tumor stage.
  • [MeSH-major] Adnexa Uteri / pathology. Genital Neoplasms, Female / surgery. Genital Neoplasms, Female / ultrasonography. Pregnancy Complications, Neoplastic / surgery. Pregnancy Complications, Neoplastic / ultrasonography
  • [MeSH-minor] Adnexal Diseases / blood. Adnexal Diseases / surgery. Adnexal Diseases / ultrasonography. Adolescent. Adult. Biomarkers, Tumor / blood. Carcinoma / blood. Carcinoma / surgery. Carcinoma / ultrasonography. Cesarean Section. Cystadenoma / blood. Cystadenoma / surgery. Cystadenoma / ultrasonography. Cysts / blood. Cysts / surgery. Cysts / ultrasonography. Female. Gestational Age. Humans. Incidence. Incidental Findings. Infant, Newborn. Middle Aged. Pregnancy. Retrospective Studies. Teratoma / blood. Teratoma / surgery. Teratoma / ultrasonography. Ultrasonography, Prenatal. Young Adult

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20939220.001).
  • [ISSN] 0300-9041
  • [Journal-full-title] Ginecología y obstetricia de México
  • [ISO-abbreviation] Ginecol Obstet Mex
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


82. Horisberger K, Hofheinz RD, Palma P, Volkert AK, Rothenhoefer S, Wenz F, Hochhaus A, Post S, Willeke F: Tumor response to neoadjuvant chemoradiation in rectal cancer: predictor for surgical morbidity? Int J Colorectal Dis; 2008 Mar;23(3):257-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor response to neoadjuvant chemoradiation in rectal cancer: predictor for surgical morbidity?
  • BACKGROUND: Increasing the rate of pathological complete remissions after neoadjuvant chemoradiation of rectal cancer has become a strategy to further improve the long-term oncological outcome of patients.
  • The median distance of the tumour from the dentate line was 5 cm.
  • Tumors were called major responsive when assigned to the regression grades 3 or 2, and minor or nonresponsive at regression grades 1 or 0.
  • Seven out of 45 patients (15.5%) with sphincter-preserving surgery suffered from suture breakdown; they all had previously shown a major response of the resected tumor.
  • Our results underline the oncological benefit of intensified neoadjuvant chemoradiation, but the severity of complications in low rectal anastomosis of patients with good response after neoadjuvant therapy should alert surgeons and oncologists.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Agents / therapeutic use. Colectomy / methods. Postoperative Complications / epidemiology. Rectal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Germany / epidemiology. Humans. Male. Middle Aged. Morbidity / trends. Neoadjuvant Therapy / methods. Neoplasm Staging / methods. Radiotherapy, Adjuvant / methods. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1993 Feb 20;341(8843):457-60 [8094488.001]
  • [Cites] Int J Colorectal Dis. 2008 Jan;23(1):67-76 [17704925.001]
  • [Cites] Dis Colon Rectum. 1997 Jul;40(7):747-51 [9221846.001]
  • [Cites] Radiology. 1998 Jan;206(1):131-6 [9423662.001]
  • [Cites] N Engl J Med. 1997 Apr 3;336(14 ):980-7 [9091798.001]
  • [Cites] Ann Oncol. 2007 Apr;18(4):738-44 [17208931.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8688-96 [16246976.001]
  • [Cites] N Engl J Med. 2001 Aug 30;345(9):638-46 [11547717.001]
  • [Cites] Semin Surg Oncol. 2003;21(4):265-70 [14648785.001]
  • [Cites] Anticancer Res. 2007 Jul-Aug;27(4C):2877-80 [17695464.001]
  • [Cites] Dis Colon Rectum. 2003 Apr;46(4):448-53 [12682535.001]
  • [Cites] J Am Coll Surg. 1995 Oct;181(4):335-46 [7551328.001]
  • [Cites] ANZ J Surg. 2005 May;75(5):286-91 [15932438.001]
  • [Cites] Br J Cancer. 2005 Apr 11;92 (7):1215-20 [15785742.001]
  • [Cites] Am J Surg. 2006 Dec;192(6):873-7 [17161111.001]
  • [Cites] Dis Colon Rectum. 2001 Jan;44(1):52-8 [11805563.001]
  • [Cites] J Surg Oncol. 2003 Jan;82(1):3-9 [12501163.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1384-90 [16979839.001]
  • [Cites] Ann Surg. 2004 Aug;240(2):260-8 [15273550.001]
  • [Cites] Br J Cancer. 2007 Mar 26;96(6):912-7 [17325705.001]
  • [Cites] J Clin Oncol. 2005 Mar 1;23 (7):1350-7 [15684318.001]
  • [Cites] Br J Surg. 1998 Mar;85(3):355-8 [9529492.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):817-25 [11821466.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8697-705 [16314629.001]
  • [Cites] Gastroenterol Clin Biol. 2005 May;29(5):509-14 [15980743.001]
  • [Cites] Onkologie. 2007 Mar;30(3):141-5 [17341902.001]
  • [Cites] Ann R Coll Surg Engl. 1991 Nov;73(6):385-8 [1759770.001]
  • [Cites] J Clin Oncol. 2006 Feb 1;24(4):650-5 [16446336.001]
  • [Cites] Br J Surg. 2006 Oct;93(10):1215-23 [16983741.001]
  • [Cites] N Engl J Med. 2004 Jul 22;351(4):337-45 [15269313.001]
  • [Cites] J Exp Clin Cancer Res. 2007 Mar;26(1):61-70 [17550133.001]
  • [Cites] Int J Colorectal Dis. 2003 Nov;18(6):495-9 [14517686.001]
  • [Cites] N Engl J Med. 2004 Oct 21;351(17):1731-40 [15496622.001]
  • [Cites] Ann Surg. 2001 Dec;234(6):780-5; discussion 785-7 [11729384.001]
  • [Cites] Dis Colon Rectum. 2005 Aug;48(8):1573-80 [15937620.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1119-24 [12637479.001]
  • [Cites] Br J Surg. 1994 Aug;81(8):1224-6 [7953369.001]
  • [Cites] Ann Surg Oncol. 2007 Oct;14(10):2773-9 [17653805.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):6199-206 [16135487.001]
  • [Cites] Colorectal Dis. 2004 Nov;6(6):462-9 [15521937.001]
  • [Cites] Dis Colon Rectum. 1999 Oct;42(10):1276-83; discussion 1283-4 [10528764.001]
  • [Cites] Dis Colon Rectum. 1982 Oct;25(7):680-4 [7128370.001]
  • [Cites] Dis Colon Rectum. 2004 Mar;47(3):279-86 [14991488.001]
  • [Cites] Br J Surg. 2003 Oct;90(10):1261-6 [14515297.001]
  • [Cites] Dis Colon Rectum. 1997 Feb;40(2):131-9 [9075745.001]
  • [Cites] Br J Surg. 1998 Apr;85(4):526-9 [9607540.001]
  • [Cites] Cochrane Database Syst Rev. 2007 Apr 18;(2):CD002102 [17443515.001]
  • (PMID = 18071720.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


83. Potthoff A, Brockmeyer NH: [HIV-associated tumors]. Hautarzt; 2006 Nov;57(11):988, 990-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [HIV-associated tumors].
  • [Transliterated title] HIV-assoziierte Tumore.
  • The role of HPV in UV-associated tumors is not yet determined.
  • [MeSH-major] HIV Infections / complications. Neoplasms / etiology. Sarcoma, Kaposi / etiology
  • [MeSH-minor] AIDS-Related Opportunistic Infections / complications. Adult. Antiretroviral Therapy, Highly Active. Anus Neoplasms / etiology. Carcinoma, Hepatocellular / etiology. Female. HIV Seropositivity / complications. Humans. Liver Neoplasms / etiology. Lung Neoplasms / drug therapy. Lung Neoplasms / etiology. Lymphoma, AIDS-Related / diagnosis. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / etiology. Male. Middle Aged. Papillomavirus Infections / complications. Risk Factors. Skin Neoplasms / etiology. Smoking / adverse effects. Uterine Cervical Neoplasms / etiology


84. Nakano I, Kornblum HI: Brain tumor stem cells. Pediatr Res; 2006 Apr;59(4 Pt 2):54R-8R
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain tumor stem cells.
  • Recent advances in stem cell research have allowed for the demonstration of the existence of cancer stem cells in acute myeloid leukemia, breast cancer, and, most recently, in brain tumors.
  • In brain tumors, putative cancer stem cells have been identified from glioblastoma multiforme, medulloblastoma and ependymoma.
  • These tumor-derived cells self-renew under clonal conditions, and differentiate into neuron- and glia-like cells as well as into abnormal cells with mixed phenotypes.
  • The tumor stem cells, but not the rest of tumor cells form secondary tumors by transplantation into immunodeficient mouse brain.
  • In this review, we discuss the cellular and molecular relationships between brain tumor stem cells and normal neural stem cells, and also the possible clinical implications of brain tumor stem cells.
  • [MeSH-major] Brain Neoplasms / pathology. Stem Cells / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16549549.001).
  • [ISSN] 0031-3998
  • [Journal-full-title] Pediatric research
  • [ISO-abbreviation] Pediatr. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 33
  •  go-up   go-down


85. Ansiaux R, Baudelet C, Jordan BF, Beghein N, Sonveaux P, De Wever J, Martinive P, Grégoire V, Feron O, Gallez B: Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment. Clin Cancer Res; 2005 Jan 15;11(2 Pt 1):743-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment.
  • PURPOSE: The aim of this work was to study changes in the tumor microenvironment early after an antiangiogenic treatment using thalidomide (a promising angiogenesis inhibitor in a variety of cancers), with special focus on a possible "normalization" of the tumor vasculature that could be exploited to improve radiotherapy.
  • EXPERIMENTAL DESIGN: Tumor oxygenation, perfusion, permeability, interstitial fluid pressure (IFP), and radiation sensitivity were studied in an FSAII tumor model.
  • Three complementary techniques were used to assess the blood flow inside the tumor: dynamic contrast-enhanced magnetic resonance imaging, Patent Blue staining, and laser Doppler imaging.
  • RESULTS: Our results show that thalidomide induces tumor reoxygenation within 2 days.
  • CONCLUSIONS: In summary, the microenvironmental changes induced by thalidomide were sufficient to radiosensitize tumors.
  • The fact that thalidomide radiosensitization was not observed in vitro, and that in vivo radiosensitization occurred in a narrow time window, lead us to believe that initial vascular normalization by thalidomide accounts for tumor radiosensitization.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • Hazardous Substances Data Bank. OXYGEN .
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • ORBi (University of Liege). Free full Text at ORBi .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15701864.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Contrast Media; 4Z8R6ORS6L / Thalidomide; K2I13DR72L / Gadolinium DTPA; S88TT14065 / Oxygen
  •  go-up   go-down


86. Dionysiou DD, Stamatakos GS: Applying a 4D multiscale in vivo tumor growth model to the exploration of radiotherapy scheduling: the effects of weekend treatment gaps and p53 gene status on the response of fast growing solid tumors. Cancer Inform; 2007 Feb 16;2:113-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Applying a 4D multiscale in vivo tumor growth model to the exploration of radiotherapy scheduling: the effects of weekend treatment gaps and p53 gene status on the response of fast growing solid tumors.
  • The present paper aims at demonstrating clinically oriented applications of the multiscale four dimensional in vivo tumor growth simulation model previously developed by our research group.
  • To this end the effect of weekend radiotherapy treatment gaps and p53 gene status on two virtual glioblastoma tumors differing only in p53 gene status is investigated in silico.
  • Tumor response predictions concerning two rather extreme dose fractionation schedules (daily dose of 4.5 Gy administered in 3 equal fractions) namely HART (Hyperfractionated Accelerated Radiotherapy weekend less) 54 Gy and CHART (Continuous HART) 54 Gy are presented and compared.
  • The model predictions suggest that, for the same p53 status, HART 54 Gy and CHART 54 Gy have almost the same long term effects on locoregional tumor control.
  • As non small cell lung carcinoma (NSCLC) may also be a fast growing and radiosensitive tumor, a comparison of the model predictions with the outcome of clinical studies concerning the response of NSCLC to HART 54 Gy and CHART 54 Gy is made.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Lett. 2006 Jan 8;231(1):102-12 [16356835.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jan 15;43(2):399-403 [10030268.001]
  • [Cites] Acta Neurochir (Wien). 1998;140(4):341-7 [9689325.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Aug 1;36(1):95-103 [8823264.001]
  • [Cites] Acta Oncol. 1999;38(7):883-93 [10606418.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Apr 30;32(1):93-8 [7721643.001]
  • [Cites] J Theor Biol. 2004 Sep 7;230(1):1-20 [15275995.001]
  • [Cites] Acta Oncol. 2001;40(8):968-75 [11845962.001]
  • [Cites] Radiother Oncol. 2000 Feb;54(2):149-56 [10699478.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Nov 1;33(4):781-96 [7591884.001]
  • (PMID = 19458763.001).
  • [ISSN] 1176-9351
  • [Journal-full-title] Cancer informatics
  • [ISO-abbreviation] Cancer Inform
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2675500
  • [Keywords] NOTNLM ; CHART / HART / fractionation / glioblastoma / p53 / radiotherapy / simulation
  •  go-up   go-down


87. Schumacher G, Eisele R, Spinelli A, Schmidt SC, Jacob D, Pratschke J, Neuhaus P: Indications for hand-assisted laparoscopic radiofrequency ablation for liver tumors. J Laparoendosc Adv Surg Tech A; 2007 Apr;17(2):153-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Indications for hand-assisted laparoscopic radiofrequency ablation for liver tumors.
  • PURPOSE: Radiofrequency ablation has established itself as the preferred treatment for irresectable liver tumors.
  • The choice of approach depends on the patient and tumor-related variables.
  • The laparoscopic approach appears to be the safest and most effective method for small tumors on the liver surface.
  • It also provides additional information on the intrahepatic tumor burden with the use of intraoperative ultrasound and staging laparoscopy.
  • Depending on the location of the tumor, mobilization of the liver or lysis of adhesions from previous surgery can require open surgery.
  • MATERIALS AND METHODS: We performed hand-assisted laparoscopy to ablate nine tumors in seven patients, enabling us to combine most of the advantages of laparoscopy and open surgery.
  • A laparoscopy of the entire abdominal cavity and a thorough examination of the entire liver via ultrasound was also performed.
  • In four patients, a complete mobilization of the right lobe was performed to obtain the easiest possible access to the tumor.
  • [MeSH-major] Catheter Ablation. Laparoscopy / methods. Liver Neoplasms / surgery
  • [MeSH-minor] Aged. Aged, 80 and over. Carcinoma, Hepatocellular / pathology. Carcinoma, Hepatocellular / surgery. Colonic Neoplasms / pathology. Colonic Neoplasms / surgery. Female. Humans. Male. Melanoma / secondary. Melanoma / surgery. Middle Aged. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17484640.001).
  • [ISSN] 1092-6429
  • [Journal-full-title] Journal of laparoendoscopic & advanced surgical techniques. Part A
  • [ISO-abbreviation] J Laparoendosc Adv Surg Tech A
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Laigle-Donadey F, Benouaich-Amiel A, Hoang-Xuan K, Sanson M: [Molecular biology of oligodendroglial tumors]. Neurochirurgie; 2005 Sep;51(3-4 Pt 2):260-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Molecular biology of oligodendroglial tumors].
  • [Transliterated title] Biologie moléculaire des tumeurs oligodendrogliales.
  • Oligodendrogliomas have been the focus of considerable interest over the last decade, ever since they were recognized as chemosensitive tumors.
  • Gliomas are the consequence of specific genetic or epigenetic alterations - activations of oncogenes and inactivation of tumor suppressor genes - resulting in the disruption of critical cellular pathways and leading to phenotypic changes.
  • There is little doubt that emerging techniques, such as CGH-array and gene profiling will be very helpful in clinical practice for refining both classification and therapeutic indications of oligodendroglial tumors.
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / pathology. Gene Expression Regulation, Neoplastic / genetics. Molecular Biology / methods. Oligodendroglioma / genetics. Oligodendroglioma / pathology. Point Mutation / genetics
  • [MeSH-minor] Chromosome Deletion. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Cyclin-Dependent Kinase 4 / genetics. Genes, Tumor Suppressor. Glycoproteins / genetics. Humans. Loss of Heterozygosity / genetics. Phenotype. Proto-Oncogene Proteins c-mdm2 / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16292170.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Glycoproteins; 0 / epidermal growth factor receptor related protein, human; EC 2.7.11.22 / CDK4 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 4; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  • [Number-of-references] 71
  •  go-up   go-down


89. Hariri A, Mascard E, Atlan F, Germain MA, Heming N, Dubousset JF, Wicart P: Free vascularised fibular graft for reconstruction of defects of the lower limb after resection of tumour. J Bone Joint Surg Br; 2010 Nov;92(11):1574-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Free vascularised fibular graft for reconstruction of defects of the lower limb after resection of tumour.
  • We describe a retrospective review of 38 cases of reconstruction following resection of the metaphysiodiaphysis of the lower limb for malignant bone tumours using free vascularised fibular grafts.
  • The mean Musculoskeletal Tumor Society score was 27.2 (20 to 30).
  • The score was significantly higher when the graft was carried out in a one-stage procedure after resection of the tumour rather than in two stages.
  • [MeSH-major] Bone Neoplasms / surgery. Bone Transplantation / methods. Fibula / transplantation. Lower Extremity / surgery

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Bone Grafts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21037355.001).
  • [ISSN] 0301-620X
  • [Journal-full-title] The Journal of bone and joint surgery. British volume
  • [ISO-abbreviation] J Bone Joint Surg Br
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


90. Shetty C, Avinash KR, Auluck A: Schwannoma of vagus nerve masquerading as a parotid tumour. Dentomaxillofac Radiol; 2006 Sep;35(5):376-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Schwannoma of vagus nerve masquerading as a parotid tumour.
  • A post-auricular swelling is the most common presentation of a parotid tumour, the majority of which are benign neoplasms like pleomorphic adenoma.
  • This case report discusses a post-styloid parapharyngeal space tumour presenting as a post-auricular mass which, on initial clinical and cytological examination, was diagnosed as pleomorphic adenoma.
  • [MeSH-major] Cranial Nerve Neoplasms / radiography. Neurilemmoma / radiography. Vagus Nerve Diseases / radiography
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male. Parotid Neoplasms / diagnosis. Pharynx / radiography. Tomography, Spiral Computed

  • Genetic Alliance. consumer health - Schwannoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16940487.001).
  • [ISSN] 0250-832X
  • [Journal-full-title] Dento maxillo facial radiology
  • [ISO-abbreviation] Dentomaxillofac Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


91. Faria MH, Gonçalves BP, do Patrocínio RM, de Moraes-Filho MO, Rabenhorst SH: Expression of Ki-67, topoisomerase IIalpha and c-MYC in astrocytic tumors: correlation with the histopathological grade and proliferative status. Neuropathology; 2006 Dec;26(6):519-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of Ki-67, topoisomerase IIalpha and c-MYC in astrocytic tumors: correlation with the histopathological grade and proliferative status.
  • Astrocytomas represent the most frequent primary tumors of the central nervous system.
  • Recently, the determination of the proliferative index of astrocytic tumors by different methods has been proposed as a valuable tool for tumor grading and also as a prognostic marker.
  • The aim of the present study was to evaluate the expression of cell proliferation-related proteins in human astrocytic tumors of different histopathological grades (WHO).
  • An immunohistochemical study of the Ki-67, Topoisomerase IIalpha (Topo IIalpha) and c-MYC proteins using the avidin-biotin-peroxidase method was performed in 55 astrocytomas (13 grade I, 14 grade II, 7 grade III and 21 grade IV) and five samples of non-tumor brain tissue (control group).
  • Ki-67, Topo IIalpha and c-MYC positive indices tended to increase according to malignant progression, were absent in non-tumor brain tissue and showed maximum values in high-grade astrocytomas (III and IV).
  • The same was not observed for Topo IIalpha and c-MYC.
  • Ki-67 antigen detection in more than 8.0% of the tumor cells distinguished astrocytoma grade IV, while a labeling index between 1.5 and 8.0% characterized astrocytomas grade III and values below 1.5% discriminated low-grade tumors (I and II).
  • These results indicate that Topo IIalpha and c-MYC expression is associated with cell proliferation in astrocytomas, although not in an exclusive way.
  • Moreover, Ki-67 antigen was found to be the best marker of cellular proliferation, and its expression predicts the grade of astrocytic tumors.
  • [MeSH-major] Astrocytoma / metabolism. Astrocytoma / pathology. Biomarkers, Tumor / metabolism. Brain Neoplasms / metabolism. Brain Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antigens, Neoplasm / metabolism. Cell Division. Child. Child, Preschool. DNA Topoisomerases, Type II / metabolism. DNA-Binding Proteins / metabolism. Female. Glioblastoma / metabolism. Glioblastoma / pathology. Humans. Immunohistochemistry. Infant. Ki-67 Antigen / metabolism. Male. Middle Aged. Prognosis. Proto-Oncogene Proteins c-myc / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17203587.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-myc; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down


92. Varticovski L, Hollingshead MG, Robles AI, Wu X, Cherry J, Munroe DJ, Lukes L, Anver MR, Carter JP, Borgel SD, Stotler H, Bonomi CA, Nunez NP, Hursting SD, Qiao W, Deng CX, Green JE, Hunter KW, Merlino G, Steeg PS, Wakefield LM, Barrett JC: Accelerated preclinical testing using transplanted tumors from genetically engineered mouse breast cancer models. Clin Cancer Res; 2007 Apr 1;13(7):2168-77
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accelerated preclinical testing using transplanted tumors from genetically engineered mouse breast cancer models.
  • PURPOSE: The use of genetically engineered mouse (GEM) models for preclinical testing of anticancer therapies is hampered by variable tumor latency, incomplete penetrance, and complicated breeding schemes.
  • EXPERIMENTAL DESIGN: Tumor fragments from tumor-bearing MMTV-PyMT or cell suspensions from MMTV-PyMT, -Her2/neu, -wnt1, -wnt1/p53(+/-), BRCA1/p53(+/-), and C3(1)T-Ag mice were transplanted into the mammary fat pad or s.c. into naïve syngeneic or immunosuppressed mice.
  • Tumor development was monitored and tissues were processed for histopathology and gene expression profiling.
  • Metastasis was scored 60 days after the removal of transplanted tumors.
  • RESULTS: PyMT tumor fragments and cell suspensions from anterior glands grew faster than posterior tumors in serial passages regardless of the site of implantation.
  • Microarray analysis revealed genetic differences between these tumors.
  • The transplantation was reproducible using anterior tumors from multiple GEM, and tumor growth rate correlated with the number of transplanted cells.
  • Similar morphologic appearances were observed in original and transplanted tumors.
  • Metastasis developed in >90% of mice transplanted with PyMT, 40% with BRCA1/p53(+/-) and wnt1/p53(+/-), and 15% with Her2/neu tumors.
  • Expansion of PyMT and wnt1 tumors by serial transplantation for two passages did not lead to significant changes in gene expression.
  • PyMT-transplanted tumors and anterior tumors of transgenic mice showed similar sensitivities to cyclophosphamide and paclitaxel.
  • CONCLUSIONS: Transplantation of GEM tumors can provide a large cohort of mice bearing mammary tumors at the same stage of tumor development and with defined frequency of metastasis in a well-characterized molecular and genetic background.
  • [MeSH-major] Disease Models, Animal. Genetic Engineering. Mammary Neoplasms, Experimental. Mice. Neoplasm Transplantation / methods
  • [MeSH-minor] Animals. Cell Proliferation. Female. Gene Expression. Gene Expression Profiling. In Situ Hybridization. Mice, Transgenic. Neoplasm Metastasis. Oligonucleotide Array Sequence Analysis. Reverse Transcriptase Polymerase Chain Reaction


93. Nikolić B, Mitrović A, Lazić J: Mean of CA 125 in making therapy decision in adnexal inflammatory tumors. Bosn J Basic Med Sci; 2006 May;6(2):3-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mean of CA 125 in making therapy decision in adnexal inflammatory tumors.
  • LABORATORY FINDINGS such are white blood count and sedimentation rate are of relative value in inflammations of the upper genital tract and adnexal inflammatory tumors.
  • Inflammatory tumors can develop in endometriotic and even in cancer adnexal masses.
  • It can also be elevated in endometriosis, inflammations and in non-gynecological malignancies.
  • Adnexal inflammatory tumor was confirmed in 57 patients.
  • Even there is no need for routine examining of serum CA 125 in adnexal inflammatory tumors it can be examined in cases with suspected Doppler ultrasonographic findings or unclear clinical findings.
  • Inflammatory tumor can develop in endometriotic tumor as well as in necrotic malignant ovary tissue.
  • These could be reasons for making decision to do the operation in cases with inflammatory tumor followed with increased CA 125, hystological assessment and serious interpretation of final results.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16879104.001).
  • [ISSN] 1512-8601
  • [Journal-full-title] Bosnian journal of basic medical sciences
  • [ISO-abbreviation] Bosn J Basic Med Sci
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Bosnia and Herzegovina
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Biomarkers, Tumor; 0 / CA-125 Antigen
  •  go-up   go-down


94. Suri A, Narang KS, Sharma BS, Mahapatra AK: Visual outcome after surgery in patients with suprasellar tumors and preoperative blindness. J Neurosurg; 2008 Jan;108(1):19-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Visual outcome after surgery in patients with suprasellar tumors and preoperative blindness.
  • OBJECTIVES: The purpose of this paper was to study the visual outcome after surgery in patients with suprasellar tumors who experienced preoperative blindness in 1 or both eyes.
  • METHODS: All patients with suprasellar tumors and no perception of light in 1 or both eyes and who underwent surgery between May 2002 and May 2006 were included in this retrospective study.
  • There were 37 cases of pituitary adenomas, 19 craniopharyngiomas, 18 meningiomas, and 5 other tumors.
  • Patients underwent either transcranial or transsphenoidal tumor decompression.
  • Bivariate analysis revealed male sex, shorter duration of blindness, presence of apoplexy, sellar tumor extension, soft tumor consistency, operative evidence of hemorrhage in tumor, and tumor histopathology (pituitary adenoma) to have significant impact on the outcome.
  • CONCLUSIONS: The present study is the largest in the existing medical literature to evaluate the factors affecting visual outcome after surgery of suprasellar tumors with preoperative blindness.
  • [MeSH-major] Blindness / physiopathology. Blindness / surgery. Brain Neoplasms / pathology. Brain Neoplasms / surgery


95. Ashour AE, Lin X, Wang X, Turnquist HR, Burns NM, Tuli A, Sadanandam A, Suleiman K, Singh RK, Talmadge JE, Solheim JC: CCL21 is an effective surgical neoadjuvant for treatment of mammary tumors. Cancer Biol Ther; 2007 Aug;6(8):1206-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CCL21 is an effective surgical neoadjuvant for treatment of mammary tumors.
  • The goal of this study was to determine the effects of administering CCL21 to orthotopic mammary tumors in terms of impact on tumor growth rate, immune cell infiltration of the primary tumor and survival.
  • We found that a single intratumoral administration of CCL21 slowed the growth of orthotopic mammary tumors and increased intratumoral infiltration by T cells, NK cells and DCs.
  • CCL21 intratumoral administration also prolonged the survival of tumor-earing mice.
  • Furthermore, mice that received intratumoral neoadjuvant CCL21 ior to surgical resection of tumors survived significantly longer than control mice.
  • The urviving neoadjuvant CCL21-reated mice, when challenged again with cl-6, had significantly slower rate of tumor growth than challenged control mice.
  • Thus, our ata indicate that CCL21 treatment prior to mammary tumor resection can significantly rolong survival and increase resistance to subsequent tumor challenge.
  • [MeSH-major] Chemokine CCL21 / therapeutic use. Mammary Neoplasms, Animal / drug therapy. Mammary Neoplasms, Animal / immunology. Neoadjuvant Therapy / methods
  • [MeSH-minor] Animals. Dendritic Cells / drug effects. Female. Killer Cells, Natural / drug effects. Lymphocytes, Tumor-Infiltrating. Mice. Mice, Inbred BALB C. T-Lymphocytes / drug effects

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17617742.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / T32 CA09476
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chemokine CCL21
  •  go-up   go-down


96. Walker C, du Plessis DG, Joyce KA, Fildes D, Gee A, Haylock B, Husband D, Smith T, Broome J, Warnke PC: Molecular pathology and clinical characteristics of oligodendroglial neoplasms. Ann Neurol; 2005 Jun;57(6):855-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular pathology and clinical characteristics of oligodendroglial neoplasms.
  • To evaluate the role of molecular genetics in the routine clinic, we investigated allelic imbalance at 1p36, 19q13, 17p13, 10p12-15, and 10q22-26 and p53 mutation in 100 oligodendroglial neoplasms diagnosed at a single treatment center between 2000 and 2003.
  • Genotype was unrelated to tumor location and could not distinguish high-grade tumors that presented de novo from those that progressed from a previous lower grade malignancy.
  • In longitudinal samples, 74% retained their initial histological differentiation, whereas 29% showed new genetic alterations, the -1p/-19q genotype being acquired in three cases.
  • In this recently diagnosed unselected series, clinical differences in tumors with and without the -1p/-19q genotype support a genetic approach to aid diagnosis and prognostication for oligodendroglial neoplasms.
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / pathology. Oligodendroglioma / genetics. Oligodendroglioma / pathology
  • [MeSH-minor] Adult. Aged. Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 10. Chromosomes, Human, Pair 17. Chromosomes, Human, Pair 19. Female. Genetic Testing. Genotype. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / genetics. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / pathology. Phenotype. Prognosis. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15929038.001).
  • [ISSN] 0364-5134
  • [Journal-full-title] Annals of neurology
  • [ISO-abbreviation] Ann. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


97. Jaworski M, Buchmann A, Bauer P, Riess O, Schwarz M: B-raf and Ha-ras mutations in chemically induced mouse liver tumors. Oncogene; 2005 Feb 10;24(7):1290-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B-raf and Ha-ras mutations in chemically induced mouse liver tumors.
  • The mitogen-activated protein kinase signalling pathway is a central regulator of tumor growth, which is constitutively activated in chemically induced mouse liver tumors.
  • We now screened 82 N-nitrosodiethylamine-induced liver tumors from C3H/He mice for mutations within the hotspot positions in the Ha-ras and B-raf genes.
  • About 50% (39/82) of tumors showed Ha-ras codon 61 mutations and 16 tumors ( approximately 20%) harbored mutations at codon 624 of the B-raf gene, which corresponds to codon 599 in human B-raf.
  • None of the tumors was mutated in both Ha-ras and B-raf.
  • The high prevalence of Ha-ras and B-raf mutations in mouse liver tumors is in striking contrast to human hepatocellular cancers which very infrequently harbor mutations in the two genes.
  • These fundamental differences between the biology of liver tumors in mice and man may be of toxicological relevance.
  • [MeSH-major] Genes, ras / genetics. Liver Neoplasms, Experimental / genetics. Mice / genetics. Point Mutation / genetics. Proto-Oncogene Proteins B-raf / genetics
  • [MeSH-minor] Animals. Cell Transformation, Neoplastic / genetics. DNA, Neoplasm / genetics. Diethylnitrosamine. Humans. Mice, Inbred C3H. Sequence Analysis, DNA


98. Yang WT, Lane DL, Le-Petross HT, Abruzzo LV, Macapinlac HA: Breast lymphoma: imaging findings of 32 tumors in 27 patients. Radiology; 2007 Dec;245(3):692-702
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast lymphoma: imaging findings of 32 tumors in 27 patients.
  • Twenty-seven women who had been diagnosed with breast lymphoma (32 tumors) and had undergone preoperative imaging were identified from the surgical pathology database (mean age, 51 years; median, 55 years; range, 19-78 years at time of diagnosis).
  • RESULTS: The mean tumor size at diagnosis was 2.9 cm (range, 1-5 cm).
  • Seventeen tumors manifested with a palpable mass, two with diffuse enlargement of the breast, and 13 were asymptomatic.
  • Mammograms of 25 tumors showed a noncalcified mass in 19, global asymmetry in four, focal asymmetry in one, and no abnormality in one.
  • US of 29 tumors showed a mass in 26 and diffuse architectural distortion in three.
  • Dynamic contrast material-enhanced MR imaging of one tumor showed an intensely and heterogeneously enhancing mass with rapid enhancement and washout characteristics.
  • PET/CT scans of 13 tumors showed intense diffuse hypermetabolism in 12 and response to therapy in all 12 tumors.
  • [MeSH-major] Breast Neoplasms / diagnosis. Lymphoma / diagnosis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) RSNA, 2007.
  • [CommentIn] Radiology. 2008 Jul;248(1):320; author reply 320 [18566185.001]
  • (PMID = 17911538.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Krysiak R, Marek B, Okopień B: [Medullary thyroid cancer - the present state of art]. Endokrynol Pol; 2008 Sep-Oct;59(5):446-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Rak rdzeniasty tarczycy - aktualny stan wiedzy.
  • Medullary thyroid cancer is a neuroendocrine tumour originating from the parafollicular C cells of the thyroid gland that accounts for about 5-10% of all thyroid carcinomas.
  • It may occur either sporadically (75%) or in familial forms (25%) in familial medullary thyroid carcinoma and multiple endocrine neoplasia types 2A and 2B.
  • Medullary thyroid cancer produce calcitonin, measurement of which indicates the presence of tumour in at-risk individuals and the effectiveness of management in treated patients.
  • Prognosis of patients with medullary thyroid cancer is variable, but the more constant factors that affect it are the stage of disease and the age of the patient.
  • The goal of treatment of patients suffering from medullary thyroid cancer is to detect and surgically remove disease at its early stage.
  • The tumour does not take up radioactive iodine, is relatively radioresistant, and there is no known effective systemic therapy for this cancer.
  • [MeSH-major] Carcinoma, Medullary / diagnosis. Carcinoma, Medullary / therapy. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / therapy
  • [MeSH-minor] Humans. Multiple Endocrine Neoplasia Type 2a / diagnosis. Multiple Endocrine Neoplasia Type 2a / genetics. Multiple Endocrine Neoplasia Type 2a / pathology. Multiple Endocrine Neoplasia Type 2a / therapy. Prognosis


100. Yuan SM, Jing H, Lavee J: Tumors and tumor-like lesions of the heart valves. Rare Tumors; 2009;1(2):e35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumors and tumor-like lesions of the heart valves.
  • Valvular tumors and tumor-like lesions may have similar morphological and clinical characteristics, and may place the patients at a high risk of stroke in different ways.
  • From January 2004 to June 2008, 11 patients underwent surgery for a suspected valvular tumor.
  • Valvular tumor and tumor-like lesions accounted for 0.32% of adult cardiac operations.
  • Valvular tumor and tumor-like lesions are rare.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21139914.001).
  • [ISSN] 2036-3613
  • [Journal-full-title] Rare tumors
  • [ISO-abbreviation] Rare Tumors
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2994454
  • [Keywords] NOTNLM ; cardiac myxoma / cardiac papillary fibroelastoma / differential diagnosis / heart valve / intracardiac thrombus / surgical resection.
  •  go-up   go-down






Advertisement